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ABSTRACT 
 
Shellie Dawn Ellis: Declining Overuse of Hormone Therapy for Localized Prostate 
Cancer: Predictors of Reimbursement Responsiveness and Emerging Patterns of Care 
(Under the direction of William R. Carpenter) 
This research examines the effects of reimbursement policy as a strategy to improve 
quality of care. We estimated the degree to which physician characteristics are associated with 
declining androgen deprivation therapy (ADT) overuse; identified the effect of reimbursement 
changes on ADT overuse; and, evaluated the impact of changing patterns of ADT overuse on 
quality of care in localized prostate cancer.  
We used SEER-linked Medicare claims and American Medical Association data to create 
three distinct longitudinal cohorts of individuals diagnosed with incident prostate cancer in the 
2000s and their physicians. Multilevel logistic regression modeling controlled for patient and 
physician characteristics associated with overuse of medical care and prostate cancer treatment 
selection, and clustering of patients within physicians. 
In the first study, time in practice was not associated with ADT overuse, but three 
patterns of ADT overuse were observed. We could not distinguish urologists who increased ADT 
overuse from those who decreased ADT overuse after MMA based on physician characteristics. 
Our findings suggest that: 1) new types of interventions will be needed to address persistent 
overuse; 2) guidelines should underscore treatment strategies for vulnerable patients; and 3) 
economic theory may need to consider clinic explanations for the volume response.  
The second study suggests that, among urologists treating early-stage and lower grade 
prostate cancer, variation in reimbursement was not associated with overuse of ADT during a 
period of guideline stability. There was a small but significant negative association between ADT 
iv 
 
overuse and excess reimbursement relative to all treatments: urologists in favorable 
reimbursement climates had lower odds of ADT overuse. Multi-specialty group practice type 
was associated with lower odds of ADT overuse. Reimbursement cuts may not be effective 
strategy to reduce overuse in all clinical scenarios.  
Finally, physicians’ pre-MMA ADT overuse was negatively associated with delivering 
guideline-concordant care post-MMA. High users of ADT pre-MMA were also more likely to 
overuse ADT and provide guideline–discordant care post-MMA. Reducing reimbursement for 
inappropriate therapy will not necessarily improve quality of care. Physicians unable to provide 
guideline-concordant care may need additional resources to align with guidelines or to adopt 
guideline-concordant technologies. 
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CHAPTER 1 INTRODUCTION 
The federally mandated National Quality Strategy has designated the overuse of health 
care as a national priority. Currently 30%–40% of health care spending in the U.S. is for the 
provision of unnecessary care. Such overuse results in patient harms, health disparities, and 
waste in a healthcare system already stretched to capacity. Overuse is of particular concern 
within the context of cancer care. Emerging evidence in cancer screening, control, and treatment 
increasingly results in situations in which providers and patients must alter their behavior to 
abandon established practices. Although strategies to address overuse in cancer care are 
becoming increasingly relevant, little research exists to guide the development of interventions 
to address overuse. New studies are needed to enable intervention development and understand 
the impact of such strategies.  
The overuse of androgen deprivation therapy (ADT) in the treatment of localized 
prostate cancer provides a model for understanding strategies to address healthcare overuse. 
ADT overuse is a harmful, costly, and persistent problem in prostate cancer treatment: 25.7% of 
men for whom it is not recommended still received it in 2005. Reimbursement cuts mandated 
by the Medicare Modernization Act (MMA) were associated with a 34% decline in ADT overuse; 
however, physician and practice characteristics that facilitated reimbursement responsiveness; 
the direct role of reimbursement in changing patterns of care; and the full impact on changing 
patterns of care on quality of care are not known. Nonetheless, sharp declines in overuse provide 
an opportunity to study the factors and consequences associated with declining overuse. 
The objective of this dissertation was to 1) describe changes in physician-level ADT 
overuse associated with the MMA and identify physician characteristics associated with 
persistent ADT overuse; 2) explore the extent to which physicians may have been responsive to 
differences in reimbursement, rather than other trends in evidence, guidelines, and practice 
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change occurring coincident with MMA; and, 3) assess the impact of changes in ADT overuse on 
contemporary quality of care.  
We matched American Medical Association physician and practice data to SEER–linked 
Medicare data for all three studies. We used distinct samples of men with clinically localized, 
incident adenocarcinoma of the prostate. Each sample was drawn from a time period 
appropriate to the research question. The aim 1 sample included 12,943 men diagnosed with 
early-stage and lower grade localized adenocarcinoma of the prostate between 2000 and 2007, 
and treated by 2,138 urologists through 2008, so that we could study change over the MMA 
implementation. Our second sample included the 2,213 urologists of 16,790 men diagnosed with 
early-stage and lower grade localized prostate cancer between January 1, 2000 and December 
31, 2003 to exploit unintentional variation in ADT reimbursement that ended in late 2002. The 
third sample included 27,315 men diagnosed with incident low-, intermediate-, or high-risk 
localized prostate cancer between 2005 and 2007, treated by 4,104 physicians of all specialties, 
selected so we could study care delivered post-MMA implementation. Each study used a 
retrospective, longitudinal observational design; however, the second study also took advantage 
of a natural experiment, allowing for difference-in-difference design features. Statistical analysis 
consisted of descriptive analysis and multilevel mixed effects logistic regression models, which 
adjusted standard errors for clustering of patients within physicians and repeated physician 
measures over time and controlled for tumor, patient, provider, and practice characteristics 
known to be associated with ADT use or reimbursement responsiveness. 
This research advances previous work studying the effect of MMA on ADT overuse. We 
followed patients for 2 years longer than previous studies to further understand the trends 
surrounding MMA. In addition, we explored physician-level changes in ADT use, rather than 
aggregated changes, to identify distinct patterns of response over the MMA period. 
Furthermore, our study is the first to assess physician-level factors and practice-level 
organizational characteristics associated with responsiveness to MMA. In Aim 2 we used 
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difference-in-difference study design features to better identify the role of reimbursement in 
ADT overuse. Where previous study designs had allowed only observation of associations 
between reimbursement change and ADT overuse, our study exploited reimbursement variation 
between and within physicians to better assess the effect of reimbursement change. Finally, our 
study is the first to assess the effects of pre-MMA ADT overuse on the global quality of care in a 
post-MMA population. 
Our original hypotheses were that: 
Hypothesis 1A: Urologists with greater time in practice would be less responsive to 
reimbursement changes; 
Hypothesis 1B: Urologists would respond to reimbursement changes uniformly; 
Hypothesis 2A: More generous reimbursement would be associated with greater overuse 
of ADT; 
Hypothesis 2B: Single specialty urology practices would be more likely to persistently 
overuse ADT than multi-specialty groups; 
Hypothesis 3A: High levels of pre-MMA primary ADT use would be associated with 
guideline-concordant care in the post-MMA period; 
Hypothesis 3B: Patient race would be associated with greater odds of receipt of 
guideline-concordant care in the post-MMA period; and, 
Hypothesis 3C: Pre-MMA ADT overuse would be negatively associated with uptake of 
new treatment modalities. 
This work is relevant to current healthcare policy. Recent health policy legislation seeks 
to cut costs within Medicare while simultaneously improving healthcare quality. Several 
experimental innovations are proposed, but fee-for-service remains the payment mechanism for 
the majority of the Medicare population. The Patient Protection and Affordable Care Act (ACA) 
will limit increases in payment to physicians across the board. Better understanding of the 
nuances of how changes in the Medicare payment structure might work across a variety of 
health conditions, each with their own set of treatment alternatives, treating physician 
conventions, and practice milieu can better inform the policy debate with regard to how best to 
transform a system on which patients, physicians, and a large healthcare industry rely. 
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Sections of the dissertation are organized as follows. Chapter 2 describes the 
complexities of prostate cancer and discusses current literature regarding prostate cancer 
treatments, quality of care, and recent reimbursement policy affecting prostate cancer 
treatment. It further discusses alternative explanations for the declining use of ADT and factors 
associated with ADT overuse and reimbursement responsiveness. Chapter 3 provides an 
overview of the methods used throughout the dissertation. It includes the underlying conceptual 
model on which the work is based, a discussion of study design and rationale, data sources, 
hypotheses, and analytical approaches. Chapters 4–6 are manuscripts corresponding to Aims 1–
3, respectively, and are intended for submission for peer-reviewed publication. Chapter 7 
summarizes the findings of this dissertation, its policy relevance, and research gaps identified. 
References are provided in a comprehensive bibliography at the conclusion of the dissertation. 
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CHAPTER 2 LITERATURE REVIEW 
The Burden of Prostate Cancer  
Prostate cancer is the second most common cancer diagnosis in men. It is diagnosed in 
an estimated 217,730 men in the United States annually (1). Although common, relatively few 
men die from the disease. Between 2003 and 2007, an estimated 32,050 men died of prostate 
cancer each year (1). Although 4% of prostate cancers are detected after they have metastasized, 
a stage in which 5-year survival is only 30.2% (1), most men are diagnosed with localized and 
regional disease, for which the survival rate is nearly 100% (1). In the recent era of widespread 
prostate specific antigen (PSA) screening, 94% of men diagnosed with prostate cancer have 
clinically localized disease (2) in which the cancer is confined within the prostate gland. In some 
areas of the country, even greater numbers of men are diagnosed in this early stage. For 
example, in a North Carolina cohort of men diagnosed between 2004 and 2007, 97% of men had 
localized disease (3). Several factors contribute to its favorable prognosis: 1) most disease is 
diagnosed in the earliest, most curable stages; 2) it is primarily an indolent cancer; and 3) 
median age of diagnosis is 67 years (1, 4). Thus, most men diagnosed with prostate cancer die 
from other causes.  
However, the favorable prognosis is not distributed equally among the population in the 
United States. Significant disparities in prostate cancer incidence and outcome in the United 
States are apparent. Age-adjusted incidence is higher among African-American men—150.4 per 
100,000 white men versus 234.6 per 100,000 black men (1). In addition, African-American men 
are often diagnosed at an earlier age than white men and have a higher prevalence of high grade 
neoplasia, suggesting that they present with a more aggressive type of cancer (5). Death rates are 
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also significantly higher among African-American men—22.8 per 100,000 white men versus 
54.2 per 100,000 black men (1)—and are particularly high in the South (6).  
For the substantial number of men who live with prostate cancer, its costs are high. 
Compared to men without prostate cancer, those diagnosed with it can experience declines in 
physical health and emotional health, and social function (7). Many suffer increased 
incontinence and major depressive disorder, with some of these effects lasting more than a year 
after diagnosis and treatment (7). With early screening, men live many years with the knowledge 
of having a cancer, albeit a slow-growing one. Coupled with the ambiguity of appropriate 
treatment, this may lead to high psychological costs, although little research addresses this 
aspect of the disease.  
Although the full burden of patient suffering is unknown, the financial costs to patients 
and society are high and continue to grow. Accumulated costs of treatment 5.5 years after 
diagnosis range from $32,135 to $69,244, depending on the treatment selected (8). In 1994, 
Medicare expenditures alone for the treatment of prostate cancer was $1.4 billion (8). By 2006, 
total prostate treatment costs had grown to $9.9 billion, (4) and by 2010 the treatment of the 2.3 
million prostate cancer survivors in the United States was estimated to be $11.9 billion (9). Costs 
are expected to grow 42% by 2020 for the care of an estimated 3.1 prostate cancer patients, 
giving prostate cancer the distinction of having the highest rate of increasing medical care costs 
among several prevalent cancers (9). A significant part of the costs of prostate cancer treatment 
is that spent on androgen deprivation therapy (ADT). Of the total prostate treatment costs paid 
by Medicare in 1994, $4.8 million was for androgen suppression therapy using luteinizing 
hormone-releasing hormone agonists, the treatment with the highest accumulated treatment 
cost (8). By the early 2000s, ADT use was responsible for almost $1 billion of annual Medicare 
spending (10). Thus, understanding how prostate cancer treatment, especially ADT, is selected 
and how treatment selection affects quality of care are crucial to improving the value of 
healthcare. 
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The Treatment of Prostate Cancer 
Risk Stratification and Classification 
Prostate cancer is an indolent disease with a long natural history, but the specific course 
of the disease depends on the stage of diagnosis. Prognosis for cancers confined to the prostate 
gland (localized disease) is better than that of cancers that have spread outside the gland 
(regional disease), and much better than that of cancers that have metastasized to the lymph 
nodes or to other organs (metastatic disease). Thus, each of these types of disease has distinct 
treatment goals. Since 1986 and the advent of widespread PSA screening, the majority of men 
have been diagnosed with localized disease, and even finer gradations of disease prognosis have 
been made. Figure 2.1 shows the six mutually exclusive prostate cancer recurrence risk 
categories generally used. Those highlighted in red are the focus of this dissertation. 
In contemporary prostate cancer, 94% of men have clinically localized disease, and less 
than 30% of these men have disease that is considered at high risk for progression, requiring 
definitive therapy. Aims 1 and 2 of this study focus on the other 70% of men, whose risk for 
Figure 2.1. Prostate Cancer Recurrence Risk Categories 
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recurrence is not considered high; and Aim 3 studies all recurrence risk groups of localized 
disease.  
Since the late 1990s, the prostate cancer recurrence risk for localized disease has been 
formally calculated and codified as the D’Amico risk classification. Based on clinical stage, 
grade, and PSA at diagnosis, the combination of risk factors has been shown to predict early PSA 
failure, a sign of disease progression (11). Figure 2.2 shows the six recurrence risk categories, 
their qualifying risk factors, and the treatments recommended by the National Comprehensive 
Cancer Network (NCCN) since 2004 (12). 
Figure 2.2. Prostate Cancer Treatment Algorithm 
 
Quality of Care in Prostate Cancer 
Although few national prostate cancer quality measures exist (13), as recurrence risk 
classifications, and subsequently, evidence of treatment effectiveness based on these risk 
stratifications has evolved, quality of care standards have emerged. Several professional 
Low 
T1-2a +  
Gleason 2-6 +  
PSA < 10 ng/mL 
Expectant Management 
Radiation Therapy (3D-CRT or brachytherapy) 
Radical Prostatectomy + pelvic lymph node dissection 
Intermediate 
T2b or  T2c or 
Gleason score 7 or  
PSA 10-20 ng/mL 
Expectant Management 
Radiation Therapy (3D-CRT + brachytherapy) 
Radical Prostatectomy + pelvic lymph node dissection 
High 
T3a or  
Gleason score 8-10 
or  
PSA > 20 ng/mL 
ADT + Radiation Therapy 
Radiation Therapy + ADT (for patients with one adverse high risk factor) 
Radical Prostatectomy + pelvic lymph node dissection 
Very High T3b-T4 ADT Radiation Therapy + ADT 
Nodal 
Involvement 
Any T, N1 
ADT 
Radiation Therapy + ADT 
Metastatic Any T, Any N, M1 ADT 
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societies and RAND Corporation investigators have developed quality of care guidelines. 
Investigators at RAND sought to develop quality of care indicators for prostate cancer focusing 
on structural features and processes of care delivery but without specifying appropriate 
treatment (14, 15). The American Urological Association (AUA), American Society of Clinical 
Oncology (ASCO), and American Society for Therapeutic Radiology and Oncology (ASTRO) have 
developed consensus- or evidence-based guidelines, but most apply to narrow therapeutic 
indications (16, 17). The only evidence-based comprehensive treatment guideline for all prostate 
cancer stages and recurrence risk categories are those developed by the NCCN. Widely accepted 
as the standard for prostate cancer treatment (3, 18), NCCN guidelines are available for prostate 
cancer screening, staging, initial treatment, and salvage therapy.  
Initial treatment guidelines, the focus of this dissertation, are based on the patient’s life 
expectancy and recurrence risk categories (12, 19). Together these criteria are used to 
differentiate appropriate from inappropriate treatment options. NCCN guidelines for prostate 
cancer treatment are complex. Mainly because of the typical indolence of prostate cancer, no 
current course of treatment for early-stage disease provides any incremental benefit (19), and 
current guidelines for treating early-stage disease provide multiple options.  
Because of rapidly emerging treatment evidence, NCCN guidelines have been updated 
frequently, in 2000, 2004, 2008, and 2010 (12, 20-22). Table 2.1 describes key differences in 
treatment that resulted from guideline changes during the period that is the focus of this 
research. Absent from Table 2.1 is the full description of the impact of treatment 
recommendations on life expectancy on treatment recommendation. Patients who have long life 
expectancies at the time of diagnosis are recommended for definitive treatment, rather than 
observation. One notable change during the period is that prior to 2004, primary ADT was 
recommended for high-risk patients expected to survive less than 5 years. Further, in 2004, 
guidelines changed in response to new evidence for the benefit of ADT adjuvant to radiation 
therapy for men with stage T3a cancers, higher grade tumors, or PSA >20 ng/mL. 
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Table 2.1. NCCN Treatment Guidelines by Recurrence Risk Category and Year 
Recurrence 
Risk 
Category 
Risk 
Classification 
Criteria 
2000–2003 NCCN 
Treatment Options 
2004–2007 NCCN 
Treatment Options 
Low T1-2a +  
Gleason 2-6 +  
PSA <10 ng/mL 
Expectant Management 
Radiation Therapy (EBRT 
or brachytherapy) 
Radical Prostatectomy 
Expectant Management 
Radiation Therapy (3D-CRT 
or brachytherapy) 
Radical Prostatectomy 
Intermediate T2b or T2c* or 
Gleason score 7 or 
PSA 10–20 ng/mL 
Expectant Management 
Radiation therapy (EBRT) 
 
Radical Prostatectomy 
Expectant Management 
Radiation Therapy (3D-CRT 
+ brachytherapy) 
Radical Prostatectomy 
High T3a or  
Gleason score 8–
10 or  
PSA >20 ng/mL 
ADT + Radiation Therapy 
Radiation Therapy Alone 
Radical Prostatectomy 
Primary ADT if <5 yr life 
expectancy 
Observe if <5 yr life 
expectancy 
ADT + Radiation Therapy 
Radiation Therapy + ADT 
Radical Prostatectomy + 
pelvic lymph node dissection 
*T2c added in 2004 
Treatment 
Three guideline-recommended treatment options are available in localized prostate 
cancer: surgery, radiation, and active surveillance (Figure 2.2, above). However, the 
appropriateness of each of these treatments depends on the patient’s prostate cancer recurrence 
risk and life expectancy (11). Surgery and radiation are recommended alternatives for all risk 
levels, but following men with active surveillance is a treatment option only for some men in 
certain circumstances. Men with low-risk disease who are treated by active surveillance, 
radiation therapy, or surgery are shown to have similar mortality (4). Thus, all three therapies 
are valid treatment options for the low-risk group, and active surveillance is thought to be 
underused (4, 12).  
Active surveillance sometimes is used interchangeably with expectant management and 
watchful waiting. All are therapeutic options that avoid definitive treatment, but they have 
distinct meanings, although the definitions have been fluid over time (4). The main distinction is 
that watchful waiting generally represents an approach in which the patient is not actively 
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followed but waits for symptoms to develop before treatment is considered, whereas active 
surveillance represents regular monitoring for changes in biopsy results, PSA levels, or tumor 
growth. Under NCCN definitions, active surveillance includes PSA testing and/or digital rectal 
exams and repeated biopsies at regular intervals to monitor disease progression. For men with 
an intermediate risk of recurrence, active surveillance is a recommended option only for those 
with less than 10 years of remaining life expectancy. For men with a high risk of recurrence, 
initial treatment with active surveillance in lieu of definitive treatment is not recommended, 
regardless of remaining life expectancy (12).  
A fourth treatment, ADT, has been the primary treatment for metastatic prostate cancer 
since the 1940s (23), originally as surgical castration and increasingly, almost exclusively, as 
medical castration in the form of gonadotropin-releasing hormone (GnRH) agonists. ADT was 
recommended for localized prostate cancer for a brief period, and even then, only under very 
narrow clinical circumstances. However, for most men during most of the last 20 years, ADT has 
not been recommended. Although ADT is effective at stopping cancer growth, among men with 
localized disease for whom there are multiple treatment alternatives, the benefits of primary 
ADT—the use of ADT in the absence of other definitive therapies—have not been shown to 
outweigh its harms.  
These harms include well-known side effects such as: hypotestosteronemia, impotence, 
weight gain, mood lability, gynecomastia, fatigue, lassitude, cognitive changes, loss of libido, and 
gastrointestinal and hematological effects (17, 24). In addition to the well-known side effects 
and resulting poor quality of life (7, 17, 24, 25), iatrogenic effects have been documented 
including increased incidence of cardiovascular risk factors (e.g., rising serum lipoproteins, 
insulin sensitivity, and obesity) and greater risk of cardiovascular disease, diabetes, 
osteoporosis, fractures, thromboembolic events, and cardiovascular death (26-28). Moreover, 
ADT has a limited window of effectiveness for tumor control; therefore, its initiation early in the 
disease trajectory limits future more definitive treatment options (29). 
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Surgical therapy for prostate cancer is generally defined as radical prostatectomy, which 
can be accomplished through open techniques (retropubic radical prostatectomy and radical 
perineal prostatectomy) or minimally invasive techniques such as minimally invasive radical 
prostatectomy (MIRP) (30). Radiation therapies can be either external beam radiation or 
surgically implanted radioactive pellets, known as brachytherapy. There are several modalities 
of external beam radiation including conventional two-dimensional radiation therapy, three-
dimensional conformal radiation therapy (3D CRT), intensity modulated radiation therapy 
(IMRT), stereotactic body radiation therapy, and proton therapy (30).  
Several other treatments are used in the initial treatment of prostate cancer, although at 
low frequency and without the recommendation of the NCCN (12, 31). In addition to ADT, 
chemotherapy is used as salvage therapy when initial therapy fails (22). Emerging therapies 
include cryosurgery and high-intensity focused ultrasound, the newest therapy currently 
available only through clinical trials. Although these therapies are not the focus of this 
dissertation, they are relevant in understanding the changes occurring in the initial treatment of 
prostate cancer. 
Preference- and Supply-sensitive Care in Localized Prostate Cancer  
Two distinct quality of care problems have emerged in localized prostate cancer care over 
the last two decades, partly because evidence for effective treatment is equivocal. Of the four 
treatments for prostate cancer, only three are currently guideline-recommended for localized 
disease: active surveillance, radical prostatectomy, and radiation therapy. Selecting among these 
options is preference-sensitive. That is, because no treatment provides a survival advantage, 
treatment selection should be based on the patients’ willingness to experience the unique 
adverse risk profile associated with the chosen therapy. However, one patient survey 
demonstrates the role of physicians in prostate treatment selection: 57% of patients cited a 
doctor’s suggestion as the most influential reason for selecting a prostate cancer treatment (32).  
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These preference-sensitive treatments are provided at the discretion of the treating physician. 
Because few demonstrated clinical and patient characteristics influence treatment choice, 
current quality improvement interventions focus on improving risk communication and 
increasing patient involvement in decision making in an effort to allow patient tolerance for the 
varied side effects to guide treatment choice. 
Less recognized in prostate cancer, however, is a second supply-sensitive quality 
problem that arose over the last two decades: the overuse of ADT. Despite increasing evidence 
that men with localized prostate cancer should not receive ADT (12, 22), its use is substantial 
among this population. Economic principles can be used to describe this quality problem. 
Supply-sensitive services are those for which the supply of a specific resource has a major 
influence on utilization rates. Variations in supply-sensitive care are due primarily to differences 
in local capacity, coupled with a payment system that ensures that existing capacity remains 
fully deployed (33). Situations in which supply and demand are not independently determined 
can also lead to supply-sensitive care (34, 35). Such situations occur commonly in medical 
decision making. Physicians, who must act dually as agents for themselves and for their 
patients, are not considered perfect agents in advising patients on their care. A perfect agent 
would recommend only the treatment a fully informed patient would demand (34). Instead, 
physicians, as providers of health services, are in a position of potential conflict of interest, in 
which they must choose between the most clinically efficacious treatment for the patient and the 
treatment that provides the best financial reward for the physician, given the marginal cost of 
treatment (36). Moreover, physicians set the quantity of health services needed and thus are 
able to induce demand, persuading patients to use services they do not need (36). Thus, in 
reimbursement environments in which the provision of the service exceeds the cost to deliver 
the service, supply-sensitive care can lead to overuse and physicians recommending treatments 
to patients who may not need them. 
14 
 
ADT Overuse in Localized Prostate Cancer 
ADT overuse in prostate cancer (i.e., the use of ADT in patients for whom it is not 
recommended) is widely believed to be an example of physician-induced demand. ADT use in 
localized prostate cancer grew steadily from the 1990s: the adjusted odds of medical ADT use 
increased almost seven fold between 1991 and 1999. By the year 2000, ADT use was seen in as 
many as 3.2% of all male Medicare beneficiaries (37, 38); and, by 2002, 44.9% of men diagnosed 
with prostate cancer, and for whom ADT was not recommended, received this treatment (39). 
ADT use peaked in 2003 and then sharply declined after 2005 (10, 40-42). Even though use 
declined in the last decade, 25.7% of men for whom it is not recommended still receive primary 
ADT (39, 40). 
The sharp declines in ADT observed in 2005 coincided with significant Medicare 
reimbursement changes for the administration of GnRH and has therefore been thought to be 
causal (42). Weight et al. provide a list of potential confounders to their observational study of 
declining ADT use in the full Medicare population (42), most of which are addressed by later 
studies that show persistent declines in the cohort for which ADT was not indicated (10, 39). 
That is, ADT use occurred among men for whom this treatment is not indicated—without 
changes in use among men for whom the treatment is clearly beneficial—suggesting that 
healthcare providers were indeed responsive to reimbursement changes in their treatment 
decisions (10, 39).  
However, no study evaluating the impact of the MMA to date has demonstrated that 
physicians were responding directly to the reimbursement changes. Notably, some evidence 
suggests that reimbursement changes may not have been responsible for changing ADT use. 
Trends in Canada and the U.S. Veterans Administration, health systems in which Medicare 
reimbursement changes would not affect use, have also experienced declining ADT use. In 
Canada, use of primary ADT has been declining since the 1990s (43). Declining use of ADT in 
the Veterans Administration Health System has been shown to mirror declines among Medicare 
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beneficiaries (44). Further, the most recent evidence suggests that even among Medicare 
beneficiaries in the United States, declines in overall ADT use among all prostate cancer 
patients, not just those with localized disease, appear to have begun prior to 2004 (40). 
As the use of primary ADT decreased up to 34% from 2003 to 2005 among men with 
incident localized prostate cancer (10, 39), active surveillance may have replaced ADT use. 
Recent analysis of Medicare claims suggest that for elderly men across all levels of prostate 
cancer risk and severity, reductions in ADT use occurred simultaneously with an increase in “no 
active therapy” (40). Moreover, the magnitude of the change was similar—a 44% decrease in 
ADT use accompanied by a 44% increase in no active therapy. These data suggest that the 
quality of care for men with localized prostate cancer may be improving. Other trends in 
prostate cancer patterns of care include the shifting of surgical and radiation therapy modalities. 
Although overall rates of surgery and radiation have remained constant, minimally invasive 
surgery has begun to offset closed surgical techniques, and newer radiation modalities such as  
IMRT and proton therapy have begun to replace other delivery methods (40). However, whether 
quality of care actually is improving depends on the patients’ recurrence risk and what 
treatments have replaced ADT. 
In addition, it is not known whether these changes in patterns of care affected all 
patients equally or were uniform among all types of providers. While ADT is underused among 
African-American men with metastatic prostate cancer (41), it is overused among African-
American men with localized prostate cancer (45). Whether African-American men were 
affected by changes in ADT use to the same degree as white men is unknown.  
Contributors to Changing Patterns of Care 
Several factors likely contributed to ADT’s rise in use (Figure 2.3). First, since its advent 
in 1986, widespread use of PSA screening led to a large increase in the number of men 
diagnosed with low- and intermediate-risk localized prostate cancer. The lack of severity of their 
disease may have not yet been fully appreciated, leading to the application of treatments known 
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to be effective in metastatic disease. In addition, many of these men, which some consider to 
have been overdiagnosed (46), may not have been candidates for surgical therapy, the main 
therapy for localized disease at the time. Secondly, aggressive (and illegal) pharmaceutical 
marketing practices coupled with liberal Medicare reimbursement for Part B drugs made ADT 
administration extremely profitable for physicians administering the drug (47, 48).  
As with its rise in use, several factors likely contributed to the decline in ADT use. First, 
because Medicare reimbursement for ADT and other physician-administered cancer drugs far 
exceeded physician costs (49), the Medicare Modernization Act of 2003 revised reimbursement 
policy for all Part B drugs (50), reducing the profitability of ADT administration in two phases. 
Effective January 1, 2004, Medicare changed reimbursement for Part B drugs from 95% of the 
average wholesale price to 85% of the wholesale price. Effective January 1, 2005, the formula 
was changed again to reimburse physicians at 106% of the average national sales price of the 
previous two quarters (47). Together these changes were associated with a 65% decrease in 
Medicare reimbursement for medical ADT from 2003 to 2005 (47). The second change is 
Figure 2.3. Timeline of Increasing ADT Use 
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thought to have cut reimbursement the most (51). However, changes in prescribing began at 
least 1 month prior to Medicare implementation in anticipation of the cuts, since physicians 
purchase the drugs they administer to patients in advance (51). 
Secondly, although affecting only a small group of patients, clinical practice guidelines 
for the treatment of high-risk localized prostate cancer also changed during the same time. From 
2000 to 2004, ADT was recommended for men with less than 5 years life expectancy whose risk 
for prostate cancer recurrence was categorized as high (20). This recommendation was dropped 
in 2004 (12). Finally, evidence of the long-term harms of ADT that predated guideline changes 
began appearing in the 1990s; thus, physicians may have been responding to new harm 
calculations and proceeding more cautiously (43).   
Reimbursement as a Quality of Care Intervention 
Although many questions remain about the cause of declining use, ADT overuse remains 
a serious quality problem, and addressing it and other overuse problems through 
reimbursement policy is a promising strategy. Although ADT use has declined since 2003, 
25.7% of men for whom it is not recommended currently receive ADT (39). Reimbursement 
policy, if it were responsible for the reduction in overuse, is a promising quality intervention. 
The 34% reduction in ADT use attributed to the policy is large relative to intensive behavioral 
and systems interventions designed to improve quality of care, which are shown to induce 
median changes of only 10% (52). Further, pay-for-performance is increasingly advocated to 
improve quality (53). However, despite emerging interest in provider responsiveness to 
reimbursement policies, evidence is lacking with regard to whether and how these policies might 
work (54, 55).  
Fortunately, opportunities exist to explore further the role of reimbursement in ADT 
overuse. Prior to MMA implementation and during a period of guideline stability (2000–2004), 
substantial variation in ADT reimbursement existed within Medicare. Although Congress sets 
reimbursement policy nationally, national policy is implemented locally among the contractors 
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responsible for paying Medicare claims—fiscal intermediaries for Part A claims and carriers for 
Part B claims. Although geographically fixed, carriers are regional and do not have uniform 
policies regarding reimbursements (56). In particular, from 1997 to October 2002, Medicare 
carriers were responsible for translating Part B drug Healthcare Common Procedure Coding 
System (HCPCS) claims into National Drug Code (NDC) indices (57). Although some HCPCS 
had only one equivalent NDC, others had 10 or more matches in 2000, resulting in substantial 
variation among carriers (49). The GnRH agonist leuprolide acetate was one of the drugs 
identified that had a more than 10% variation in reimbursement across Medicare. In contrast, 
another GnRH agonist, goserelin acetate, was uniformly reimbursed across the carriers (49). In 
addition to the variability among regional carriers, reimbursements changed at different rates 
over time based on revisions to the average wholesale price for specific NDCs (57). Exploiting 
this variation in ADT reimbursement enables one to isolate the effect of ADT reimbursement 
changes in urologists’ use of ADT between 2000 and 2003.  
Determinants of ADT Overuse 
In general, overuse is believed to derive from both provider and patient demand (35). 
Providers may suggest non-indicated treatments in the course of 1) early innovation; 2) 
practicing defensive medicine, or 3) inducing demand to increase their profitability. Patient 
demand for specific treatments arises from health education efforts, direct-to-consumer 
advertising, prior treatment experiences (such as with antibiotics), and the treatment 
experiences of others.  
Although clinical characteristics and patient preferences may have influenced the 
medical decision to prescribe ADT to men with localized prostate cancer, there is little evidence 
to support this supposition. In fact, most variation in prostate cancer treatment has been 
attributed to the physician. Research in the Cancer of the Prostate Strategic Urologic Research 
Endeavor (CaPSURE) cohort, a national registry of prostate cancer treatment, found high 
variation among healthcare practices in the selection of therapy (31). The wide variations in care 
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delivered were not explained by disease characteristics as measured by the CAPRA score, an 
indicator of disease severity. 
In particular, variation in ADT use in the 1990s can be explained by physician 
characteristics. A study among urologists identified in the Surveillance, Epidemiology, and End 
Results-linked Medicare claims database found substantial variation in ADT use by provider. 
The authors partitioned the variance by three categories and found that only 4% was due to 
patient characteristics and 10% was due to tumor characteristics, whereas the largest part of the 
variance that could be explained (23%) was due to the urologist (58).  
Patient reports support these findings: 57% of men report their physician as being most 
influential in their prostate cancer treatment decision (32). Thus, understanding provider 
characteristics associated with ADT overuse are crucial to developing interventions for its 
elimination (59).  
Urologist Characteristics Associated with ADT Overuse  
Urologists provide the majority of prostate cancer care as they perform the biopsy 
necessary for confirming the prostate cancer diagnosis. Although patients are referred to 
medical oncologists in late-stage disease and increasingly to radiation oncologists in localized 
disease, most primary ADT is prescribed by urologists (58). Among fee-for-service Medicare 
patients, overall ADT use (across all recurrence risk categories) between 1992 and 2002 was 
associated with female, non-board–certified, and non-academically affiliated urologists. 
However, among patients for whom the benefit of ADT was uncertain, physician characteristics 
associated with ADT overuse shifted over time. Both the least and most clinically experienced 
physicians prescribed more ADT than their moderately experienced peers. Across the period of 
1992 to 2002, physicians with no or minor academic affiliation were more likely to overuse ADT, 
and increasing panel size was associated with greater odds of overuse. Lack of strong academic 
affiliation was the strongest predictor of ADT overuse from 1992–1995, but lack of board 
certification, lack of academic affiliation, and increasing panel size did increase the odds of ADT 
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overuse by the 1996–2002 period. Together, these patterns of ADT use suggest that either 
physicians with greater knowledge and professional affiliations were more cautious in adopting 
ADT or that non-academic physicians were more responsive to financial incentives (60).  
Although this single study provides important information regarding ADT use and 
overuse, no research to date describes characteristics associated with change in overuse. 
Previous studies clarify the clinical population for which ADT use declined (10, 39). Sharp 
declines in ADT use occurred among men for whom it is not indicated, without changes in use 
among men for whom the treatment is clearly beneficial. However, no information is available 
that indicates whether the change was universal among all physicians or occurred among 
isolated pockets of physicians or practices. Nor have the characteristics of physicians who 
eliminated overuse and those who did not been explained. 
Clinical Experience as an Indicator of Quality of Care 
Although counterintuitive, clinical experience has been found to be associated with lower 
quality of care (61). Physicians with greater amounts of clinical experience are believed to 
neglect maintenance of their technical knowledge, missing changes in clinical practice 
guidelines and emerging technology. These physicians experience clinical inertia, practicing as 
they always have done. For prostate cancer, established physicians may be less likely to be aware 
of and responsive to emerging evidence and recommendations against ADT in men with low-
risk prostate disease. In addition, physicians later in their career are thought to be less 
responsive to reimbursement cuts, because they are more likely to have repaid educational and 
business loans, personal mortgages, and their children’s college expenses (57).  
A better understanding of the effects of clinical experience on efforts to address overuse 
among urologists is important not only because of the harms already described, but also because 
recent trends suggest urologists are staying in practice past traditional retirement age to address 
perceived physician shortages (62). If end of career issues influence quality of care, we can 
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expect the magnitude of the problem to persist, and further reimbursement cuts are unlikely to 
address the problem.  
Reimbursement Responsiveness 
Little is known about what might make providers more or less responsive to 
reimbursement changes. Nonetheless, variation in responsiveness to financial disincentives has 
been documented (35, 63). Previous observations of fee freezes or reimbursement cuts has 
shown that physicians generally increase the quantity of services provided (36, 51, 64, 65). This 
is so well established that reimbursement policy planners usually compensate for a set increase 
in volume when estimating the impact of a reimbursement cut (66). However, this volume 
response has not been demonstrated uniformly (36). Moreover, reasons for these variations 
have not been adequately explained (63). The proposed research fills this gap by addressing 
factors associated with variation in response to reimbursement changes.   
Practice Factors Associated with Patterns of Care 
The prostate cancer treatment decision is strongly associated with preferences of the 
treating physician (58, 60, 67). However, different models of practice organization may affect 
responsiveness to reimbursement by shaping the kinds of care that can be substituted when 
certain therapeutic options are discounted. In particular, physicians in certain types of multi-
specialty practices are expected to have a greater number of treatment options to offer their 
patients and subsequently be more likely to lower ADT use. However, it is not known how 
different models of multi-specialty group practice organization influence changes in care.  
Depending on the specialty configuration, one might expect different degrees of change 
in ADT use. For example, one might expect healthcare providers in comprehensive 
multispecialty practices to be insulated from reimbursement policy as they are more likely to 
provide patient-centered care, coordinate decision making, and optimize informed decision 
making. Therefore, they would be more likely to have low levels of baseline ADT overuse and to 
maintain those low levels over time. Single-specialty group practices may have high levels of 
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baseline use and increase their overuse of ADT, as that strategy may be their only means of 
replacing revenue. 
An emerging type of multi-specialty practice organization, in which a urology group 
practice hires a radiation oncologist to provide IMRT, may have a different response. Because of 
the substantial investment required to build IMRT facilities, this treatment is well reimbursed. 
However, to justify the investment, a certain number of referring urologists are needed to 
support the optimal use of the equipment. Thus, a new urologist-centric practice organization 
has developed (68, 69). Subsequently, IMRT is more readily available in select group practices 
that organize in this way and may lead to physician inducement (69, 70). Physicians in 
urologist-centric multi-specialty practices might have the greatest levels of early ADT use and be 
very responsive to reimbursement policy changes because they have other options for replacing 
revenue. However, it not known whether physicians in these types of practices were more likely 
to replace ADT use with IMRT and less likely to adopt active surveillance. 
Significance and Innovation 
The proposed research is significant in several respects: it addresses a prevalent 
condition for which the treatment varies by patient race; it investigates the mechanisms by 
which federal reimbursement policy designed to reduce healthcare costs may also improve 
quality of care; and it will improve understanding of the moderating effects on reimbursement 
policy. Moreover, it will enable future quality of care interventions to target a harmful, costly, 
and persistent problem. Localized prostate cancer treatment quality drastically improved in 
2000s. However, the problem remains that 25.7% of men for whom it is not recommended still 
receive ADT, and racial differences may persist. Continued efforts are needed to further 
understand barriers and facilitators to change. The relative contributions of physician and 
practice factors to responsiveness to reimbursement disincentives are not known, but efforts to 
reach remaining urologists are critical. Although overuse remains substantial, the 34% 
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reduction in use from 2003 to 2005 provides an opportunity to identify facilitators and barriers 
to treatment discontinuation. 
Moreover, the approach to the proposed research is innovative. This study addresses a 
poorly studied quality of care issue: overuse. Approximately 30% to 40% of healthcare spending 
in the U.S. has been attributed to overuse, the provision of unnecessary care or care for which 
the harms outweigh the benefits (71-73). Overuse results in patient harms, health disparities and 
waste in a healthcare system already stretched to capacity (73). As a result, overuse recently has 
been designated one of six national priorities in the National Quality Strategy, a strategic plan 
mandated by the 2010 Patient Protections and Affordable Care Act (74). Overuse is particularly 
important to address within the context of cancer care, because changes in evidence supporting 
cancer screening and control increasingly result in situations in which providers and patients 
must alter their behavior to abandon established practices. Thus, strategies to address overuse 
in cancer care are becoming increasingly relevant.  
Despite the recent spotlight on overuse as a significant quality problem, relatively little 
research actually focuses on this problem (71, 75). Few quality measures assess overuse, and 
most of the research that is available describes the degree to which overuse exists in a few 
distinct clinical areas. Although broad strategies such as academic detailing have been used 
successfully to limit prescribing (76), few studies evaluate interventions designed to limit 
overuse. As a whole, the field lacks overarching models that consolidate empirical findings into 
principals for addressing the problem. Even reviews of successful quality improvement 
strategies do not differentiate whether the goal is to stop an established behavior or start a new 
one (77-79). 
Yet overuse is a distinct quality problem with potentially different determinants than 
underuse. Whereas adopting new behaviors requires that the new behavior be: 1) advantageous 
to the intended user; 2) compatible with the users’ culture and values; 3) minimally complex; 4) 
easy to test prior to adoption; and 5) easy to observe prior to adoption (80), little is known about 
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principles of relinquishing established behaviors. Thus, interventions to reduce overuse may be 
quite different in their structure as well as their goals (76, 81). Implementation research 
suggests the factors that facilitate adoption of new technology, but we know little about factors 
that facilitate or impede discontinuation of disproven technology (Rogers 2003).  
In summary, the current healthcare environment is faced with reducing costs while 
increasing healthcare quality. Yet our tool kit to address these simultaneously is limited. Quality 
interventions are known to work modestly, and little effort has been made to delineate the 
contexts in which they may be successful. Misaligned incentives are cited as a substantial 
impediment to quality care (82), but little research focuses on how change in reimbursement 
policy affects quality. The proposed research will address these problems and identify ways to 
improve quality while reducing overall healthcare costs, addressing key national priorities to 
improve quality of care for all Americans.   
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CHAPTER 3 STUDY DESIGN AND METHODS 
Overview and Rationale 
The three aims of this dissertation are executed as longitudinal, retrospective analyses of 
three distinct cohorts of men diagnosed with incident adenocarcinoma of the prostate and 
treated by physicians participating in fee-for-service Medicare. Aim 2 additionally exploits a 
natural experiment producing exogenous variation in reimbursement and allows for difference-
in-difference design features. Data come from SEER-linked Medicare claims and the American 
Medical Association’s physician Masterfile. Three unique study cohorts are formed including 
patients diagnosed from 2000–2007 (Aim 1); 2000–2003 (Aim 2); 2005–2007 (Aim 3); and 
their treating physicians. Aim 1 uses the binary outcome ADT use measured at the patient level. 
Aim 2 also uses the binary outcome ADT use, also measured at the patient level. Aim 3 uses the 
binary outcome NCCN guideline concordance measured at the patient level. Aim 1 analyses 
include the explanatory variables time in practice, a dichotomous measure of physicians’ length 
of time since graduating from medical school, and group practice type, a categorical indicator of 
the multi-specialty organization of urology group practices. In Aim 2, the explanatory variables 
are reimbursement generosity, an index that measures excess reimbursement relative to the 
national average spending on ADT, and group practice type. The explanatory variables of Aim 3 
is pre-MMA ADT use, measured as a physicians’ average ADT use among non-metastatic T1 and 
T2 well- and moderately differentiated incident prostate cancer patients between 2000 and 
2003, and patient race, a categorical indicator of five race/ethnic groups. Each of the three 
analyses uses multilevel mixed logistic regression to control for tumor, patient, physician, 
practice, and environmental characteristics and to account for clustering of patients within 
physician and physicians across time.  
26 
 
Conceptual Foundation 
The overall model of medical decision making that underlies this research (Figure 3.1) is 
derived from Andersen and Aday’s Behavioral Model of Health Service Use (83, 84), which 
identifies the external, macro-, and micro-level factors that affect processes of care. The 
Behavioral Model of Health Service Use is adapted to consider the influences on medical 
decision making from the healthcare provider’s perspective. The conceptual model is further 
informed by more recent efforts to incorporate economic theory into medical decision making 
(85) and draws more directly from economic and behavioral response theory to conceptualize 
how both the reimbursement context and reimbursement changes may influence physicians to 
induce demand for health services and respond to reimbursement changes (64, 86). 
 
 
Outcomes. In this physician-centric model of medical decision making, the ultimate 
outcomes are process outcomes—what care is delivered and whether it is guideline-concordant 
Figure 3.1. Conceptual Model 
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(85). More distal (and less controllable) outcomes from the physician perspective are the patient 
and societal outcomes traditionally studied. Quality of care is judged relative to the concordance 
of the care that is delivered with national prostate cancer guidelines.  
Medical Decision. The outcome guideline-concordant care is derived from the medical 
decision that is made for each patient. Although care delivered, as measured in claims data, may 
not fully represent the care recommended, it does represent the care recommended by the 
physician that the patient consented to receive. For men with localized prostate cancer there is 
an array of treatment options including surgery, radiation therapy, active surveillance, ADT, no 
treatment, and several other treatments including combinations of these frequently used 
treatments and other less frequently used treatments such as cryosurgery and high-intensity 
focused ultrasound.  
Multiple patient-, provider-, practice-, and environmental-level factors directly or 
indirectly influence the medical decision. 
Patient Factors. Patient factors influence each medical decision through both clinical 
presentation and personal circumstances and preferences. Patients present with prostate cancer 
of varying levels of severity, which warrant different treatment approaches. However, their life 
expectancy, other health concerns, and physical and emotional stamina may all be considered in 
the treatment decision, as some therapies have different cost/benefit trajectories or require 
different levels of commitment to complete. Different therapies also require varying levels of 
social support to either complete treatment or endure treatment side effects; thus the patients’ 
level of social support and community resources are also important. Physicians also may 
integrate their patients’ preferences for the treatment options presented in the medical decision. 
Physician Factors. Physician’s treatment decisions and willingness to change prescribing 
behavior are influenced by their own personal perceptions of disease and treatment risk, their 
personal valuation of individual patients, and their personal comfort with inducing demand. 
Economic theory suggests that physicians’ treatment decisions are also influenced by their 
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economic self-interest. Physicians act as imperfect agents for their patients. They are ethically 
bound to choose the best treatment for their patients, but they also must balance their own 
financial solvency against the “costs” of the treatments offered. Because they rely on the delivery 
of healthcare for their livelihood and well-being, they may respond to incentives from the 
healthcare delivery system to optimize their income. In balancing these varying influences, 
physicians may be more motivated to treat African-American patients medically with ADT if 
they perceive that these patients are at higher risk of death from their disease and if they 
perceive that these patients are not candidates for surgery or radiation therapy. Physicians’ 
medical decisions are also influenced by professional characteristics, such as medical 
professionalization, specialty professionalization, and experience (55).  
Practice Factors. Medical decisions also are influenced by the practice milieu indirectly 
shaping the physicians’ opportunities for treatment and behavior change, thereby shifting their 
perspectives of disease and treatment risk and their personal comfort with inducing demand. 
The size of the practice, number and types of other physicians in the environment, types and 
volume of patients seen in the practice, and compensation arrangements all contribute to the 
weighting of patient and clinical factors for any treatment decision. The specialty organization of 
the practice in particular is expected to contribute to the treatment decision. Multi-disciplinary 
teams have been shown to improve treatment outcomes (87, 88) and are generally believed to 
improve the quality of cancer care by increasing coordination, communication, and decision 
making (89). However, some multidisciplinary groups are organized around particular 
treatment modalities, which may lead to inducement of certain services the practices are 
organized to deliver (69), possibly at the expense of other treatment options.  
Compensation arrangements include both the physician’s compensation structure as 
well as the physicians’ and practices’ combination of healthcare payers and plans that affect the 
way care is compensated. Depending on how they are paid, individual physicians may balance 
varying amounts of leisure time and personal income against their moral and professional 
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obligation to do no harm. Under fee-for-service payment arrangements, physicians are paid 
based on the quantity of service provided, and their income increases when they provide more 
services (when cost for providing the services remains the same). Physicians may therefore 
recommend more services to optimize income (36). However, the extent to which they do this is 
also influenced by the relative influence of the reimbursement policies of a particular payer. 
Providers see patients insured by a variety of payers, each with different payment levels. 
Although physicians are thought to optimize income (whether stopping at an income target or 
increasing to a maximum), response to change in reimbursement may produce varying 
behaviors (36). Although it seems that physicians would induce demand when faced with 
decreases in reimbursement, instead multiple behavioral responses can result from a decrease 
in reimbursement: providers can increase, replace, or drop the discounted service (36).  
Environmental Factors. Medical decisions are also influenced by environmental factors. 
Within the prostate cancer treatment decision, environmental factors include the 
reimbursement policy of individual payers, especially Medicare; local coverage determinations 
of the Medicare fiscal intermediaries; business trends that affect the structure of treating 
practices (86); state policies that affect practice structures; research that provides evidence of 
harms and informs clinical practice guidelines (which in turn defines the appropriate patient for 
treatment); and, the community practice patterns that are informed by and influence the 
individual physicians’ practice styles.  
Specific Aims 
Following from this conceptual model and evidence from the published literature 
presented above are testable hypotheses, organized into the specific aims proposed in this 
dissertation. 
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Aim 1: Estimate the degree to which physician characteristics are associated 
with changes in ADT overuse. 
Hypothesis 1A: Among urologists treating ADT-ineligible men from 2000 to 2009, 
urologists with more time in practice will be less likely to reduce ADT overuse following 
reimbursement changes. 
Hypothesis 1B: Among urologists in group practice treating ADT-ineligible men from 
2000 to 2008, urologists will respond to reimbursement changes uniformly. 
Aim 2: Estimate the degree to which reimbursement changes are associated with 
ADT overuse. 
Hypothesis 2A: Among urologists of ADT-ineligible prostate cancer patients, 
reimbursement will be positively associated with ADT overuse.  
Hypothesis 2B: Among urology group practices, physicians in single-specialty group 
practice will be more likely to overuse ADT than physicians in multi-specialty group 
practice. 
Aim 3: Assess the impact of pre-MMA ADT overuse on the quality of post-MMA 
prostate cancer treatment for localized prostate cancer. 
Hypothesis 3A: Among clinically localized prostate cancer patients, physicians’ pre-
MMA ADT overuse will be positively associated with receipt of guideline-concordant 
care in the post-MMA period. 
Hypothesis 3B: Patterns of care associated with changes in ADT use will be similar for 
African-American men compared to white men, resulting in similar levels of guideline 
concordance for African-American men. 
Hypothesis 3C: Pre-MMA ADT overuse will be negatively associated with uptake of 
new treatment modalities. 
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Data 
This study links two datasets to accomplish its aims: 1) the most recent Surveillance, 
Epidemiology and End Results (SEER)-linked Medicare database, co-developed by the National 
Cancer Institute (NCI) and the Centers for Medicare and Medicaid Services (CMS), and 2) data 
on physicians and practices from the American Medical Association.  
Surveillance, Epidemiology, and End Results-Medicare Linked Database (SEER-
Medicare)  
The SEER registry is a collection of 17 population-based registries of all diagnosed 
cancers in 14 geographic areas, currently representing 26% of the U.S. population (90). Patients 
in the SEER 17 grouping are drawn from nine states (California (in 4 registries), New Mexico, 
Hawaii, Utah, Connecticut, Iowa, Kentucky, Louisiana, and New Jersey); three metropolitan 
areas (Metro Atlanta, Seattle and Detroit); one rural area (rural Georgia); and one ethnic group 
population registry (Alaska Natives). Although the SEER population tends to be more urban and 
has a higher proportion of foreign-born persons than the general U.S. population, SEER data 
are comparable with regard to measures of poverty and education. As of the 2000 census, when 
the SEER registry included 11 registries, it represented 26.3% of the African-American 
population in the U.S. (90). SEER data include patient demographics, primary tumor site, 
morphology, stage at diagnosis, first course of treatment, and vital status follow-up. Routine 
quality control activities ensure highly reliable data (90).  
SEER data from 16 of the registries are linked to Medicare data. Medicare is an 
administrative claims database covering hospital services, physician services, some drug 
therapy, and other medical services for more than 97% of the U.S. population 65 years of age 
and older. Provided by CMS, Medicare claims are linked to registry data and packaged as de-
identified SEER-Medicare files linked by a SEER case identifier (91). Thus, for each elderly 
prostate cancer patient identified in one of the SEER registries and covered by Medicare fee-for-
service, virtually complete claims for treatment are available. 
32 
 
We used Medicare Provider Analysis and Review (MEDPAR), outpatient claims, durable 
medical equipment (DME), and carrier files for sample selection, outcome, and treating 
provider identification, but used only carrier files to study response to reimbursement in Aim 2, 
because other files do not identify physicians, reimbursement, or both. 
The American Medical Association (AMA) Masterfile  
The AMA Masterfile is a comprehensive database of physician and practice 
characteristics, covering approximately 800,000 member and non-member practicing, retired, 
and deceased physicians in the U.S. Most data originate from training records collected annually 
with 96%–98% response rates. American Board of Medical Specialties certification data are 
collected annually. These data are confirmed and supplemented by annual surveys of one-third 
of physicians each year (response rate approximately 40%) and other physician regulatory 
agencies (92). Prostate cancer patients’ physicians were identified within the Medicare data by 
Unique Physician Identification Number (UPIN) and sent to AMA to provide a matched file of 
physician personal characteristics. Physician matching has been reported to be 98.7% complete 
and consistent across SEER site and geographic areas for the six most common cancers, 
including prostate cancer (92). 
Although some practice-level data are available within the AMA Masterfile, additional 
practice data are available for a subset of group practices. Data are collected by survey every 3 
years. Data completion in this subset ranges from 20% to 100% complete and for many variables 
approximates the proportion of urologists in group practice.  
Study Sample and Inclusion/Exclusion Criteria 
For Aim 1, we identified all men diagnosed with incident adenocarcinoma of the prostate 
between January 1, 2000 and December 31, 2007. Only patients experiencing their first and 
only cancer, as indicated by SEER, were included. We excluded patients whose comorbidities 
could not be ascertained and/or whose initial treatment could not be ascertained including 
those who were younger than 66 years and lacking a complete year of claims; diagnosed at 
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autopsy, by death certificate, or at a nursing/convalescent facility; not enrolled in fee-for-service 
(defined as continuous Part A and B coverage and not in a Health Maintenance Organization 
(HMO) for at least 12 months post diagnosis; died within 12 months of diagnosis; and/or 
diagnosed in Louisiana (due to disruptions in health services cause by Hurricane Katrina). The 
Tumor Node Metastasis (TNM) staging system was used to restrict the cohort conservatively to 
patients for whom ADT is not a NCCN guideline-recommended treatment across the study 
period. Men in the ADT-ineligible sample were those who lacked evidence of nodal or metastatic 
involvement and had no greater than unilateral, stage T2 tumors and World Health 
Organization grades 1–2 (10). Thus, we excluded men diagnosed with 1) T1 or T2 cancers with 
Gleason scores 8–10; 2) T2b tumors before 2002 when the staging definition changed; 3) T2c 
tumors after 2002 when the category was added; or, 4) T3a tumors. Men receiving external 
beam radiation therapy were also excluded, because the appropriateness of their ADT receipt 
could not be ascertained. Treating physicians were identified from claims. After limiting claims 
to those submitted for initial prostate cancer treatment, the physician responsible for the 
majority of prostate cancer-related treatment claims was considered the treating physician. 
For Aim 2, we identified all patients in the SEER registries who had an incident 
diagnosis of adenocarcinoma of the prostate (ICD-9 diagnosis code 185 and histology code 
8140) between January 1, 2000 and December 31, 2002. Only patients experiencing prostate 
cancer as their first and only cancer, as identified by SEER, were included. We excluded patients 
younger than 66 years of age at diagnosis because their comorbidities could not be ascertained. 
We excluded those whose initial treatment decision could not be ascertained because they 
lacked observation throughout the full treatment window and were 1) were diagnosed at 
autopsy, death certificate, or at a nursing/convalescent facility; 2) died within 12 months of 
diagnosis; 3) were not continuously enrolled in fee-for-service (defined as Part A and B coverage 
and not in an HMO for 12 months post diagnosis); or 4) had no treatment claims. The TNM 
staging system was used to restrict the patient sample to those ineligible for ADT. Following 
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previous work, men in the ADT-ineligible sample were limited to those who lacked evidence of 
nodal or metastatic involvement and who had no greater than unilateral, stage T2 tumors and 
WHO grades 1–2 (10). In addition, we excluded men with less than 5 years actuarial life 
expectancy following an algorithm used previously (93), because NCCN guidelines for this 
period allowed for the use of primary ADT in men with limited life expectancy (20, 93). Because 
urologists prescribe 95% of primary ADT to localized prostate cancer patients (37, 93), we 
excluded non-urologists based on specialty information in the AMA data.  
In Aim 3, we identified all men diagnosed with incident adenocarcinoma of the prostate 
between January 1, 2005 and December 31, 2007. Only patients experiencing their first and only 
cancer were included. We excluded patients whose comorbidities and/or initial treatment could 
not be ascertained including those who were younger than 66 years; diagnosed at autopsy, death 
certificate, or at a nursing/convalescent facility; not enrolled in fee-for-service (defined as 
continuous Part A and B coverage and not in an HMO for at least 12 months post diagnosis); or 
died within 12 months of diagnosis. The TNM staging system was used to restrict the cohort to 
men with clinically localized prostate cancer. We excluded men with 1) tumors clinically staged 
T3b or greater; 2) any evidence of nodal involvement; or, 3) any evidence of metastases. 
Treating physicians were identified in Medicare claims. After limiting claims to those submitted 
for initial prostate cancer treatment and identifying the primary therapy received, the physician 
responsible for the most primary therapy treatment claims was considered the treating 
physician. 
Physician Assignment 
Treating physicians were identified from claims files. After limiting claims to those 
submitted for primary prostate cancer treatment, the provider responsible for the most initial 
treatment claims was considered the treating provider, consistent with most studies identifying 
providers (28). Providers identified in claims were matched by encrypted Unique Physician 
Identifier Number (UPIN) or National Provider Identifier (NPI) to AMA data, a process which 
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excluded non-physician providers. Because we excluded non-urologists as treating providers, no 
patients receiving external beam radiation were included. 
Variables and Measurement 
Dependent Variables 
Aims 1 and 2 use ADT use as the dependent variable. ADT in conjunction with radiation 
is recommended therapy for some men with high-risk disease; however, ADT alone is not 
recommended. Thus, the outcome, primary ADT use, is a binary variable defined for each 
patient as initial treatment claim for a Healthcare Common Procedure Coding System (HCPCS) 
code for medical ADT administered within 1 year from the SEER date of diagnosis without 
another non-surveillance prostate treatment administered within the treatment window. Non-
surveillance treatments included orchiectomy, radical prostatectomy, all forms of radiation 
therapy planned or delivered (brachytherapy, conformal, IMRT, proton therapy), 
chemotherapy, and cryotherapy. All claims files were used to identify treatment delivered. Codes 
for other hormonal treatments were not considered part of the primary ADT definition. Table 
3.1 lists procedure codes used. 
Table 3.1. Treatment Claims 
Treatment ICD-9 Codes CPT/HCPCS Codes 
Active Surveillance-
Standard 
 [84152-84154, G0103 (PSA) OR 
G0102 (DRE)] + 99201-99215 
(E&M)  
Active Surveillance-
NCCN 
60.1, 60.11 (biopsy) [84152-84154, G0103 (PSA) OR 
G0102 (DRE) OR + 99201-99215 
(E&M)] + 55700, 55705, 55706, 
76942, 10021, 10022, 88172, 88173, 
C1710, or G0416-9 (Biopsy) 
Radical Prostatectomy 60.4, 60.5, 60.60-60.69 55801, 55810, 55812, 55815, 55821, 
55831, 55840, 55842, 55845, 00865 
Minimally Invasive 
Radical Prostatectomy 
 55866 
Radiation Planning and 
Management 
 77261, 77262, 77263, 77299, 77427, 
77431, 77499 
Conformal Radiation Revenue center 330, 333, 339 77310, 77315, 77321, 77407, 77408, 
77409, 77411, 77412, 77413, 77414, 
77416 
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Brachytherapy 92.20, 92.27, 92.28 55860, 55875, 55876, 76873, 77326, 
77327, 77328, 77761, 77762, 77763, 
77776, 77777, 77778, 77781, 77782, 
77783, 77784, 77785, 77786, 77787, 
77789, 77790, 77799, Q3001, A9527, 
C1715, C1716, C1717, C1719, 
C1728,C2616, C2634, C2635, 
C2636, C2637, C2638, C2639, 
C2640, C2641, C2642, C2643, 
C2698, C2699, C9725, 0182T 
IMRT  77301, 77338, 77418, 0073T, G0174, 
G0178 
Proton Therapy 92.24, 92.26 77380, 77381, 77520, 77522, 77523, 
77525 
Androgen Deprivation 
Therapy (GnRH 
agonist) 
 J0128, J9202, J1950, J9217, J9218, 
J9219, J3315, J9225, J9226 or 
C9216, C9430, S0165 
Orchiectomy 62.3, 62.41, 62.42 54520, 54522, 54530 54535, or 
54690 
Other 99.25, V58.1x, V66.2, V67.2 
(chemotherapy); 92.24, 92.26 
(other radiation); 60.21, 60.29 
(other prostatectomy); 92.21, 
92.22, 9233, 92.25, 92.29, V58.0, 
V6.61, V6.71 (other radiation) 
55873 (cryosurgery), 
96400-96549, Q0083-Q0085 
(chemotherapy); J9999 (unspecified); 
77432, 77435 (stereotactic radiation); 
77371, 77372, 77373, 0082T, 0083T, 
G0251, 77750-60, 77774, 77775, 
77779, 77780, 77791-98, 77305, 
77402, 77403, 77404, 77406, 77423, 
G0339, G0340 (other radiation) 
Abbreviations: ICD-9: International Classification of Diseases, 9th Revision; CPT: Current 
Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; PSA: Prostate-
specific Antigen; E&M: Evaluation and Management 
 
Because reimbursement may affect the prescription of both primary ADT and adjuvant 
ADT, we also created an outcome variable for Aim 2 sensitivity analysis that captured any ADT 
used alone or in conjunction with any other therapy. Neither primary nor adjuvant ADT was 
guideline-recommended for our cohort during the study period. 
The binary outcome used in Aim 3, guideline concordance, was derived from the 2004 
NCCN prostate cancer treatment algorithm effective throughout the study period (12). The 
algorithm stratifies patients by stage, grade, PSA, and in some cases, the presence of multiple 
risk factors. The low-risk group includes men with T1–2a stage, Gleason grade 2–6, and PSA 
<10 ng/mL. The intermediate-risk group includes men with T2b or T2c stage, Gleason grade 7, 
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or PSA 10–20 ng/mL. The high-risk group includes men with PSA >20 ng/mL, Gleason grade 
>7, or stage T3a. Concordant treatments are assigned for each risk category. To identify the 
initial treatment received, we reviewed patients’ claims to categorize initial treatment into one 
of five mutually exclusive options: 1) active surveillance; 2) radiation therapy; 3) radical 
prostatectomy; 4) primary ADT; and, 5) other less frequently used treatments (See Table 3.1 
above for relevant codes). Where two treatment modalities were possible, we further split the 
category to distinguish them for some analyses, but excluded non-concordant modalities based 
on NCCN recommendations. Only treatment received within 18 months of diagnosis and only 
the first treatment following diagnosis was considered as the initial treatment decision, except 
where ADT was considered adjuvant to another therapy. Although SEER registry data and 
Medicare claims are roughly comparable for radiation therapy and surgery (94, 95), and their 
use in combination ascertains additional treatment, SEER data tend to underestimate use of 
medical therapies including ADT (37). In addition, registry data may inaccurately represent 
active surveillance (96). Thus, for consistency, treatment was derived from Medicare claims 
only. Each treatment is defined as follows: 
• Active surveillance was defined in two ways: 1) standard surveillance was defined as 
at least one claim for PSA or digital rectal exam (DRE), at least two prostate cancer 
specialist visits within the initial treatment window, and the absence of any other 
definitive prostate therapy; 2) NCCN surveillance was defined as at least two claims 
for PSA or DRE and at least one claim for needle biopsy of the prostate, in the 
absence of other definitive treatment (12). Although DRE claims are rarely coded, 
some claims did include them, which we counted as a component of surveillance, but 
neither definition required a DRE claim. 
• Radiation therapy was defined as either EBRT (two- or three-dimensional conformal 
radiation therapy), IMRT, or brachytherapy, with or without ADT, from claims 
definitions used in prior studies (18, 97, 98) and from search of International 
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Classification of Disease-9 (ICD-9) and Current Procedural Terminology (CPT) 
dictionaries (99). Other forms of radiation (stereotactic-body radiation and proton 
therapy) are not guideline-recommended and were not included in this category but 
were considered as “other” therapy. 
• Radical prostatectomy consisted of 1) open prostatectomy (retropubic, or perineal 
radical prostatectomy); and 2) MIRP, distinguished from other prostatectomies by 
CPT code. 
• Primary ADT was considered ADT use in the absence of other definitive therapy. 
ADT included either orchiectomy or a GnRH agonist, as neither are guideline-
concordant for clinically localized disease (39, 100). 
• Other therapy included cryosurgery, chemotherapy, and therapy combinations not 
included in the NCCN guidelines (e.g., radical prostatectomy with adjuvant ADT). 
Key Explanatory Variables 
In Aim 1, the explanatory variables included time in practice and group practice type. 
Time in practice was calculated as the difference between a patient’s SEER diagnosis date 
(averaged as the 15th day of the month) and the date of a physicians’ medical degree (from the 
AMA Masterfile). We dichotomized time in practice as <20 versus ≥20 years. Previous studies 
assessing practice outcomes have defined time in practice as a continuous variable (101), 
dichotomized as we have done (102) as a categorical variable with cut points at 5- or 10-year 
increments (103-105), or as categories of low, medium, and high experience (60), with little 
theoretical rationale. We tested model fit for all specifications, including a quadratic term. The 
dichotomized specification best fit our data reflecting urology practice patterns. 
Group practice organizational type is a series of mutually exclusive indicator variables 
denoting the treating practice as a single specialty urology group, multi-specialty group, or 
urology-radiation oncology group (all urologists with two or fewer radiation oncologists). 
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Variables in this construct were self-reported by practice representatives to the AMA and 
provide a practice-level description. 
The key explanatory variable in Aim 2 is reimbursement generosity. Group practice 
organizational type, defined above, is also used. Although Congress sets reimbursement policy 
nationally, the national policy is implemented locally among contractors responsible for paying 
claims (fiscal intermediaries for Part A claims and carriers for Part B claims). Often, regional 
carriers do not have uniform implementation policies (56). In particular, from 1997 through 
2002, carriers were responsible for translating Part B drug Healthcare Common Procedure 
Coding System (HCPCS) claims into National Drug Code (NDC) indices (57). Although some 
HCPCS had only one equivalent NDC, others had 10 or more matches, resulting in substantial 
reimbursement variation (49). Reimbursement for the GnRH agonist leuprolide acetate varied 
more than 10%, whereas another GnRH agonist, goserelin acetate, was uniformly reimbursed 
(49). In addition to variability among carriers, reimbursements changed at different rates over 
time due to changes in the average wholesale price for specific NDCs (57).  
Exploiting this variation and following the method developed by Jacobson and 
colleagues (57), the key explanatory variable, reimbursement generosity, was operationalized as 
the sum of the weighted average difference between the urologists’ reimbursement and the 
national mean reimbursement for each agent the urologist prescribed. Weights were derived as 
the ratio of SEER registry-wide spending on a regimen to total spending on all ADT agents. 
Differences in the index reflect the variation in reimbursement specific to each carrier, so that a 
positive association between reimbursement generosity index (RGI) and ADT use would 
indicate that urologists are inducing demand. Any score greater than one indicates excess 
reimbursement, or reimbursement greater than the national average.  
Unlike in Jacobson’s study of chemotherapy use in late-stage cancers, in our study some 
urologists may not have prescribed ADT for any of their patients; RGI was mathematically 
undefined (0/0) for those urologists. Thus, we created two additional constructs to be used in 
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sensitivity analyses. First, we calculated a second RGI that included the costs of each ADT 
modality relative to all other care provided to this population, with weights adjusted to capture 
this additional “non-ADT treatment” category. This measure allowed us to assess the question of 
substitution, because urologists can substitute lost income not only from increasing the quantity 
of discounted services, but also by increasing or selecting alternate treatments they can offer 
(106), especially in localized prostate cancer where there are multiple treatment options. 
However, although there are multiple treatment options, a given patient may not be eligible for 
all of them. For that reason, we also created a third version of the RGI, which assumed the SEER 
average reimbursement for urologists who did not prescribe any ADT. 
The RGI was calculated as:  
𝑅𝑖𝑡 = ∑ �𝑃𝑖𝑡𝑔 − 𝑃𝑡𝑔�𝑊𝑡𝑔𝑔∈𝑔(𝑖,𝑡)∑ 𝑊𝑡𝑔𝑔∈𝑔(𝑖,𝑡)  
where Pitg is the average reimbursement for patients receiving GnRH agonist g prescribed by 
provider i in year t, and Ptg is the SEER average reimbursement of GnRH agonist g in year t. Wtg, 
the weight for GnRH agonist g, is the ratio of SEER-wide spending on that regimen to total 
spending on all GnRH agonists. Each medical ADT regimen was dose-standardized by 
converting each instance of GnRH agonist in use on separate days to a monthly dosing regimen. 
Intended duration was determined from the unit designation of the “carrier 
miles/time/units/serv count” field in carrier claims or the “revenue center unit count” field in 
outpatient claims. Claims for 12-month implant were assumed to represent 12 months of 
therapy regardless of unit designation.  
The key explanatory variable for Aim 3, pre-MMA ADT use, is a provider-level measure 
based on the 3-year period of time preceding the first MMA implementation in 2004. It is 
calculated as each physicians’ average annual proportion of patients receiving primary ADT, 
defined as GnRH agonists claims only, during the pre-MMA years 2000–2003. Orchiectomy is 
excluded from the independent variable definition, because MMA affected only reimbursement 
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for medical ADT and not surgical ADT. Thus, we would not expect orchiectomy to be displaced 
by other care. Patient race is defined from SEER data and measured by five categories: 1) Non-
Hispanic White; 2) Black or African-American; 3) Hispanic; 4) Other; or 5) Unknown. 
Control Variables 
In addition, we included physician, practice, and patient constructs associated with 
prostate treatment decision, quality of care, or responsiveness to incentives in all three aims.  
Patient Factors 
Clinical Factors: Because staging systems used in SEER changed over the study period, 
Extent of Disease-1988 3rd edition variables for patients diagnosed from 2000–2003 and 
Collaborative Staging variables for patients diagnosed 2004–2007 were mapped to American 
Joint Committee on Cancer staging variables used for treatment by the National Comprehensive 
Cancer Network guidelines (12, 20). We included age and the NCI Comorbidity Index (NCI CI), 
which is derived from relevant medical conditions appearing in hospital and physician claims; it 
predicts mortality in prostate cancer with greater statistical efficiency than other common 
comorbidity measures such as the Charlson Comorbidity Index (107).   
Treatment Support: We compared men married/living with a partner to those single, 
widowed or divorced, and those with missing marital status. We also assessed their use of 
consultations in the prostate cancer treatment decision (108). Primary Care Use was >1 visit to 
the same primary care physician occurring in 1) the 12 months prior to diagnosis; and, 2) the 
window between diagnosis and treatment. Specialist Care Use was three binary variables 
indicating presence of >1 prostate-related carrier claim filed by a radiation oncologist, urologist, 
or medical oncologist between diagnosis and the earliest of first treatment date or 12 months 
(108). 
Healthcare access: We included several geographic indicators: SEER region, collapsed 
by state; rurality of the community in which the patient resided at diagnosis (<2,500 residents 
versus >2,500 residents); and community deprivation defined as quartile of median income of 
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the patients’ zip code of residence and as quartiles of proportion of adults residing in the 
patients’ zip code with less than high school education.    
Provider Factors   
Using data available from the AMA and Medicare Hospital files, we controlled for: (1) 
physician gender; (2) medical professionalization defined by a binary indicator of board 
certification and a categorical indicator measuring the degree of affiliation with an academic 
institution (none, some, or missing) (109, 110); and (3) training location (U.S. versus non-U.S.).  
Practice Factors  
We controlled for panel size, measured by tertiles of the number of Medicare fee-for-
service prostate cancer patients/year/physician (60). A providers’ ability to spread practice 
income losses across other providers may affect his or her ability to compensate for 
reimbursement cuts and may limit exposure to emerging research. Thus, we controlled for 
practice type (solo practitioner,  group practice or missing). Finally, because a physician’s 
patient panel also affects decision making, we controlled for the proportion of a practice’s 
Medicare patients that are minority, categorized into tertiles following other studies of prostate 
cancer care in minority-enriched practices (111). 
The degree to which providers are reliant on a particular payer will influence the 
providers’ responsiveness to reimbursement cuts. Thus, for the analyses assessing group 
practices, we also controlled for the practices’ self-reported proportion of Medicare and 
Medicaid patients. We expected those with greater proportions of Medicare patients to change 
overuse to a greater degree. We also controlled for practice size, a practice-reported count of the 
number of providers in each practice. 
Environmental factors 
 In Aim 1, we controlled for changes due to MMA and other temporal factors by including 
indicator variables for diagnosis in each MMA implementation period: pre-MMA, 2000–2003; 
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MMA implementation, 2004–2005; and, post-MMA, 2006–2007. In Aims 2 and 3, we 
controlled for time by including variables for each year of the study.  
Statistical Analyses 
Across all Aims, bivariate analyses were conducted with t-tests and analysis of variance 
(continuous variables) and Pearson chi-squared tests (binary and categorical variables), as 
appropriate. In Aim 1, descriptive statistics are shown by patient for patient-level factors and by 
physician for physician-level factors (rather than patient-physician observations). Previous 
studies demonstrate high intraclass correlation among providers in prostate cancer treatment 
(58). Thus, to test the main hypotheses we used multilevel mixed logistic regression models that 
controlled for clustering of patients within provider and for repeated measures of physicians 
over time to calculate odds ratios and differential effects. We calculated the fixed portion of 
marginal effects for time in practice in each MMA period using mean and modal values of 
covariates. Interaction terms were constructed to test differential effects by MMA 
implementation period. 
Model fit was tested in a 50% random sample. Likelihood ratio tests were used to 
determine appropriateness of inclusion of constructs in the model and of allowing both 
intercepts and slopes to vary randomly by physician. We compared random slope and random 
intercept model fit with the Bayesian Information Criterion (BIC). Stata/SE 12.1 was used for all 
analyses (112). 
Aim 1 Sensitivity Analysis. Only 14% of all prostate cancer patients (including those with 
advanced disease) are thought to have prostate-specific antigen (PSA) levels greater than 20 
ng/mL—the cut point qualifying localized prostate cancer patients for high-risk disease. In 
addition, a sizeable number of men qualify for high-risk disease based on more than one risk 
factor. Thus, some men in our sample may have been eligible for ADT. Because we cannot 
exclude men based on PSA levels, the analysis was repeated in a subsample of men with <5 years 
actuarial life expectancy at year of diagnosis and age <88 for most years, except 2004, when 5-
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year life expectancy was reached at age 89, and 2005, when 5-year life expectancy was reached 
at age 87 (113-120). 
For Aim 2, we used multiple imputation to impute missing values of the proportions of 
Medicare patients seen within practices. We categorized RGI dichotomously, dividing the 
sample into a group whose reimbursement generosity was negative or zero and a group whose 
reimbursement generosity was positive, and then conducted bivariate analyses with Pearson’s 
chi-squared tests and t-tests to describe sample differences by reimbursement level. Descriptive 
statistics are presented for the sample of patients, the main unit of analysis, but physician 
characteristics are aggregated by physician. Due to high intraclass correlation among providers 
in prostate cancer treatment (58), we used multilevel mixed logistic regression models that 
controlled for clustering of patients within provider and for repeated measures of physicians 
over time. We created a sub-sample, further limiting the cohort to urologists identified by the 
AMA as practicing in a group practice to study the moderating effect of group practice 
organizational type on RGI and included an interaction term to capture it. Statistical 
significance was evaluated at α=0.05 for all tests. Stata/SE 12.1 was used for all analyses (112). 
For Aim 3, we stratified the patient sample by physician guideline concordance and 
assessed differences between groups by comparing the frequencies and proportions of binary 
and categorical variables and the means and standard deviations of each continuous variable. 
We used a common benchmark (121) to stratify physician guideline concordance; physicians 
were defined as high-concordance when 80% or more patients received guideline-concordant 
care, or alternatively defined as non-high concordance. Multilevel logistic regression was used to 
model the association between pre-MMA ADT use on guideline-concordant care. Separate 
multilevel logistic regression models comparing the effect of pre-MMA use on each modality 
alternative within multi-modality treatment options were run. Statistical significance was 
determined at α=0.05, and Stata/SE 12.1 was used for all analyses (112). 
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CHAPTER 4 CHANGES IN PRIMARY ANDROGEN DEPRIVATION THERAPY 
OVERUSE: RESPONSE TO REIMBURSEMENT AND CHARACTERISTICS 
ASSOCIATED WITH CHANGE 
Introduction 
Prostate cancer is a prevalent and costly disease for which the guideline-recommended 
treatment options are equivocal for most men (1, 9, 19). Nonetheless, the harms of one widely 
used treatment in the previous two decades, primary androgen deprivation therapy (PADT), are 
known to outweigh its benefits among men with localized disease (22, 26-29). Although ADT, a 
long-lasting physician-administered drug that blocks testosterone to slow tumor growth, is 
recommended for some men receiving radiation, ADT by itself was recommended only for a 
small group of patients with localized disease in the early 2000s. 
Despite the paucity of data supporting its clinical effectiveness in localized disease, PADT 
use in localized prostate cancer grew steadily from the 1990s, peaking in 2003 (10, 18, 40-42). 
Although clinical characteristics and patient preferences were thought to influence ADT overuse, 
most variation in prostate cancer treatment has been attributed to physician practice style (31, 
58). Aggressive pharmaceutical marketing practices and liberal Medicare reimbursement for 
Part B drugs made ADT extremely profitable for physicians administering the drug (47, 48), 
costing Medicare more than $1 billion annually. Because Medicare reimbursement for 
physician-administered drugs covered under Medicare Part B (including ADT) far exceeded 
physician costs, the Medicare Modernization Act (MMA) of 2003 reduced the profitability of 
ADT administration in two phases implemented January 1, 2004 and January 1, 2005. Together 
these policies were associated with a 65% decrease in physician reimbursement for ADT from 
2003 to 2005 (47). Subsequently, ADT use declined 34% after 2005. Although most of the 
decline occurred among men for whom ADT was not indicated (10, 39), 25.7% of men for whom 
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it is not recommended received PADT in 2005 (39, 40). Thus, understanding characteristics of 
physicians who persistently overuse ADT—despite reimbursement changes—is essential to 
improving quality of care. 
Although prior results are mixed, physicians with the longest time in practice may be the 
least receptive to reimbursement changes (57). Experienced physicians’ lack of response is 
concerning. Urologists are delaying retirement due to perceived physician shortages (62), and 
the delay might further slow quality improvement in prostate cancer care. In addition, a 
decrease in reimbursement can result in multiple behavioral responses, motivating providers to 
increase, replace, or drop the discounted service (36). Previous analysis of cancer specialists’ 
response to the MMA suggests that physicians increased the use of discounted treatments (51, 
57), so it is possible that reimbursement changes may have intensified ADT overuse.  
This study sought to investigate the role of physician characteristics in persistent ADT 
overuse in localized prostate cancer by: 1) developing a model of physician characteristics 
associated with persistent and increasing overuse; 2) assessing whether time in practice was 
associated with persistent and increasing overuse; and, 3) identifying patterns of response to 
reimbursement changes. We hypothesize that physicians with greater time in practice may be 
less responsive to reimbursement changes. 
Methods 
We conducted a retrospective, longitudinal analysis using a large, national population-
based sample of elderly prostate cancer patients. The study was approved by the Institutional 
Review Board of the University of North Carolina at Chapel Hill. 
Data Sources 
We linked the Surveillance, Epidemiology and End Results (SEER)-Medicare database to 
the American Medical Association (AMA) physician Masterfile. SEER is a collection of 
population-based cancer registries in 17 geographic areas (90). Data are linked to administrative 
claims of Medicare, which covers medical services for more than 97% of the U.S. population 65 
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years of age and older, approximately 81% of whom are covered under fee-for-service (91, 122). 
The AMA Masterfile is a comprehensive database describing approximately 800,000 member 
and non-member physicians in the United States. Confirmed data originate from training and 
certification records and are supplemented by data from annual surveys of one-third of 
physicians and other physician regulatory agencies (92).  
Cohort Definition 
Patient Selection Criteria. We identified all men diagnosed with incident 
adenocarcinoma of the prostate between January 1, 2000 and December 31, 2007. Only patients 
experiencing their first and only cancer, as indicated by SEER, were included. We excluded 
patients whose comorbidities could not be ascertained and/or whose initial treatment could not 
be ascertained including those who were younger than 66 years and lacking a complete year of 
claims; diagnosed at autopsy, death certificate, or at a nursing/convalescent facility, for similar 
reasons; not enrolled in fee-for-service (defined as continuous Part A and B coverage and not in 
an HMO for at least 12 months post diagnosis); died within 12 months of diagnosis; and/or 
diagnosed in Louisiana (due to disruptions in health services cause by Hurricane Katrina). The 
Tumor Node Metastasis (TNM) staging system was used to restrict the cohort conservatively to 
patients for whom ADT is not NCCN guideline-recommended across the study period. Men in 
the ADT-ineligible sample were those who lacked evidence of nodal or metastatic involvement 
and had no greater than unilateral, stage T2 tumors and World Health Organization grades 1–2 
(10). Thus, we excluded men diagnosed with 1) T1 or T2 cancers with Gleason scores 8–10; 2) 
T2b tumors before 2002 when the staging definition changed; 3) T2c tumors after 2002 when 
the category was added; or, 4) T3a tumors. Men receiving external beam radiation therapy were 
also excluded, because the appropriateness of their ADT receipt could not be ascertained.  
Physician Inclusion Criteria. Treating physicians were identified from claims. After 
limiting claims to those submitted for prostate cancer treatment, the physician responsible for 
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the majority of prostate cancer-related initial treatment claims was considered the treating 
physician.  
Measures 
Dependent Variable. ADT in conjunction with radiation is recommended therapy for 
some men with high-risk disease; however, ADT alone is not recommended. Thus, the outcome 
primary ADT use is a binary variable defined for each patient as an initial treatment claim for a 
HealthCare Common Procedure Coding System (HCPCS) code for medical ADT administered 
within 1 year from the SEER date of diagnosis without another non-surveillance prostate 
treatment administered within the treatment window. Non-surveillance treatments included 
orchiectomy, radical prostatectomy, all forms of radiation therapy planned or delivered 
(brachytherapy, conformal, IMRT, proton therapy), chemotherapy, and cryotherapy. All claims 
files were used to identify treatment delivered. Codes for other hormonal treatments were not 
considered part of the primary ADT definition. Appendix A lists the procedure codes used. 
Explanatory Variables. Time in practice was calculated as the difference between a 
patient’s SEER diagnosis date (averaged as the 15th day of the month) and the date of a 
physicians’ medical degree (from the AMA Masterfile). We dichotomized time in practice as <20 
versus ≥20 years. Previous studies assessing practice outcomes have defined time in practice 
with little theoretical rationale as: a continuous variable (101); dichotomized as we have done 
(102); a categorical variable with cut points at 5- or 10-year increments (103-105); or, as 
categories of low, medium, and high experience (60). We tested model fit for all specifications, 
including a quadratic term. The dichotomized specification best fit our data reflecting urology 
practice patterns.  
Control Variables. We controlled for changes due to MMA and other temporal factors by 
including indicator variables for diagnosis in each MMA implementation period: pre-MMA, 
2000–2003; MMA implementation, 2004–2005; and post-MMA, 2006–2007. In addition, we 
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included physician, practice, and patient constructs associated with prostate treatment decision, 
quality of care, or responsiveness to incentives.  
Provider Factors: Using data available from the AMA and Medicare Hospital files, we 
controlled for: (1) physician gender; (2) medical professionalization defined by both a binary 
indicator of board certification and a categorical indicator measuring the degree of affiliation 
with an academic institution (none, some, or missing) (109, 110); and, (3) training location 
(U.S. versus non-U.S.). Practice factors included panel size (58), measured by tertiles of the 
number of Medicare fee-for-service prostate cancer patients/year/physician (60); practice type 
(solo practitioner, group practice or missing); and tertiles of proportion of a practice’s Medicare 
patients that are minority (111). 
Patient Factors: 
Clinical Factors: Because staging systems used in SEER changed over the study period, 
Extent of Disease-1988 3rd edition variables for patients diagnosed from 2000–2003 and 
Collaborative Staging variables for patients diagnosed 2004–2007 were mapped to American 
Joint Committee on Cancer staging variables used for treatment by the National Comprehensive 
Cancer Network guidelines (12, 20). We included age and the NCI Comorbidity Index (NCI CI) 
with uniform weights, which is derived from relevant medical conditions appearing in hospital 
and physician claims (107, 123).   
Treatment Support: We compared men married/living with a partner to those single, 
widowed, or divorced and those with missing marital status. We also assessed proclivity to seek 
care and men’s use of consultations in the prostate cancer treatment decision (108). Primary 
Care Use was any claim in the 12 months prior to diagnosis (86). Primary care consultation was 
>1 visit to the same primary care physician occurring in both 1) the 12 months prior to 
diagnosis; and, 2) the window between diagnosis and treatment (108). Specialist Care was three 
binary variables indicating the presence of ≥1 prostate-related carrier claim filed by a radiation 
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oncologist, urologist, or medical oncologist between diagnosis and the first treatment date or 12 
months, whichever is earlier (108). 
Patients’ healthcare access: We included several geographic indicators: SEER region, 
collapsed by state; rurality of the community in which the patient resided at diagnosis (<2,500 
residents versus ≥2,500 residents); and community deprivation, defined as quartile of median 
income of the patients’ zip code of residence and as quartiles of proportion of adults residing in 
the patients’ zip code with less than high school education.  
Analysis 
Bivariate analyses were conducted with t-tests and analysis of variance (continuous 
variables) and Pearson chi-squared tests (binary and categorical variables). Descriptive statistics 
are shown by patient for patient-level factors and by physician for physician-level factors (rather 
than patient-physician observations). Previous studies demonstrate high intraclass correlation 
among providers in prostate cancer treatment (58). Thus, to test the main hypotheses we used 
multilevel mixed logistic regression models that controlled for clustering of patients within 
provider and for repeated measures of physicians over time to calculate odds ratios and 
differential effects. We calculated the fixed portion of marginal effects for time in practice in 
each MMA period using mean and modal values of covariates. Interaction terms were 
constructed to test differential effects by MMA implementation period. 
Model fit was tested in a 50% random sample. Likelihood ratio tests were used to 
determine the appropriateness of inclusion of constructs in the model and of allowing both 
intercepts and slopes to vary randomly by physician. We compared random slope and random 
intercept model fit with the Bayesian Information Criterion (BIC). Stata/SE 12.1 was used for all 
analyses (112). 
Sensitivity Analysis. Only 14% of all prostate cancer patients (including those with 
advanced disease) are thought to have prostate-specific antigen (PSA) levels >20 ng/mL—the 
cut point qualifying localized prostate cancer patients for high-risk disease. In addition, a 
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sizeable number of men qualify for high-risk disease based on more than one risk factor. Thus, 
some men in our sample may have been eligible for ADT. Because we cannot exclude men based 
on PSA levels, the analysis was repeated in a subsample of men with <5 years actuarial life 
expectancy at year of diagnosis: age <88 for most years, except 2004, when 5-year life 
expectancy was reached at age 89, and 2005, when 5-year life expectancy was reached at age 87 
(113-120).  
Results 
Urologists prescribed 94.6% of the primary ADT observed in the cohort. Thus, we 
excluded other physicians from the main analysis. Consequently, the final sample included 
12,943 men diagnosed with T1 and T2 well- or moderately-differentiated prostate cancer from 
2000 through 2007, and treated through 2008 by 2,138 urologists (Figure 4.1).  
ADT Overuse. Among the men treated by urologists from 2000–2008, 18.5% received 
primary ADT (Table 4.1). However, primary ADT overuse decreased from 21.0% before MMA 
implementation to 17.6% during the implementation phase, and ultimately to 13.6% following 
full deployment of the policy (Figure 4.2). 
Time in Practice. In the unadjusted analysis, more experienced urologists’ rates of ADT 
overuse declined less sharply over time compared to their less experienced counterparts (Figure 
4.2). Overall, 19.4% of patients of more experienced urologists received primary ADT whereas 
16.9% of patients of less experienced urologists received this treatment (Table 4.1). However, the 
patients of more experienced physicians differed from patients seen by their less experienced 
peers. Experienced physicians’ patients were slightly older, spread disproportionately across 
SEER regions, and were more likely to be non-Hispanic black, Hispanic, unmarried, or live in 
communities with fewer resources (Table 4.1). Slightly less than two-thirds of urologists had 
been in practice ≥20 years, and they were more likely to be male or U.S.-trained; lack medical 
school affiliation; or be solo practitioners than physicians with fewer years in practice (Table 
4.2).  
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Adjusted Analysis. A multilevel random intercepts model best fit the training data; 
coefficients were similar in the validation data. The interaction of time in practice and MMA 
period was not jointly significant and therefore not included in the final model (Table 4.3). After 
adjusting for patient and physician characteristics and secular changes, time in practice was not 
associated with primary ADT overuse or increasing overuse (OR 0.89, 95% CI 0.75, 1.05). 
However, being a solo practitioner substantially increased the odds of primary ADT overuse 
compared to urologists in group practice (OR 1.65, 95% CI 1.34, 2.02). In addition, having a 
medical school affiliation was associated with lower odds of overuse (OR 0.65, 95% CI 0.55, 
0.77), compared to those with no affiliation.  
At the patient level, increased age, greater comorbidity, being in a racial/ethnic minority, 
high utilization of primary care in the prior year, and receiving a radiation oncology consultation 
prior to treatment were associated with increased odds of primary ADT overuse (Table 4.3). 
Non-Hispanic blacks (OR 1.76; 95% CI 1.37-2.27), Hispanics (OR 1.41; 95% CI 1.12, 1.79), and 
men of “other” race (OR 1.44; 95% CI 1.04, 1.99) all had greater odds of receiving unnecessary 
ADT compared to Non-Hispanic whites. Receiving a primary care consultation and being in the 
highest income category was associated with lower odds of ADT overuse.  
In sensitivity analysis, removing 453 men who were NCCN guideline-ineligible for 
primary ADT by virtue of their age and year of diagnosis produced no difference in the size or 
significance of effects (analysis not shown). When examining differential effects for the fixed 
effects portion of provider and practice characteristics (Table 4.4), partial effects of time in 
practice were not significant and did not differ by MMA period (confidence intervals not 
shown). In contrast, differential effects of practice type and medical school affiliation were 
significant.  
Physician Practice Changes. Although overall primary ADT use declined incrementally 
over the period, in unadjusted analysis three patterns of physician response appeared (Figure 
4.3). Static users (n=1,478) had low levels of ADT use at entry into the cohort and either 
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continued to use primary ADT infrequently following MMA implementation or contributed data 
in only one MMA period. This group treated the most patients (n=5,809). Among those who had 
the highest levels of primary ADT use in 2000 (n=394), overuse averaged 23.1% over the period 
but decreased sharply in 2004, and by 2008 these decreasing users had levels of use similar to 
static users. A third group of urologists (n=276), increasing users, sharply increased their use of 
primary ADT in 2004 and maintained even higher levels of primary ADT use after MMA 
implementation. Their average overuse was 32.6% among the 2,817 patients they treated over 
the study period. 
Discussion 
The purpose of this study was to create a model of physician characteristics associated 
with changes in ADT overuse; test the association of time in practice with ADT overuse; and, 
describe physician-level changes in ADT use. Contrary to some previous work (61), time in 
practice was not associated with urologists’ overuse of ADT in localized prostate cancer after 
adjusting for other physician and patient factors. Two prevailing theories offer insight into why 
this may be so. Economic theory suggests that physicians’ treatment decisions and willingness to 
change prescribing habits are influenced by their need to balance ethical obligations to choose 
the best treatment for their patients and their own financial interests to limit the marginal 
“costs” of the treatments offered (86). Although this suggests physicians may respond to 
financial incentives to optimize income, physicians later in their career may be less responsive to 
reimbursement cuts because they are more likely to have repaid major debts (57). Educational 
theory suggests more experienced physicians may be less aware of and responsive to emerging 
evidence and guideline recommendations. Thus, even if more experienced physicians were not 
responding to reimbursement, they still may not have changed their patterns of ADT overuse. 
Our results are similar to an earlier study (60) in which the least and most experienced 
urologists were more likely to use ADT for treating prostate cancer patients. However, when the 
sample was restricted to patients for whom ADT had uncertain benefit (similar to our cohort), 
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time in practice was not a significant factor. Studies that have found time in practice to be 
associated with poor quality of care have not been conducted in fee-for-service Medicare, but in 
HMOs and the Canadian health system (124-128). These differences in findings based on 
reimbursement context suggest that more experienced physicians may succumb to clinical 
inertia or lapsed technical skill, but this may be overcome by changing or aligning financial 
incentives. Interestingly, our study differs from a recent study that found a significant inverse 
relationship between time in practice and cost across treatments and physician specialties (105). 
Of note, that cross-sectional study was limited to between-physician comparisons and care 
delivered in the state of Massachusetts, a state with the third highest HMO penetration among 
the United States (129). Our study assessed not only between-physician differences among 
urologists with varying experience levels but also within-physician differences (i.e., changes in 
physicians’ treatment decisions for similar patients as they gained time in practice).  
Although our study design did not rule out cohort effects in which the training 
experience imprints a physician signature, time in practice by itself does not appear to affect 
overuse. Instead, we found that ADT overuse was concentrated in solo practitioners. Other 
studies assessing physician characteristics of ADT overuse have not considered practice type in 
their analyses (60), although solo practice has been identified as a barrier to innovation 
adoption (130). Whether these physicians are isolated from other physicians who might 
influence them to align with guidelines or are more motivated by financial factors to prescribe 
ADT is unknown. Nonetheless, because ADT overuse was found among 25.7% of patients seen in 
solo practices (compared to 17.1% of patients seen in group practices), and more urologists 
(23%) practice as solo practitioners than any other surgical specialty (131), they are an 
important target for quality improvement.  
Urologists who overuse ADT also were more likely to lack professional affiliation with a 
medical school, which may make them hard to reach for intervention. Other studies have also 
found professional affiliation to be associated with higher quality of care (132). Physicians 
55 
 
affiliated with medical schools may have resources (e.g., trainees, tumor boards) that encourage 
guideline-concordant practice. Alternately, physicians who affiliate with a medical school may 
lack motivation for financial gain, as it is well established that academic physicians forgo 
compensation (133, 134). We cannot identify reasons for this association, but either motivation 
could make it difficult to engage these physicians in traditional quality improvement efforts. 
Consistent with other studies, we found that ADT overuse declined precipitously over the 
2000s, a drop that was coincident with reimbursement policy changes (10, 39). Our study shows 
that ADT overuse continued on a downward trajectory in the 2 years following full MMA 
implementation. Nonetheless, ADT overuse remains a problem even in the post-MMA period, in 
which 14% of men with T1 or T2 tumors and well- or moderately differentiated cancer were 
prescribed primary ADT. Post-MMA consensus guidelines do not recommend PADT for these 
men, as harms are well-recognized without evidence of benefit (21, 22, 26-28). Of concern, 
primary ADT use among men with high-risk localized prostate cancer is even higher (135); thus 
the problem may extend to an even larger group of men than studied here. Moreover ADT 
overuse remains costly. Direct Medicare costs—not including the treatment of adverse events 
attributable to ADT—have been estimated at $42 million per year for all risk groups (135). 
We also hypothesized that urologists might intensify ADT overuse in response to the 
reimbursement cut. Although ADT overuse significantly declined, in this study we identified 
three distinct types of volume response: 1) static use; 2) decreasing use; and, 3) increasing use. 
Economists have observed a volume response to other cancer care reimbursement changes (51, 
57), but interestingly, not among urologists in other reimbursement contexts (64, 65, 136, 137). 
Because we identified differing responses among physicians in a single specialty subject to the 
same reimbursement change, we further explored characteristics of these physicians. Non-
responders, those who had low rates of use that remained stable over time, differed from 
responders in both physician characteristics and patient panels (data not shown).  
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Although we observed two distinct patterns among responders, we could not distinguish 
urologists who increased from those who decreased ADT utilization based on physician 
characteristics. The largest group of responders, urologists who decreased ADT overuse, began 
the study period with high rates of overuse but sharply decreased use to that of non-responders. 
However, a sizeable group of urologists sharply increased ADT overuse coincident with 
reimbursement cuts. Although increasing users diminished in number over the study period, 
they saw a large number of patients and are a cause for concern and a target for intervention: 
their ADT overuse remains over 30%. Responders—both increasing and decreasing users—
shared statistically similar physician characteristics (Table 4.5). The patient panels of increasing 
users were significantly different than those of decreasing users (Table 4.6); however, increasing 
users’ patients were older, had more comorbid conditions, and were more likely to be non-
Hispanic black or “other” race. They resided in communities with fewer resources and were less 
likely to receive radiation oncology consultations. Although we cannot distinguish whether 
urologists were responding to their changing patient population or were more likely to have 
more socially vulnerable patients, the characteristics of patients within these practices may 
point toward another source of prostate cancer treatment disparities. In addition, our study 
suggests an alternative explanation for volume response. Economic studies rarely assess patient-
level factors in accounting for induced demand following reimbursement cuts (138). Urologists 
who increased ADT overuse coincident with reimbursement cuts had older patients than 
urologists who decreased ADT overuse after MMA implementation. Studies consistently show 
that older patients are more likely to be prescribed ADT, despite the lack of recommendation for 
this treatment. Our study suggests that increasing overuse could be a rational but clinically 
inappropriate response to a changing patient panel. For increasing overusers, the lack of 
treatment alternatives, and possibly referral options, for older patients may encourage overuse. 
Future assessments of volume response should consider characteristics of the patient panel to 
better understand responsiveness to financial incentives. 
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There are several limitations of our study. First, we excluded patients treated by non-
physician providers. As a result, our sample disproportionately excluded younger men, 
minorities, patients in the lower median income quartiles, those with well-differentiated or T1 
tumors, and those not receiving primary ADT. Thus, our findings do not represent the full 
experience of these patients and cannot be extrapolated to treatment decisions made by mid-
level providers, even in a fee-for-service environment. Secondly, we restricted our study to 
urologists because they make most treatment decisions about ADT for patients with localized 
prostate cancer. Thus, our findings may not be generalizable to other physician specialties. 
Third, PADT was recommended for a small group of men in the early 2000s. However, in 
sensitivity analysis, removing patients likely to have fewer than 5 years life expectancy did not 
change the results. Finally, although we used a national registry, patients in SEER are not 
selected randomly. Nonetheless, the SEER population is comparable to the U.S. population in 
terms of poverty and education, and represents more than 26% of the African-American 
population in the U.S. (90). Further, characteristics of urologists in our study mirror national 
trends (139), suggesting that these results are generalizable.   
Research and Policy Implications 
Approximately 30%–40% of healthcare spending in the U.S. has been attributed to 
overuse, the provision of unnecessary care for which harms outweigh benefits (71-73). Overuse 
results in patient harms, health disparities, and waste in a healthcare system already stretched 
to capacity (73). Despite being designated a significant quality problem and national priority 
(74), relatively little research focuses on the problem of overuse or strategies to address it (71, 
75). We found that among urologists providing care in fee-for-service Medicare, physicians’ time 
in practice, whether a proxy for diminishing economic motivation or educational disinterest, 
was not associated with overuse. Physician retirement, even if delayed, may not result in 
improving prostate cancer quality. Future studies should compare the effect of time in practice 
58 
 
among physicians practicing in multiple payer environments, or control for the proportion of 
care that is delivered under fee-for-service mechanisms. 
In addition, we found that reimbursement policies may not have uniform results in some 
physician populations, suggesting that additional research assessing physician response to 
reimbursement is necessary. Reimbursement strategies may need to be tailored to physician 
specialty, practice dynamics, and patient panels to reduce overuse overall. We also 
demonstrated that the patient panels of increasing users differ significantly from that of 
urologists who responded to reimbursement cuts in the expected direction. Of concern, older 
patients and minority patients were more vulnerable to overuse, despite reimbursement changes 
to disincentivize ADT use. Quality in prostate cancer care may be improved by discouraging the 
use of primary ADT in the oldest patients, but research and guidelines are needed to address 
appropriate treatment for the oldest patients. No localized prostate cancer studies of which we 
are aware adequately account for the overuse of ADT in ethnic and racial minorities. Whether 
unmeasured frailty, incomplete reporting of disease severity, patient preference, or physician 
bias is responsible should be determined. Finally, we identified an important group of 
physicians who may need additional support in reducing overuse. Although ADT overuse has 
declined significantly during and after MMA implementation, overuse remains high among 
professionally isolated urologists. Most physician intervention studies target all physicians or 
work through networks of physicians affiliated with academic research partners. Few studies 
focus on the needs of solo practitioners who lack these affiliations. Finally, understanding the 
characteristics of group practice that make it protective against primary ADT overuse could be 
instructive. Whether the added financial vulnerability of physicians practicing on their own 
engenders this behavior or whether isolation from timely and relevant knowledge prevents 
adoption of quality of care practices should be determined. 
  
59 
 
Figure 4.1. Cohort Exclusions 
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Figure 4.2. Change in ADT Overuse by Time in Practice 
  
*unadjusted 
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Figure 4.3. Change in ADT Overuse by Year: Behavioral Response 
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Table 4.1. Sample Characteristics by Physician Time in Practice—Patient 
Characteristics 
  Overall <20 years ≥20 years  
   N (%) or Mean (Standard Deviation) p-value
 
N=12,943 N=4,273 N=8,670 
 
     Primary ADT 18.5 721 (16.9%) 1,679 (19.4%) <0.001 
Period of MMA Implementation 
  
0.51 
Pre-MMA Implementation 54.3 2,290 (53.6%) 4,734 (54.6%) 
 MMA Implementation Period 23.1 1,009 (23.6%) 1,981 (22.8%) 
 Post-MMA Implementation 22.6 974 (22.8%) 1,955 (22.5%) 
 T Stage 
   
0.48 
T1 79.9 3,428 (80,2%) 6,910 (79.7%) 
 T2 20.1 845 (19.8%) 1,760 (20.3%) 
 Grade 
   
0.009 
Well differentiated, 2–4 5.0 179 (4.2%) 471 (5.4%) 
 Moderately differentiated 5–7* 92.9 4,008 (93.8%) 8,017 (92.5% 
 Missing 2.1 86 (2.0%) 182 (2.1%) 
 Comorbidities 
   
0.14 
0 67.3 2,930 (68.6%) 5,778 (66.6%) 
 1 21.4 891 (20.9%) 1,882 (21.7%) 
 2 6.7 268 (6.3%) 602 (6.9%) 
 ≥3  4.6 184 (4.3%) 408 (4.7%) 
 Mean Age (SD) 74.1 (6.1) 73.4 (6.0) 74.4 (6.2) <0.001 
Race/ethnicity 
   
0.004 
Non-Hispanic White 77.8 2,298 (79.5%) 6,678 (77.0%) 
 Non-Hispanic Black 6.6 273 (6.4%) 586 (6.8%) 
 Hispanic 7.5 280 (6.6%) 688 (7.9%) 
 Other 4.1 177 (4.1%) 350 (4.0%) 
 Missing 4.0 145 (3.4%) 368 (4.2%) 
 Marital Status 
   
0.04 
Not Married 19.7 799 (18.7%) 1.751 (20.2%) 
 Married 68.4 2934 (68.7% 5920 (68.3% 
 Missing 11.9 540 (12.6%) 999 (11.5%) 
 Pre-treatment Primary Care Use 
  
0.49 
0–2 visits in prior year 18.9 805 (18.8%) 1,645 (19.0%) 
 3–5 visits in prior year 43.6 1,892 (44.3%) 3,747 (43.2% 
 ≥6 visits in prior year 37.5 1,576 (36.9% 3,278 (37.8%) 
 Primary Care Consultation 
   
0.08 
No 43.9 1,831 (42.9%) 3,854 (44.5%) 
 Yes 56.1 2,442 (57.1%) 4,816 (55.5%) 
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Radiation Oncology Consultation 
  
0.41 
No 84.9 3,610 (84.5%) 7,373 (85.0%) 
 Yes 15.1 663 (15.5%) 1,297 (15.0%0 
 Medical Oncology 
Consultation 
   
0.63 
No 96.4 4,122 (96.5%) 8,349 (96.3%) 
 Yes 3.6 151 (3.5%) 321 (3.7%) 
 Urology Consultation 
   
0.41 
No 1.0 49 (1.1%) 86 (1.0%) 
 Yes 99.0 4,226 (98.9%) 8,584 (99.0%) 
 Rural Residence 
   
0.83 
No 98.1 4,193 (98.1% 8,503 (98.1%) 
 Yes 1.9 80 (1.9%) 167 (1.9%) 
 SEER Region 
   
<0.001 
Seattle 4.4 226 (5.3%) 345 (4.0%) 
 Connecticut 6.0 274 (6.4% 508 (5.9%) 
 Detroit 7.0 291 (6.8% 617 (7.1%) 
 Hawaii 0.9 45 (1.1%) 77 (0.9%) 
 Iowa 6.2 261 (6.1% 538 (6.2% 
 New Mexico 3.8 144 93.4%) 347 (4.0%) 
 California 39.2 1,597 (37.4%) 3,479 (40.1%) 
 Utah 4.3 223 (5.2%) 333 (3.8%) 
 Georgia 2.7 108 (2.5%) 236 (2.7%) 
 Kentucky 9.7 373 (8.7%) 887 (10.2%) 
 New Jersey 15.7 731 (17.1%) 1,303 (15.0%) 
 Median Income of Patients' 
Communities 
  
<0.001 
<$35,031 20.7 759 (17.8%) 1923 (22.2%) 
 $35,051–$46,079 24.8 1,033 (24.2%) 2,181 (25.2%) 
 $46,084–$60,668 24.3 1,103 (25.8%) 2,040 (23.5%) 
 $60,669–$200,008 25.8 1,182 (27.7%) 2,163 (24.9%) 
 Missing 4.3 196 (4.6%) 363 (4.2%) 
 Proportion of Patient's Community w/o High School Education <0.001 
0%–9.7% 25.7 1,166 (27.3%) 2,163 (24.9%) 
 9.7%–15.5% 24.3 1,126 (26.4%) 2,014 (23.2%) 
 15.5%–25.2% 23.1 966 (22.6%) 2,019 (23.3%) 
 25.2%–100% 22.7 821 (19.2%) 2,116 (24.4%) 
 Missing 4.3 194 (4.5%) 358 (4.1%)   
P-values by t-test for continuous variables and chi2 test for binary / categorical variables 
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Table 4.2. Sample Characteristics by Physician Time in Practice—Physician 
Characteristics 
 
Overall <20 years ≥20 years 
 
 
Mean (Standard Deviation) or Percent p-value 
 
N=2,138 N=923 N=1,215 
 
     Mean Primary ADT Use 2000–
2007 (SD) 0.2 (0.3) 0.2 (0.3) 0.2 (0.3) <0.001 
Time in Practice 100.0% 923 (38.8%) 1215 (61.2%) <0.001 
Physician Gender 
   
<0.001 
Male 97.7% 877 (95.0%) 1212 (99.8%) 
 Female 2.3% 46 (5.0%) 3 (0.2%) 
 Board Certified 
   
0.65 
No 6.8% 60 (6.5%) 85 (7.0%) 
 Yes 93.2% 863 (93.5%) 1130 (93.0%) 
 US Trained 
   
<0.001 
No 15.9% 39 (4.2%) 301 (24.8%) 
 Yes 84.1% 884 (95.8%) 914 (75.2%) 
 Medical School Affiliation 
   
0.009 
None 44.2% 373 (40.4%) 571 (47.6%) 
 Some 53.9% 530 (57.4%) 623 (51.3%) 
 Missing  1.9% 20 (2.2%) 21 (1.7%) 
 Physician Prostate Panel Size 
   
0.58 
0–20 prostate patients/year 64.3% 589 (63.8%) 785 (64.6% 
 21–37 prostate patients/year 27.5% 251 (27.2%) 336 (27.7%) 
 ≥38 prostate patients/year 8.3% 83 (9.0%) 94 (7.7%) 
 Solo Practitioner 
   
<0.001 
No 72.3% 740 (80.2%) 805 (66.3%) 
 Yes 21.6% 89 (9.6%) 373 (30.7%) 
 Missing 6.1% 94 (10.2%) 37 (3.0%) 
 Proportion of Patients Minority 
   
0.69 
0%–6.1% 38.0% 360 (39.0%) 453 (37.3%) 
 6.2%–19.5% 27.5% 253 (27.4%) 336 (27.7%) 
 ≥20.0%  34.4% 310 (33.6%) 426 (35.1%) 
 P-values by t-test for continuous variables and chi2 test for binary/categorical variables; time 
invariant physician measures described at first entry into cohort 
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Table 4.3. Multilevel Logistic Regression Model of Time in Practice on Primary 
ADT Overuse 
  
Odds 
Ratio 
95% Confidence 
Limits 
Time in Practice 0.89 0.75 1.05 
Physician Gender 0.92 0.45 1.89 
Board Certified 1.00 0.71 1.41 
US Trained 0.78 0.62 0.99 
Medical School Affiliation (compared 
to none)* 
   Some 0.65 0.55 0.77 
Missing 0.82 0.39 1.73 
Prostate Patient Panel Size (compared to 0–20 
patients/year) 
  21–37 prostate patients/year 1.04 0.89 1.21 
≥38 prostate patients/year 1.00 0.83 1.22 
Solo Practitioner (compared to 
group practice)* 
   Yes 1.65 1.34 2.02 
Missing 0.82 0.55 1.23 
Proportion of Patients Minority (compared to 
0%–6.1% minority)* 
  6.2%–19.5% 0.79 0.66 0.93 
≥20.0%  0.81 0.66 1.00 
Period of MMA Implementation (compared to 
Pre-MMA Implementation* 
  MMA Implementation Period 0.78 0.68 0.91 
Post-MMA Implementation 0.54 0.46 0.64 
T Stage 1.36 1.19 1.57 
Grade (compared to Well 
Differentiated) 
   Moderately differentiated 5–7* 3.12 2.33 4.17 
Missing 4.90 3.15 7.60 
Comorbidities (Compared to None) 
   1 1.29 1.13 1.48 
2 1.25 1.01 1.55 
≥3  1.46 1.14 1.87 
Age (continuous) 2.30 1.88 2.82 
Age squared 1.00 0.99 1.00 
Race/ethnicity (compared to Non-
Hispanic White)* 
   Non-Hispanic Black 1.76 1.37 2.27 
Hispanic 1.41 1.12 1.79 
Other 1.44 1.04 1.99 
Missing 1.84 1.40 2.41 
66 
 
Marital Status (compared to 
Unmarried) 
   Married 0.91 0.79 1.05 
Missing 1.64 1.34 1.99 
Pre-treatment Primary Care Use (compared to 
0–2 visits in prior year)* 
  3–5 visits in prior year 1.64 1.38 1.96 
≥6 visits in prior year 1.73 1.44 2.10 
Primary Care Consultation 0.42 0.37 0.48 
Radiation Oncology Consultation 1.73 1.47 2.05 
Medical Oncology Consultation 1.03 0.76 1.40 
Urology Consultation 6.03 2.93 12.41 
Rural Residence 0.94 0.62 1.44 
Region (compared to Seattle) 
   Connecticut 4.45 2.56 7.74 
Detroit 2.39 1.36 4.19 
Hawaii 4.78 2.02 11.30 
Iowa 3.38 1.90 6.01 
New Mexico 2.63 1.37 5.04 
California 2.54 1.56 4.15 
Utah 1.46 0.76 2.83 
Georgia 2.44 1.27 4.70 
Kentucky 3.17 1.85 5.44 
New Jersey 5.49 3.32 9.08 
Median Income of Patients' Communities 
(compared to <$35,031) 
  $35,051–$46,079 0.83 0.69 1.00 
$46,084–$60,668 0.83 0.66 1.05 
$60,669–$200,008 0.66 0.50 0.88 
Missing 6.60 0.72 60.11 
Proportion of Patient's Community w/o High School 
Education (compared to <9.7%) 
 9.7%–15.5% 1.18 0.98 1.43 
15.5%–25.2% 1.24 0.99 1.55 
25.2%–100% 1.17 0.89 1.54 
Missing 0.11 0.01 0.99 
Constant 0.00 0.00 0.00 
N=12,943 patients; 2,138 urologists 
*Constructs tested for joint significance by likelihood ratio test of nested models: 
Medical school affiliation—X2=24.36, p<0.001 
Solo practitioner— X2=574.55, p<0.001 
Proportion of patients minority— X2=7.90, p=0.019 
Period of MMA implementation— X2=59.46, p<0.001 
Race/ethnicity— X2=39.33, p<0.001 
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Table 4.4. Differential Effect of Physician Characteristics 
Construct 
MMA 
Period 
Differential 
Effect 
Standard 
Error 
p-
value 
Time in Practice Pre -0.008 0.006 0.162 
 
During -0.007 0.005 0.165 
 
Post -0.005 0.004 0.169 
Solo Practice Pre 0.040 0.010 0.000 
 
During 0.033 0.009 0.000 
 
Post 0.025 0.007 0.000 
Some Medical School 
Affiliation Pre -0.024 0.005 0.000 
 
During -0.020 0.005 0.000 
 
Post -0.014 0.003 0.000 
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Table 4.5. Comparison of Physician and Practice Characteristics of Behavioral 
Responders—Physician Characteristics 
 
Decreasing 
Users  
(N=394) 
Increasing Users  
(N=276) p-value 
       
Primary ADT 0.3 (0.2) 0.3 (0.2) <0.001 
Time in Practice 
  
0.25 
<20 years 36.5 32.2 
 ≥20 years 63.5 67.8 
 Gender 
  
0.5 
Male 98.7 99.3 
 Female 1.3 0.7 
 US Trained 
  
0.34 
No 15.0 17.8 
 Yes 85.0 82.2 
 Board Certified 
  
0.34 
No 4.8 6.5 
 Yes 95.2 93.5 
 Medical School Affiliation 
  
0.37 
No 54.8 59.4 
 Some 44.9 40.6 
 Missing 0.3 0.0 
 Physician Prostate Panel 
Size 
  
0.61 
0–20 prostate patients/year 32.5 30.4 
 21–37 prostate patients/year 42.9 46.7 
 ≥38 prostate patients/year 24.6 22.8 
 Solo Practitioner 
  
0.89 
No 72.1 71.4 
 Yes 24.6 24.6 
 Missing 3.3 4.0 
 Proportion of Patients 
Minority 
  
0.3 
1 28.4 31.5 
 2 36.5 30.8 
 3 35.0 37.7 
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Table 4.6. Comparison of Physician and Practice Characteristics of Behavioral 
Responders—Patient Panel Characteristics 
 
Patients of 
Physicians who 
Increased ADT  
Patients of 
Physicians who 
Decreased ADT  p-value 
 
Mean (Standard Deviation) or % 
  (N=4,317) (N=2,817) 
Primary ADT 23.2 30.5 <0.001 
Time in Practice 
  
<0.001 
<20 years 31.5 26.8 
 ≥20 years 68.5 73.2 
 T Stage 
  
0.02 
T1 78.2 80.4 
 T2 21.8 19.6 
 Grade 
  
0.02 
Well differentiated, 2–4 4.5 5.9 
 Moderately differentiated 5–7* 93.2 91.9 
 Missing 2.3 2.1 
 Comorbidities 
  
0.18 
0 65.8 63.8 
 1 22.7 23.0 
 2 6.8 7.7 
 ≥3  4.8 5.5 
 Age (continuous) 74.6 (6.1) 75.1 (6.3) <0.001 
Race/ethnicity 
  
<0.001 
Non-Hispanic White 78.7 75.6 
 Non-Hispanic Black 5.1 8.0 
 Hispanic 8.7 6.8 
 Other 2.9 5.3 
 Missing 4.6 4.3 
 Marital Status 
  
0.75 
Not Married 19.3 19.2 
 Married 67.2 66.7 
 Missing 13.5 14.2 
 Pre-treatment Primary Care 
Use 
  
0.15 
0–2 visits in prior year 18.6 17.5 
 3–5 visits in prior year 43.2 42.1 
 ≥6 visits in prior year 38.2 40.4 
 Primary Care Consultation 
  
0.9 
No 44.4 44.2 
 Yes 55.6 55.8 
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Radiation Oncology 
Consultation 
  
<0.001 
No 84.3 87.7 
 Yes 15.7 12.3 
 Medical Oncology 
Consultation 
  
0.12 
No 96.2 96.9 
 Yes 3.8 3.1 
 Urology Consultation 
  
0.07 
No 0.8 1.2 
 Yes 99.2 98.8 
 Rural Residence 
  
0.38 
No 98 97.7 
 Yes 2.0 2.3 
 SEER Region 
  
<0.001 
Seattle 2.3 2.4 
 Connecticut 8.1 4.4 
 Detroit 6.9 8.1 
 Hawaii 0.3 1.4 
 Iowa 6.9 5.6 
 New Mexico 6.3 2.6 
 California 39.1 34.4 
 Utah 4.5 5.1 
 Georgia 1.4 2.2 
 Kentucky 9.2 15.1 
 New Jersey 14.9 18.6 
 Median Income of Patients' Communities 
 
0.003 
$2,506–$35,031 21.2 24.6 
 $35,051–$46,079 26.4 25.7 
 $46,084–$60,668 23.3 23.6 
 $60,669–$200,008 24.9 22.7 
 Missing 4.2 3.4 
 Proportion of Patient's Community w/o High School Education <0.001 
0%–9.7% 25.6 21.5 
 9.7%–15.5% 24.9 23.1 
 15.5%–25.2% 24.0 23.4 
 25.2%–100% 21.4 28.6 
 Missing 4.1 3.4 
 
P-values by t-test for continuous variables and chi2 test for binary / categorical variables 
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CHAPTER 5 EFFECT OF REIMBURSEMENT CHANGES ON PRIMARY ANDROGEN 
DEPRIVATION THERAPY OVERUSE 
Introduction  
Approximately 30-40% of healthcare spending in the U.S. has been attributed to 
overuse, the use of care in patients for whom it is not recommended (71-73). Overuse results in 
patient harms, health disparities and waste in a healthcare system already stretched to capacity 
(73). Despite being designated a significant quality problem and a national priority (74), 
relatively little research focuses on interventions to address overuse (71, 75). One strategy for 
limiting overuse is to decrease financial incentives. Specifically, limiting reimbursement is 
attractive because it may save money and simultaneously improve quality (39, 52).  
Androgen deprivation therapy (ADT) in the form of Gonadotropin-releasing Hormone 
(GnRH) agonists is standard treatment for metastatic prostate cancer; however, primary ADT 
has not been guideline recommended for most men diagnosed with localized disease for a 
decade (12, 20). Nonetheless, by 2002, 44.9% of men diagnosed with prostate cancer, and for 
whom ADT was not recommended, received it (39).  Because Medicare spent almost $1 billion 
annually on ADT  (10, 37, 38), almost half of which was unnecessary, and Medicare 
reimbursement for physician-administered drugs, including ADT, far exceeded physician costs, 
the Medicare Modernization Act of 2003 (MMA) revised reimbursement policy for Part B drugs; 
this reduced reimbursement for ADT by 65% (47).  
By 2005, sharp declines in ADT use were observed, suggesting reimbursement 
influenced treatment decisions (10, 39, 42). Other evidence suggests reimbursement changes 
may not have been responsible for this trend because: (1) declining ADT use also occurred in 
Canada and the Department of Veterans Affairs, health systems where Medicare policy should 
not affect use (43, 44) and (2) downward trends were observed among Medicare beneficiaries 
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prior to 2004 (40).  However, no study has evaluated whether urologists were responding 
directly to MMA reimbursement policy.  Thus, we investigate the effect of reimbursement on 
ADT overuse.   In addition, we assess how the specialty organization of urology group practices 
may have affected the effect of reimbursement on ADT overuse. We hypothesize that more 
generous reimbursement will be associated with greater overuse of ADT and that single specialty 
urology practices will be more likely to overuse ADT than multi-specialty groups. 
Methods 
Prior to MMA and during a period of clinical practice guideline stability (2000-2003), 
substantial variation in ADT reimbursement existed within Medicare. Differences in ADT 
reimbursement occurred because of the different drugs available, varying reimbursement by 
Medicare carriers which are grouped geographically, and by year of use. Exploiting this 
variation, this study examines the association of ADT reimbursement with urologists’ use of 
ADT from January 2000 through December 2003, among clinically localized prostate cancer 
patients during a period of guideline stability. The study was approved by the Institutional 
Review Board of the University of North Carolina at Chapel Hill. 
Data Sources 
We linked the Surveillance, Epidemiology and End Results (SEER)-Medicare database to 
the American Medical Association (AMA) Masterfile. SEER data include patient demographics, 
primary tumor site, morphology, and stage at diagnosis for a population-based sample of U.S. 
residents diagnosed with cancer (90). Medicare administrative claims data include hospital 
services, physician services, physician-administered drug therapy and other medical services, 
regardless of where care was provided. We used Medicare Provider Analysis and Review, 
outpatient, Durable Medical Equipment, and Carrier files for sample selection, outcome and 
treating provider identification, but used only carrier files to study response to reimbursement, 
as other files do not identify physicians, reimbursement, or both (57).  The AMA Masterfile 
includes physician and practice characteristics from approximately 800,000 US physicians. 
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Most data originate from training records collected annually (96-98% response rates). Data 
collected from physician regulatory agencies are confirmed and supplemented by annual 
surveys of one third of physicians each year (92). Additional group practice data, collected by 
survey of practice representatives, also were available from the AMA.  
Cohort Definitions 
Patients. We identified all patients who had an incident diagnosis of adenocarcinoma 
of the prostate (International Classification of Disease, 9th Revision, Clinical Modification (ICD-
9) diagnosis code 185 and International Classification of Diseases for Oncology, Third Edition  
histology code 8140) between January 1, 2000 and December 31, 2003. Only patients 
experiencing prostate cancer as their first and only cancer, as defined by SEER, were included. 
We excluded patients < 66 years at diagnosis whose comorbidities could not be ascertained; 
and, men whose initial treatment decision could not be ascertained because they lacked 
observation throughout the full treatment window, including those who 1) were diagnosed at 
autopsy, death certificate, or at a nursing/convalescent facility; 2) died within 12 months of 
diagnosis; 3) were not continuously enrolled in fee-for-service; or 4) had no treatment claims. 
The Tumor Node Metastasis Staging System was used to restrict the cohort to those for whom 
ADT is not guideline-recommended (lacked evidence of nodal or metastatic involvement and 
who had no greater than unilateral, stage T2 tumors and World Health Organization grade 1-2) 
(3). In addition, we excluded men with less than five years actuarial life expectancy following an 
algorithm used previously (93), because National Comprehensive Cancer Network (NCCN) 
guidelines allowed for the use of primary ADT in men with limited life expectancy during this 
window (20, 93).  
Urologists.  Because they prescribe 95% of primary ADT to localized prostate cancer 
patients (37, 93), we restricted the cohort to treating urologists.  First, we used patients’ claims 
files to identify the treating provider, defined as the physician responsible for the most primary 
treatment claims (105). Providers identified in claims were matched by encrypted Unique 
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Physician Identifier Number or National Provider Identifier to AMA Masterfile data (which 
excluded non-physician providers).   
Measures 
Dependent Variables. The outcome, primary ADT use, is a binary variable defined as 
any claim for medical ADT administered within one year after the SEER date of diagnosis, 
unless another non-surveillance prostate treatment was also administered within the treatment 
window. Non-surveillance treatments included orchiectomy, radical prostatectomy, 
brachytherapy, chemotherapy, and cryotherapy. All claims files were used to identify treatment 
delivered using HealthCare Common Procedure Coding System (HCPCS), Current Procedural 
Terminology, and ICD-9-CM procedure and revenue center codes (93) (Appendix A).  
Although primary ADT is the most prevalent form of ADT overuse, reimbursement also 
may affect other forms of overuse. Thus, we created an outcome that captured any ADT used in 
conjunction with any other therapy or alone for use in sensitivity analyses.  
Explanatory Variables. Claims are paid by local fiscal intermediaries (Part A) and 
carriers (Part B), which lack uniform reimbursement policies (56). From 1997-2002, carriers 
were responsible for translating Part B drug HCPCS claims into National Drug Code (NDC) 
indices (57). While some HCPCS had only one equivalent NDC, others had > 10 matches, 
resulting in substantial reimbursement variation (49). In addition to variability among carriers, 
reimbursements changed at different rates over time due to changes in average wholesale prices 
for specific NDCs (57).  
To exploit this variation in ADT reimbursement, the key explanatory variable, 
reimbursement generosity index (RGI), was operationalized as the sum of the weighted average 
difference between the urologists’ and the national mean reimbursement for each drug the 
urologist prescribed (57). Weights were derived as the ratio of SEER registry-wide spending on a 
regimen to total spending on all ADT agents (see Appendix B).  Differences in the index reflect 
variation in reimbursement specific to each carrier and over time as well as changes in the mix 
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of drugs prescribed by each physician in any year. Any score greater than one indicates excess 
(greater than the national average) reimbursement. Thus, a positive association between RGI 
and ADT use would indicate that urologists are inducing demand. 
Some urologists may not have prescribed ADT for any of their patients. Because RGI 
could not be computed for these urologists, they were excluded from the analysis.  Thus, we 
created two additional constructs for sensitivity analyses. First, we calculated a second RGI 
which included the costs of each ADT modality relative to all other care provided to this 
population, with weights adjusted to capture this additional “non-ADT treatment” category. This 
allowed us to assess whether urologists substituted for lost income by increasing the quantity of 
discounted services or selecting alternate treatments (106).  Second, we created a revised RGI 
that assumed the SEER average reimbursement for urologists who did not prescribe any ADT. 
Group practice organizational type is a series of mutually exclusive categories of the 
treating practice: single specialty urology group; multi-specialty group; or urology-radiation 
oncology group (all urologists with two or fewer radiation oncologists). This was self-reported by 
practice representatives to the AMA. 
Control Variables. Patient, urologist, and practice variables were selected based upon 
the  literature on prostate treatment decisions, quality of care, or responsiveness to incentives.  
Patient-Level Factors. Disease severity included tumor stage, as measured by SEER 
Extent of Disease-1988 3rd edition variables, and grade, categorized as low (Gleason 2 to 4) or 
intermediate (Gleason 5 to 7) by SEER. Comorbidities were measured by the NCI Comorbidity 
Index (NCI CI) (107). Patient demographics included age; and marital status (married/living 
with a partner versus single, widowed or divorced, or missing).  Healthcare use included:  prior 
primary care use (any claim in the 12 months prior to diagnosis) (86); specialist consultation 
(three binary variables indicating presence of > 1 prostate-related carrier claim filed by a 
radiation oncologist, urologist or medical oncologist between diagnosis and the earliest of first 
treatment date or 12 months) (108); and, primary care consultation (>1 visit to the same 
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primary care physician occurring in both 1) the 12 months prior to diagnosis; and, 2) the window 
between diagnosis and treatment) (108). To control for environmental resources and 
community norms, we controlled for SEER region, collapsed by state, rurality of patient’s 
residence (urban versus rural), and community deprivation (quartiles of median income and 
proportion of adults with less than 12 years of education in the patients’ zip code of residence) 
(140).  
Provider-Level Factors. Using data from the AMA and Medicare Hospital files, we 
measured: (1) Physician gender; (2) time in practice; and (3) medical professionalization  (109, 
110) defined as board certification (yes/no) and degree of affiliation with an academic 
institution (categorical); (4) panel size (number of prostate cancer patients/year/urologist); (5) 
practice type (solo; group practice; or missing); and (6) proportion minority Medicare patients 
within a practice (categorized into quartiles) (111). Using self-reported data from the AMA 
Masterfile, we included proportion of Medicare patients (<25%/>25%) in group practice 
analyses.  
Finally, we controlled for time by including variables for each year of the study.  
Statistical Analysis 
We used multiple imputation for missing values of the proportions of Medicare patients 
seen within practices (141). We dichotomized RGI (negative or zero versus positive) and used 
Pearson’s chi-squared tests and t-tests to compare across reimbursement levels. Descriptive 
statistics are presented for the sample of patients, the main unit of analysis, and the sample of 
physicians. Due to high intraclass correlation among patients treated by the same urologist (58), 
we used multilevel mixed logistic regression models which controlled for clustering of patients 
within provider. We conducted sensitivity analyses with alternate specifications of RGI and 
samples of urologists and with varying definitions of the outcome. We created a sub-sample, 
further limiting the cohort to urologists identified by the AMA as practicing in a group practice. 
77 
 
Statistical significance was evaluated at α =0.05 for all tests. Stata/SE 12.1 was used for all 
analyses (112). 
Results 
The final sample (Figure 1) included 15,128 men with T1 or T2 well- or moderately-
differentiated prostate cancer treated by 1,800 ADT-using urologists between 2000 and 2003. 
Twenty four percent (3,653/15,128) of patients were treated with primary ADT. Among the 
ADTs used, goserelin acetate implants (3.6 mg) and leuprolide acetate injections (7.5 mg) were 
most frequently used. All other androgen deprivation modalities (leuprolide acetate implant, 
triptorelin pamoate injection, leuprolide acetate injection 3.5 mg, leuprolide acetate injection 1 
mg, and orchiectomy) made up less than 3% of ADT use combined.  
Average reimbursement generosity for all androgen deprivation therapy combined over 
the study period was 2.93, but fluctuated by treatment year and among urologists who 
prescribed ADT. Average reimbursement generosity among ADT-prescribing urologists for both 
ADTs and all other non-ADT treatments combined was -1.54.   
In unadjusted analysis, among urologists who prescribed ADT, primary ADT use was 
higher among patients treated by urologists who received ADT reimbursement greater than the 
national average than it was among patients whose urologists received unfavorable 
reimbursement (i.e., negative or zero) (Table 1). However, at the physician level, there was no 
difference in the proportion of their fee-for-service localized prostate cancer patients prescribed 
primary ADT between urologists in unfavorable and favorable reimbursement climates (Table 
2). Each group prescribed primary ADT to 30% of patients (p=0.56). ADT-prescribing urologists 
in favorable reimbursement areas were more likely to have some medical school affiliation 
(p<0.001) and more likely to be in group practice (p=0.03) than urologists in unfavorable 
reimbursement areas. 
After controlling for patient, urologist, and practice characteristics and accounting for 
the correlation of patients within urologists, excess reimbursement for ADT, relative to other 
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ADTs, was not associated with ADT overuse among urologists who prescribed primary ADT to 
their T1 and T2 well- or moderately-differentiated prostate cancer patients (OR 1.00, 95% CI, 
0.99, 1.00)  (Table 3). However, the odds of primary ADT (OR 0.99; 95% CI 0.99, 0.99) use, 
relative to all treatments, decreased with an increase in RGI. Although the result was 
statistically significant, practically, the effect was very small. In additional sensitivity analysis, 
when considering all urologists (n=16,789) and assuming that non-prescribers were reimbursed 
at the SEER national average, primary ADT overuse was negatively associated with 
reimbursement, although the effect size was small and confidence intervals rounded to cross one 
(OR 0.99, 95% CI 0.99, 1.00). For every dollar of reimbursement above the national average, 
there was a 0.59 percentage point reduction in the odds of prescribing unnecessary (table not 
shown). Results for all models were qualitatively similar whether we used primary ADT or any 
ADT use as the outcome. 
Results also were similar among urologists practicing in group settings (Table 4). Among 
the subset of urology group practices whose physicians prescribed ADT, reimbursement 
generosity was not associated with ADT overuse (OR 1.00; 95% CI 1.00, 1.00). Among all 
urologists in group practice selecting among all therapies, we found a very small, but significant, 
negative association of reimbursement with ADT overuse, but the confidence intervals rounded 
to one (OR 0.99; 95% CI 0.99, 1.00). Results from models considering any ADT use were 
similar. Physicians practicing in a multispecialty group environment were less likely to prescribe 
PADT (OR 0.79; 95% CI 0.64, 0.97). Urology group practices with at least one radiation 
oncologist did not differ in use of PADT from statistically urology group practices.   
Discussion 
Because Medicare reimbursement far exceeded the cost of physician-administered drugs 
such as ADT, the MMA of 2003 reduced reimbursement for Part B.  While studies observed 
dramatic decreases in ADT use, no study has evaluated whether urologists were responding 
directly to MMA reimbursement policy. Contrary to our hypothesis, we found no evidence to 
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suggest excess reimbursement was associated with greater ADT overuse. The overuse of ADT in 
men with early stage and lower grade prostate cancer appeared at first to be greater for those 
who received more generous reimbursement. However, the relationship did not persist after 
adjusting for patient and physician factors known to be associated with ADT use. However, 
when we broadened our definition of reimbursement to be relative to all prostate cancer 
treatments, we observed a significant but small association in the unexpected direction. Excess 
reimbursement was associated with less overuse, not more, though the magnitude of this 
difference was nominal. Results were similar in sensitivity analysis that examined all urologists 
and assumed average ADT reimbursement for non-ADT users. 
Our main findings differ from two studies which found the implementation of MMA to 
be associated with declining ADT use (10, 39). These observational studies assessed the change 
in ADT use over time. However, a wide range of factors—emerging evidence, guideline changes, 
prosecution of illegal marketing practices, and practice reorganization—could have led to the 
changes observed in the 2 studies (12, 20, 28, 43, 48, 69, 142). In contrast, we conducted our 
study during a period of guideline stability, controlled for other trends and exploited variation in 
reimbursement that occurred both within and between urologists. Thus, our study design 
isolated the effect of excess reimbursement, providing a stronger comparison than the within-
provider comparison measured in earlier studies. Our study contributes to a body of work which 
does not support the hypothesis that reimbursement cuts alone drove down the overuse of ADT 
(43, 44). A more recent study using join point analysis found no association between MMA and 
decreasing use of ADT adjuvant to radical prostatectomy (143). Our findings are also consistent 
with other studies using the reimbursement generosity index to assess reimbursement changes. 
In a study assessing the effect of MMA on chemotherapy use in other cancers, reimbursement 
cuts were associated with increased use of chemotherapy, rather than the expected drop in use 
(51). The phenomenon of increasing the quantity of services when faced with a price reduction is 
well described in the economics literature (36, 51, 64, 65, 105). Our earlier study of response to 
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MMA demonstrated that while some urologists decreased ADT overuse coincident with MMA 
implementation, a smaller but substantial group of urologists increased ADT overuse during the 
same time (93). In the current study among ADT users, differential volume response may have 
negated any effect reimbursement differences may have had.  
Because our findings differed based on our urologist sample and including only the 
reimbursement generosity of ADT versus reimbursement generosity relative to all treatments, 
we suspect that while at least some urologists who experienced lower or declining 
reimbursement may have intensified their overuse of ADT to make up for their declining 
revenues, others may have substituted other therapies for their lower stage and grade prostate 
cancer patients. Rather than ADT reimbursement affecting practice patterns, it is possible that 
other treatments urologists could offer their patients over the MMA implementation period—
which on average were reimbursed with greater generosity than any ADT modality—may have 
impacted ADT overuse. Whether these alternate therapies may have been available only to a 
subset of urologists or limited by the types of patients seen in some urologists’ practices is not 
known. But, the treatments patients received in the favorable and unfavorable reimbursement 
generosity areas differed slightly.  
In other studies, physicians faced with differing reimbursement select the more highly 
reimbursed modality, suggesting that they are responsive to reimbursement within the bounds 
of treatments they are willing—or able—to prescribe (51). However, in some situations the 
physician may also alter the mix of treatments offered to align the care provided with better 
reimbursement (51, 105). We examined the effect of urology group practice organization on 
reimbursement generosity by repeating our analysis in a subset of urologists in group practices, 
expecting that practice organizational types suggestive of differing treatment resources, may 
have better access to alternative treatments and be less likely to overuse ADT. We found that 
physicians in multi-specialty group practices did offer less PADT, supporting our hypothesis. We 
did not find a similar effect among urology-radiation oncology practices, but the number of 
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urology-radiation oncology practices in our sample was small, partly because this practice type 
was just emerging in the beginning of the decade.  
Our study has several limitations that warrant careful interpretation of results. First, 
from 2000-2004, primary ADT was recommended for men with less than five years of life 
expectancy whose risk for prostate cancer recurrence was high (20). We excluded men with 
stage and grade consistent with high recurrence risk. However, our cohort may have included 
men with high risk disease who could not be identified through SEER.  To minimize this bias, we 
excluded men with less than five years of actuarial life expectancy, the target group to whom the 
ADT recommendation actually applied. Second, we were unable to control for the proportion of 
a physicians’ patients who were in fee-for service Medicare in our main analysis.  When this 
variable was included in the group practice analyses, we found that physicians with greater 
concentrations of Medicare patients had greater odds of ADT overuse, suggesting practices may 
switch to patients with other payers. However, few urology practices treat high proportions of 
Medicare patients and data collected during this time suggest that urologists’ maintained stable 
portions of Medicare patients (62, 144, 145). Nonetheless, we used a dataset of practice 
information never before used for research, so results regarding organization type should be 
interpreted cautiously. Finally, measurement error and our sampling strategy may have 
interfered with our ability to detect a relationship between ADT overuse and reimbursement.  
Conclusions 
Despite declining use, ADT overuse remains a serious quality problem in 14% of patients 
in whom it is not clinically recommended (93). Although policy makers and payers may view 
changes in reimbursement as a promising strategy to reduce overuse, this was not the case in 
our study of ADT. In a large, national sample of urologists ADT reimbursement generosity was 
not associated with primary ADT use. We conducted multiple sensitivity analyses: varying our 
definition of ADT overuse; considering reimbursement relative to ADT; and, comparing among 
all urologists treating patients in our cohort and only those who prescribed ADT during the 
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study. In these analyses our findings were robust that ADT reimbursement changes were not 
associated with practice changes. However, in analyses comparing ADT relative to all treatments 
provided, we detected a small, but negative association with ADT use, suggesting that other 
treatments’ reimbursement may have encouraged some physicians to limit their ADT overuse. 
Additional research on physician response to reimbursement when opportunities for treatment 
substitution are available should be investigated. 
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Figure 5.1. Cohort Exclusions 
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Table 5.1. Characteristics of Patients of ADT-Prescribing Urologists 
 
Overall 
ADT 
Reimbursement 
< to National 
Average 
ADT 
Reimbursement  
> National 
Average 
 
 
Mean (Standard Deviation) or % 
   N=15,128 N= 5,932 N= 9,196 p 
Primary ADT 3,653 (24.1%) 1,356 (22.9%) 2,297 (25.0%) 0.003 
Reimbursement 
Generosity Index 2.9 (69.6) -48.0 (65.6) 35.8 (49.5) <0.001 
Year Treated 
   
<0.001 
2000 3,317 (21.9%) 1,332 (22.5%) 1.985 (21.6%) 
 2001 3,894 (25.7%) 1,618 (27.3%) 2,276 (24.7%) 
 2002 4,421 (29.2%) 1,890 (31.9%) 2,531 (27.5%) 
 2003 3,496 (23.1%) 1,092 (18.4%) 2,404 (26.1%) 
 T Stage 
   
0.08 
T1 6,296 (41.6%) 2,417 (40.7%) 3,879 (42.2%) 
 T2 8,832 (58.4%) 3,515 (59.3%) 5,317 (57.8%) 
 Grade 
   
<0.001 
Well differentiated, 2-
4 759 (5.0%) 333 (5.6%) 426 (4.6%) 
 Moderately 
Differentiated, 5-7 13,867 (91.7%) 5,439 (91.7%) 8,428 (91.6%) 
 Missing 502 (3.3%) 160 (2.7%) 342 (3.7%) 
 Comorbidities 
   
<0.001 
0 10,245 (67.7%) 4,129 (69.6%) 6,116 (66.5%) 
 1 3,298 (21.8%) 1,240 (20.9%) 2,058 (22.4%) 
 2 998 (6.6%) 354 (6.0%) 644 (7.0%) 
 3 or more 587 (3.9%) 209 (3.5%) 378 (4.1%) 
 Age, in years 73.9 (5.5) 73.7 (5.5) 73.9 (5.5) 0.03 
Race/ethnicity 
   
<0.001 
Non-Hispanic White 12,008 (79.4%) 4,878 (82.2%) 7,130 (77.5%) 
 Non-Hispanic Black 1,175 (7.8%) 303 (5.1%) 872 (9.5%) 
 Hispanic 925 (6.1%) 352 (5.9%) 573 (6.2%) 
 Other 550 (3.6%) 249 (4.2%) 301 (3.3%) 
 Missing 470 (3.1%) 150 (2.5%) 320 (3.5%) 
 Marital Status 
   
0.01 
Not Married 2,767 (18.3%) 1,022 (17.2%) 1,745 (19.0%) 
 Married 10,231 (67.6%) 4,086 (68.9%) 6,145 (66.8%) 
 Missing 824 (14.1%) 5,923 (13.9%) 9,196 (14.2%) 
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Pre-treatment 
Primary Care Use 
   
0.19 
0-2 visits in prior year 2,991 (19.8%) 1,135 (19.1%) 1,856 (20.2%) 
 3-5 visits in prior year 6,753 (44.6%) 2,693 (45.4%) 4.060 (44.1%) 
 6 or more visits in 
prior year 5,384 (35.6%) 2,104 (35.5%) 3,280 (35.7%) 
 Primary Care 
Consultation 
   
0.21 
No 7,104 (47.0%) 2,823 (47.6%) 4,281 (46.6%) 
 Yes 8,024 (53.0%) 3,109 (52.4%) 4,915 (53.4%) 
 Radiation Oncology 
Consultation 
   
0.008 
No 10,805 (71.4%) 4,309 (72.6%) 6,496 (70.6%) 
 Yes 4,323 (28.6%) 1,623 (27.4%) 2,700 (29.4%) 
 Medical Oncology 
Consultation 
   
0.04 
No 14,603 (96.5%) 5,703 (96.1%) 8,900 (96.8%) 
 Yes 525 (3.5%) 229 (3.9%) 296 (3.2%) 
 Urology 
Consultation 
   
0.008 
No 156 (1.0%) 45 (0.8%) 111 (1.2%) 
 Yes 14,972 (99%) 5,887 (99.2%) 9,085 (98.8%) 
 Rural Residence 
   
<0.001 
No 14,835 (98.1%) 5,768 (97.2%) 9,067 (98.6%) 
 Yes 293 (1.9%) 164 (2.8%) 129 (1.4%) 
 SEER Region 
   
<0.001 
Seattle 751 (5.0%) 644 (10.9%) 107 (1.2%) 
 Connecticut 1,037 (6.9%) 477 (8.0%) 560 (6.1%) 
 Detroit 1,270 (8.4%) 108 (1.8%) 1,162 (12.6%) 
 Hawaii 163 (1.1%) 105 (1.8%) 58 (0.6%) 
 Iowa 1,133 (7.5%) 439 (7.4%) 694 (7.5%) 
 New Mexico 368 (2.4%) 51 (0.9%) 317 (3.4%) 
 California 4,498 (29.7%) 1,982 (33.4%) 2,516 (27.4%) 
 Utah 678 (4.5%) 631 (10.6%) 47 (0.5%) 
 Georgia 332 (2.2%) 27 (0.5%) 305 (3.3%) 
 Kentucky 1,212 (8.0%) 670 (11.3%) 542 (5.9)% 
 Louisiana 1,233 (8.2%) 340 (5.7%) 893 (9.7%) 
 New Jersey 2,453 (16.2%) 458 (7.7%) 1,995 (21.7%) 
 Median Income of Patients' 
Communities 
  
<0.001 
$2,506-35,031 3,574 (23.6%) 1,495 (25.2%) 2,079 (22.6%) 
 $35,051-46,079 3,817 (25.2%) 1,660 (28.0%) 2,157 (23.5%) 
 $46,084-60,668 3,563 (23.6%) 1,351 (22.8%) 2,212 (24.1%) 
 $60,669-200,008 3,596 (23.8%) 1,205 (20.3%) 2,391 (26.0%) 
 Missing 578 (3.8%) 221 (3.7%) 357 (3.9%) 
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Proportion of Patient's Community w/o High School 
Education 
 
0.002 
0-9.7% 3,615 (23.9%) 1,499 (25.3%) 2,116 (23.0%) 
 9.7-15.5% 3,720 (24.6%) 1,469 (24.8%) 2,251 (24.5%) 
 15.5%-25.2% 3,569 (23.6%) 1,313 (22.1%) 2,256 (24.5%) 
 25.2%-100% 3,653 (24.1%) 1,431 (24.1%) 2,222 (24.2%) 
 Missing 571 (3.8%) 220 (3.7%) 351 (3.8%)   
P-values by t-test for continuous variables and chi2 test for binary / categorical 
variables   
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Table 5.2. Characteristics of ADT-Prescribing Urologists 
 
Overall 
ADT 
Reimbursement 
< to National 
Average 
ADT 
Reimbursement  
> National 
Average 
   Mean (Standard Deviation) or %   
 N=1800 N= 701 N= 1,099 p 
Proportion of Patients in 
Practice Receiving 
Primary ADT 0.3 (0.3) 0.3 (0.3) 0.3 (0.3) 0.56 
Reimbursement 
Generosity Index 2.9 (73.6) -37.0 (62.2) 28.4 (68.9) <0.001 
Time in Practice 
   
0.42 
<20 years 686 (38.1%) 259 (36.9%) 427 (38.9%) 
 >20 years 1,114 (61.9%) 442 (63.1%) 672 (61.1%) 
 Gender 
   
0.41 
0 1,763 (97.9%) 689 (98.3%) 1,074 (97.7%) 
 1 37 (2.1%) 12 (1.7%) 25 (2.3%) 
 U.S. Trained 
   
0.29 
0 298 (16.6%) 108 (15.4%) 190 (17.3%) 
 1 593 (83.4%) 593 (84.6%) 909 (82.7%) 
 Board Certified 
   
0.55 
0 113 (6.3%) 41 (5.8%) 72 (6.6%) 
 1 1,687 (93.7%) 660 (94.2%) 1,027 (93.4%) 
 Medical School Affiliation 
   
<0.001 
0 903 (50.2%) 391 (55.8%) 512 (46.6%) 
 1 854 (47.4%) 294 (41.9%) 560 (51.0%) 
 2 43 (2.4%) 16 (2.3%) 27 (2.5%) 
 Physician Prostate Panel Size 
   
0.45 
0-20 prostate patients/year 1,195 (66.4%) 474 (67.6%) 721 (65.6%) 
 21-37 prostate patients/year 454 (25.2%) 175 (25.0%) 279 (25.4%) 
 38 or more prostate 
patients/year 151 (8.4%) 52 (7.4%) 99 (9.0%) 
 Practice Type 
   
0.03 
Group Practice 1,274 (70.8%) 471 (67.2%) 803 (73.1%) 
 Solo Practice 442 (24.6%) 193 (27.5%) 249 (22.7%) 
 Missing 84 (4.7%) 37 (5.3%) 47 (4.3%) 
 Proportion of Patients 
Minority 
   
<0.001 
1 668 (37.1%) 295 (42.1%) 373 (33.9%) 
 2 522 (29.0%) 211 (30.1%) 311 (28.3%) 
 3 610 (33.9%) 195 (27.8%) 415 (37.8%)   
P-values by t-test for continuous variables and chi2 test for binary / categorical variables   
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Table 5.3. Regression Results: Reimbursement Excess, ADT Users Only 
    Odds Ratio 
95% Confidence 
Interval 
Reimbursement 
Generosity Index 
 
1.00 1.00 1.00 
Time in Practice <20 years 1.00 
  
 
>20 years 0.98 0.84 1.14 
Gender Male 1.00 
  
 
Female 1.12 0.58 2.18 
Training Location Foreign Trained 1.00 
  
 
US Trained 1.00 0.81 1.23 
Board Certification None 1.00 
  
 
Board Certified 0.77 0.57 1.04 
Medical School 
Affiliation None 1.00 
  
 
Some 0.94 0.80 1.09 
 
Missing 2.00 1.21 3.30 
Practice Type Group Practice 1.00 
  
 
Solo Practice 1.27 1.07 1.52 
 
Missing 0.86 0.58 1.26 
Physician Prostate 
Panel Size <20 prostate patients/year 1.00 
  
 
21-37 prostate patients/year 0.75 0.65 0.86 
 
38 or more prostate 
patients/year 0.81 0.68 0.96 
Proportion of 
Patients Minority <6.1% 1.00 
  
 
6.2-19.5% 0.94 0.80 1.10 
 
>20% 1.14 0.95 1.38 
T Stage T1 1.00 
  
 
T2 1.91 1.72 2.13 
Grade Well differentiated, 2-4 1.00 
  
 
Moderately Differentiated, 5-7 2.26 1.78 2.88 
 
Missing 3.50 2.50 4.91 
Comorbidities 0 1.00 
  
 
1 1.40 1.24 1.57 
 
2 1.43 1.18 1.72 
 
3 or More 2.07 1.65 2.60 
Age, in years 
 
1.78 1.38 2.30 
Age2 
 
1.00 1.00 1.00 
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Race/ethnicity Non-Hispanic White 1.00 
  
 
Non-Hispanic Black 1.42 1.17 1.73 
 
Hispanic 1.25 1.00 1.56 
 
Other 1.30 0.94 1.79 
 
Missing 1.95 1.50 2.53 
Marital Status Unmarried 1.00 
  
 
Married/Living with Partner 0.79 0.70 0.90 
 
Missing 1.85 1.56 2.18 
Rural Residence Urban 1.00 
  
 
Rural 0.98 0.68 1.43 
SEER Region Seattle 1.00 
  
 
Connecticut 1.76 1.14 2.73 
 
Detroit 0.99 0.64 1.54 
 
Hawaii 1.15 0.53 2.51 
 
Iowa 1.37 0.87 2.15 
 
New Mexico 1.14 0.64 2.01 
 
California 1.03 0.71 1.50 
 
Utah 1.11 0.67 1.87 
 
Georgia 1.16 0.67 2.01 
 
Kentucky 1.00 0.65 1.55 
 
Louisiana 1.52 0.99 2.34 
 
New Jersey 1.79 1.22 2.63 
Proportion of 
Patient's 
Community w/o 
High School 
Education 0-9.7% 1.00 
  
 
9.7-15.5% 1.09 0.92 1.29 
 
15.5%-25.2% 1.19 0.97 1.45 
 
25.2%-100% 1.16 0.91 1.48 
 
Missing 0.25 0.02 3.35 
Median Income of 
Patients' 
Communities 
$2,506-35,031 
1.00 
  
 
$35,051-46,079 0.97 0.82 1.13 
 
$46,084-60,668 0.82 0.67 1.01 
 
$60,669-200,008 0.81 0.62 1.04 
 
Missing 3.55 0.27 46.68 
Radiation Oncology 
Consultation No  1.00 
  
 
Yes 0.26 0.23 0.31 
Medical Oncology 
Consultation No 1.00 
  
 
Yes 0.88 0.65 1.19 
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Urology 
Consultation No 1.00 
  
 
Yes 5.62 3.19 9.90 
Primary Care 
Consultation No 1.00 
  
 
Yes 0.41 0.36 0.46 
Pre-treatment 
Primary Care Use 0-2 visits in prior year 1.00 
  
 
3-5 visits in prior year 1.58 1.36 1.83 
 
6 or more visits in prior year 1.89 1.60 2.22 
Year Treated 2000 1.00 
  
 
2001 1.04 0.90 1.20 
 
2002 1.10 0.95 1.27 
 
2003 0.93 0.80 1.08 
Constant   0.95 0.87 1.04 
N=15,128         
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Table 5.4. Logistic Regression of Reimbursement Generosity on Primary ADT Overuse 
among Group Practice Organizations 
    
Odds 
Ratio 
95% Confidence 
Interval 
Reimbursement 
Generosity Index 
 
1.00 1.00 1.00 
Group Practice Type Urology  1.00   
 Multispecialty 0.79 0.64 0.97 
 Urology-Radiation Oncology 1.61 0.18 14.35 
Time in Practice <20 years 1.00   
 
>20 years 0.99 0.83 1.19 
Gender  Male  1.00   
 
Female 1.52 0.80 2.89 
Training Location Foreign Trained  1.00   
 
US Trained 0.74 0.54 1.01 
Board Certification None 1.00   
 
Board Certified 0.49 0.29 0.81 
Medical School 
Affiliation None 1.00   
 
Some 0.79 0.65 0.94 
 
Missing 1.83 0.89 3.78 
Physician Prostate 
Panel Size <20 prostate patients/year 1.00   
 
21-37 prostate patients/year 0.71 0.59 0.84 
 
38 or more prostate 
patients/year 0.77 0.62 0.95 
Proportion of 
Patients Minority <6.1%  1.00   
 
6.2-19.5% 0.94 0.78 1.13 
 
>20% 1.26 1.00 1.58 
Proportion of 
Patients Medicare  <25% (reference) 1.00   
 
>25% 1.49 1.09 2.04 
T Stage T1  1.00   
 
T2 1.41 1.25 1.59 
Grade Well differentiated, 2-4 1.00   
 
Moderately Differentiated, 5-
7 2.28 1.68 3.09 
 
Missing 4.42 2.86 6.83 
Comorbidities 0 1.00   
 
1 1.29 1.11 1.49 
 
2 1.36 1.07 1.72 
 
3 or More 1.64 1.20 2.24 
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Age, in years 
 
1.35 1.00 1.82 
Age2 
 
1.00 1.00 1.00 
Race/ethnicity Non-Hispanic White 1.00   
 
Non-Hispanic Black 1.31 1.04 1.65 
 
Hispanic 1.61 1.19 2.18 
 
Other 1.33 0.89 1.99 
 
Missing 1.04 0.72 1.49 
Marital Status Unmarried 1.00   
 
Married/Living with Partner 0.85 0.73 0.99 
 
Missing 1.17 0.95 1.45 
Rural Residence Urban 1.00   
 
Rural 1.30 0.84 1.99 
SEER Region Seattle 1.00   
 
Connecticut 1.89 1.06 3.40 
 
Detroit 1.14 0.64 2.04 
 
Hawaii 1.72 0.37 7.99 
 
Iowa 1.50 0.83 2.69 
 
New Mexico 1.49 0.67 3.29 
 
California 1.11 0.65 1.88 
 
Utah 1.05 0.50 2.19 
 
Georgia 1.25 0.63 2.48 
 
Kentucky 1.29 0.73 2.28 
 
Louisiana 2.25 1.24 4.10 
 
New Jersey 2.64 1.53 4.53 
Proportion of 
Patient's Community 
w/o High School 
Education 0-9.7% 1.00   
 
9.7-15.5% 1.05 0.88 1.26 
 
15.5%-25.2% 0.93 0.75 1.17 
 
25.2%-100% 1.33 0.89 1.99 
 
Missing 1.04 0.72 1.49 
Median Income of 
Patients' 
Communities $2,506-35,031 1.00   
 
$35,051-46,079 1.01 0.82 1.24 
 
$46,084-60,668 0.84 0.65 1.08 
 
$60,669-200,008 0.72 0.52 0.98 
 
Missing 1.61 0.11 22.96 
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Radiation Oncology 
Consultation No  1.00   
 
Yes 2.19 1.90 2.53 
Medical Oncology 
Consultation No 1.00   
 
Yes 1.24 0.90 1.69 
Primary Care 
Consultation No 1.00   
 
Yes 0.62 0.54 0.72 
Pre-treatment 
Primary Care Use 0-2 visits in prior year 1.00   
 
3-5 visits in prior year 1.48 1.23 1.77 
 
6 or more visits in prior year 1.84 1.50 2.24 
Year Treated 2000 1.00   
 
2001 0.92 0.78 1.09 
 
2002 0.97 0.81 1.16 
 
2003 0.71 0.59 0.86 
Constant   0.00 0.00 0.01 
N=7,096 patients; n=780 physicians     
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CHAPTER 6 EFFECT OF PRE-MMA ANDROGEN DEPRIVATION THERAPY 
OVERUSE ON POST-MMA QUALITY OF CARE FOR LOCALIZED PROSTATE 
CANCER 
Introduction  
Primary androgen deprivation therapy (PADT) for the treatment of localized prostate 
cancer has been a growing quality of care problem since the 1990s, especially for African 
Americans (37, 59, 146, 147). Comparative effectiveness studies (148, 149) and clinical practice 
guidelines do not support the use of PADT, the  use of ADT as the only treatment, in patients 
with localized prostate cancer (12, 19, 20, 146, 147), and the evidence of its harms—including 
increased risk for osteoporosis, fractures, heart disease, diabetes, thromboembolic events, and 
cardiac death—continues to mount (26-28). Medicare reimbursement policy changes associated 
with the Medicare Modernization Act (MMA) are thought to have brought about a marked 
decline in the overuse of PADT for the treatment of patients with clinically localized prostate 
cancer over the last decade. MMA significantly lowered reimbursement paid to physician 
practices for Part B drugs, including those used for PADT. Use of PADT fell as much as 34% 
from 2003 to 2005 among men with localized disease (10, 39), an acknowledged improvement 
in quality of care. However, the full impact of the declining use of PADT on quality of care 
depends on: 1) the type of care that replaced PADT use; and, 2) the appropriateness of that care 
based on a patients’ prostate cancer recurrence risk. 
Contemporaneous with declining PADT use, prostate cancer treatment underwent 
dramatic changes, in advance of evidence to support guideline changes. Although overall rates of 
guideline-concordant therapies—radical prostatectomy, radiation therapy, and non-definitive 
therapy—increased (150, 151), the modalities of these treatments changed. Minimally invasive 
radical prostatectomy (MIRP) replaced open prostatectomy (151, 152). Intensity modulated 
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radiation therapy (IMRT) rapidly replaced external beam radiation (EBRT) (40, 153). Although 
it is unknown whether biopsy-driven surveillance has replaced less intensive surveillance 
methods, non-definitive therapy has replaced PADT (40).  
Although, evidence of the comparative effectiveness and harms of these new modalities 
is emerging (98, 152, 154-156), not all new modalities are equally endorsed, thus quality of 
prostate cancer care depends on the modality used. The National Comprehensive Cancer 
Network (NCCN) guidelines acknowledge that MIRP procedures—laparoscopic radical 
prostatectomy (and later, robotic prostatectomy)—may have equal outcomes compared to open 
prostatectomy when performed by “highly experienced” surgeons. Nonetheless, they emphasize 
the developmental nature of laparoscopic methods and ultimately recommended retropubic and 
perineal prostatectomy, although most recent guidelines are more accepting of MIRP (12, 21). 
On the other hand, NCCN guidelines have recommended both radiation modalities, EBRT and 
IMRT, for almost a decade. Similarly, for a decade NCCN has recommended following men with 
prostate-specific antigen (PSA) testing and/or digital rectal exams and repeated biopsies at 
regular intervals to monitor disease progression (22). Further, some research suggests that these 
new modalities might not be adopted equally in minority populations, creating potential 
disparities in care. 
Not only does guideline concordance depend on the treatment modality chosen, but it is 
also risk category-specific. NCCN treatment recommendations are based on D’Amico categories, 
thresholds of tumor stage, Gleason grade, and PSA levels at which biochemical failure is 
predicted (11, 22). Although PADT (ADT used as the sole treatment) is not recommended for 
any recurrence risk, other therapies are recommended only for some risk levels. Active 
surveillance is guideline-concordant care for patients with low- and intermediate-risk disease 
but not for those with high-risk prostate cancer (12). Such lack of risk group differentiation can 
mask whether care delivered is guideline-concordant (3, 18). For example, previous studies 
assessing changes in active surveillance do not consider an individual patients’ recurrence risk 
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(40) and subsequently, the appropriateness of this pattern of care change. In addition, some 
therapies are concordant when delivered in conjunction with certain therapies: ADT adjuvant to 
external beam and intensity modulated radiation is guideline-concordant for some, but not all 
risk groups, but it not guideline-concordant when combined with brachytherapy, another third 
radiation modality. 
Therefore, we risk-stratified prostate cancer patients to examine the association of 
physicians’ pre-MMA PADT use and NCCN guideline-concordant initial treatment among a 
post-MMA, population-based cohort of men with incident prostate cancer. We hypothesize that 
higher levels of baseline non-concordant PADT use will be associated with guideline-concordant 
care in the post-MMA period and that racial differences in quality will be resolved. Nonetheless, 
we further explore the modalities of treatment currently being delivered to describe how 
emerging technologies have affected quality of care. 
Methods 
We identified the initial prostate cancer treatment provided to a large population-based 
cohort of elderly prostate cancer patients for retrospective analysis. The study was approved by 
the Institutional Review Board of the University of North Carolina at Chapel Hill. 
Data Sources 
We matched Surveillance, Epidemiology and End Results (SEER)- linked Medicare data 
to American Medical Association (AMA) physician data (90, 91, 157, 158) for patients diagnosed 
with prostate cancer from 2005 to 2007 within 17 SEER registries and treated through July 
2009. 
Cohort Definition 
Patient Selection Criteria. We identified all men diagnosed with incident 
adenocarcinoma of the prostate between January 1, 2005 and December 31, 2007. Only patients 
experiencing their first and only cancer, identified by SEER, were included. We excluded 
patients whose comorbidities and/or initial treatment could not be ascertained, including those 
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who were younger than 66 years; diagnosed at autopsy, death certificate, or at a 
nursing/convalescent facility; not enrolled in fee-for-service (defined as continuous Part A and B 
coverage and not in a health maintenance organization for at least 18 months post diagnosis; or 
died within 18 months of diagnosis. The Tumor Node Metastasis (TNM) staging system was 
used to restrict the cohort to men with clinically localized prostate cancer by excluding men with 
1) tumors clinically staged T3b or greater; 2) any evidence of nodal involvement; or, 3) any 
evidence of metastases.  
Physician Inclusion Criteria. Treating physicians were identified in Medicare claims. 
After limiting claims to those submitted for prostate cancer treatment and identifying the 
primary therapy received with an algorithm giving preference to the most definitive therapies, 
the physician responsible for the most initial primary therapy treatment claims was considered 
the treating physician.  
Measures 
Dependent Variable. Guideline concordance, a binary outcome, was derived from the 
2004 NCCN prostate cancer treatment algorithm (12). Although a guideline update was issued 
in 2007 (159), NCCN did not change risk stratification or initial treatment recommendations, so 
this outcome remained stable throughout the study period. The algorithm stratifies patients by 
stage, grade, PSA, and in some cases, the presence of multiple risk factors. The low-risk group 
includes men with T1–2a stage, Gleason grade 2–6, and PSA <10 ng/mL. Intermediate risk 
includes men with T2b or T2c stage, Gleason grade 7, or PSA 10–20 ng/mL. The high-risk group 
includes men with PSA >20 ng/mL, Gleason >7, or stage T3a. Concordant treatments were 
assigned for each risk category.  
For initial treatment received, we used claims to categorize patients into one of five 
mutually exclusive options: 1) active surveillance; 2) radiation therapy; 3) radical prostatectomy; 
4) PADT; and, 5) other less frequently used treatments (See Appendix C for relevant codes). 
Only the first treatment received within 18 months of diagnosis was considered as the initial 
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treatment decision, except where ADT was considered adjuvant. Although SEER registry data 
and Medicare claims are roughly comparable for radiation therapy and surgery (94, 95) and 
their use in combination ascertains additional treatment, SEER data tend to underestimate use 
of medical therapies including ADT (37). In addition, registry data may inaccurately represent 
active surveillance (96). Thus, for consistency, treatment was derived from Medicare claims 
only. Each treatment was defined as follows: 
• Radiation therapy was defined as either EBRT (2- or 3-dimensional conformal 
radiation therapy), IMRT, or brachytherapy, with or without ADT from claims 
definitions used in prior studies (18, 97, 98) and from search of International 
Classification of Disease-9 (ICD-9) and Current Procedural Terminology (CPT) 
dictionaries (99). Other forms of radiation (stereotactic-body radiation and proton 
therapy) are not guideline-recommended and were considered as “other” therapy. 
• Radical prostatectomy consisted of 1) guideline-concordant open prostatectomy 
(retropubic, or perineal radical prostatectomy); and 2) guideline-discordant MIRP, 
distinguished by CPT code. 
• Primary ADT was considered ADT use in the absence of other definitive therapy. 
ADT included either orchiectomy or a GnRH agonist, as neither are guideline-
concordant for clinically localized disease (39, 100).  
• Active surveillance was defined in two ways: 1) guideline-discordant surveillance 
denoted >1 claim for PSA or digital rectal examination (DRE),  >2 prostate cancer 
specialist visits, and the absence of any other definitive prostate therapy within the 
initial treatment window; 2) guideline-concordant surveillance was defined as >2 
claims for PSA or DRE and >1 claim for needle biopsy of the prostate, in the absence 
of other definitive treatment (12). Although DRE claims are rarely coded, some 
claims did include them, which we counted as a component of surveillance, but 
neither definition required a DRE claim. 
99 
 
• Other therapy included cryosurgery, chemotherapy, and therapy combinations not 
included in the NCCN guidelines (e.g., radical prostatectomy with adjuvant ADT). 
Explanatory Variables 
Pre-MMA PADT use is a provider-level measure based on the 4-year period preceding 
the first MMA implementation in 2004. It is calculated as each physicians’ average annual 
proportion of patients receiving primary ADT, defined as GnRH agonists claims only, during the 
pre-MMA years 2000–2003. Orchiectomy is excluded, because MMA did not affect surgical 
ADT and should not be replaced by other care. Patient race is defined from SEER data and 
measured by five categories: 1) non-Hispanic white; 2) black or African-American; 3) Hispanic; 
4) other; or, 5) unknown.  
Control Variables 
We controlled for patient and, physician characteristics associated with prostate 
treatment selection, quality of care, or responsiveness to incentives.  
Clinical Factors. We used the SEER Collaborative Staging variables to assign patients to 
American Joint Committee on Cancer stage categories used for treatment by the NCCN 
guidelines (12, 20). Both grade and PSA are quantitative variables in SEER records. Although 
PSA and grade are used to stratify D’Amico risk groups, as described above, we also controlled 
for them, because earlier studies have suggested that men with higher risk levels are more likely 
to receive guideline discordant care (135, 160). We included age and the NCI Combined 
Comorbidity Index (NCICI), which is derived from relevant medical conditions appearing in 
both hospital and physician claims using uniform weights (107, 123). 
Treatment Support. We compared men married/living with a partner to those single, 
widowed, divorced, or missing marital status. We also assessed men’s use of consultations in the 
prostate cancer treatment decision (108). Primary Care Consultation was >1 visit to the same 
primary care physician occurring during 1) the 12 months prior to diagnosis; and, 2) the window 
between diagnosis and treatment. Specialist Care Consultation was three binary variables 
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indicating presence of >1 prostate-related carrier claim filed by a radiation oncologist, urologist, 
or medical oncologist between diagnosis and the first treatment date or 18 months, whichever is 
earlier (108). 
Healthcare access: We included several geographic indicators: SEER region, grouped by 
state; rurality of the community in which the patient resided at diagnosis; and community 
deprivation, defined as median income of the patients’ zip code of residence and as proportion 
of adults residing in the patients’ zip code with less than high school education.  
 Provider Factors: Using data from the AMA and SEER-Medicare Hospital files, we 
controlled for: (1) physician gender; (2) time in practice, (years between a patient’s SEER 
diagnosis date and the date of a physicians’ medical degree (from the AMA) dichotomized as 
<20 and ≥20 years; (3) physician specialty (urology, radiation oncology, medical oncology, 
primary care, or other); (4) medical professionalization, defined by a binary indicator of board 
certification and a categorical indicator measuring the degree of affiliation with an academic 
institution (none, some, or missing) (109, 110); and (5) training location (U.S. versus non-U.S.). 
Practice factors included panel size (58), measured by quartiles of the number of prostate cancer 
patients/year/physician; practice type (group practice, solo practice, or missing); and 
proportion of a practice’s Medicare patients that are minority (quartiles); and quartiles of the 
proportion of a practice’s Medicare patients that are minority (111). 
 Statistical Analysis 
We stratified the patient sample by receipt of guideline-concordant care and assessed 
differences between groups using Pearson’s chi-squared tests and t-tests for categorical and 
continuous variables, respectively. We used a common benchmark (121) to stratify physician 
guideline concordance, with physicians defined as high-concordance when 80% or more 
patients received guideline-concordant care, or alternatively defined as low–concordance. 
Multilevel logistic regression was used to model the association between pre-MMA ADT use and 
guideline-concordant care post-MMA. Separate multilevel logistic regressions comparing the 
101 
 
effect of pre-MMA use on each emerging modality within multi-modality treatment categories 
(MIRP in radical prostatectomy; IMRT in radiation therapy; and, NCCN surveillance among all 
surveillance) were run. Statistical significance was determined at α=0.05, and Stata/SE 12.1 was 
used for all analyses (112). 
Results 
We identified 27,315 men diagnosed with localized prostate cancer from 2005 through 
2007 who met our inclusion criteria. Care for these men was provided by 4,104 physicians of all 
specialties paid under fee-for-service Medicare during the 18-month treatment window (Figure 
6.1). 
Among elderly prostate cancer patients, 15,876 (58%) received some type of radiation 
therapy; 5,573 (20%) received either open or laparoscopic radical prostatectomy; 3,420 (13%) 
received other treatments including ADT, and 2,446 (9%) received some form of active 
surveillance. Treatment received differed by risk category (p<0.001) (Figure 6.2).  
After assigning guideline concordance based on D’Amico risk and treatment received, 
overall NCCN guideline concordance was 60.1% and reached 75.3% overall when considering 
MIRP and non-biopsy surveillance as concordant therapies. Guideline concordance was higher 
for men in the high risk category  (62.7%) than for men in the low (61.5%) and intermediate risk 
(56.3%) categories (p<0.001) (Figure 6.2). NCCN guideline concordance was also higher among 
younger men and those with less severe cancer and fewer comorbidities (all at p<0.001) (Table 
1). Additional unadjusted results (Table 2) showed that of the 4,104 physicians providing care in 
the post-MMA period, those providing guideline-concordant care had lower average pre-MMA 
PADT overuse (p<0.001).  
After controlling for patient and physician characteristics, greater physician pre-MMA 
PADT use was associated with lower odds of providing guideline-concordant initial treatment in 
the post-MMA period (OR 0.25, 95% CI 0.19, 0.34). Female physicians had greater odds of 
providing guideline-concordant care than male physicians (OR 1.32, 95% CI 1.03, 1.69). 
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Physicians’ time in practice was not associated with provision of guideline concordant care (OR 
1.06, 95% CI 0.95, 1.20), nor was board certification (OR 1.10, 95% CI, 0.84, 1.42). We found no 
racial/ethnic differences in receipt of guideline-concordant care, other than for men whose race 
was missing from the SEER registry (Table 6.3). 
Compared to conventional modalities, the odds of receiving all three of the newer 
modalities (MIRP, IMRT, and NCCN surveillance) increased over time in this cohort (Tables 6.4 
and 6.5). Compared to 2005, the odds of a patient receiving MIRP was two times greater in 
2006 (OR 2.39; 95% CI 1.75, 3.25) and almost four times greater in 2007 (OR 3.92; 95% CI 2.86, 
5.36). Compared to 2005, the odds of a patient receiving IMRT was one and half times greater in 
2006 (OR 1.49, 95% CI1.32, 1.69) and two times greater in 2007 (OR 2.15; 95% CI 1.88, 2.46). 
Thirty-eight percent of patients receiving any radical prostatectomy had MIRP (2,107/5,573). A 
majority of patients receiving radiation (63%) received IMRT (10,071/15,876). Only 7% of 
surveillance patients received the level of surveillance recommended by NCCN (171/2,446).  
In separate analyses for each treatment category, the modality of treatment used was not 
associated with pre-MMA PADT overuse. Among the 6,265 men who received some form of 
radical prostatectomy, their treating physicians’ pre-MMA PADT overuse was not associated 
with use of MIRP rather than open radical prostatectomy (OR 2.63, 95% CI 0.90, 7.67). Among 
the 15,876 who received radiation, pre-MMA PADT overuse was not associated with use of 
IMRT over the other radiation modalities (OR 1.15, 95% CI 0.39, 3.44). Too few patients 
received NCCN-concordant active surveillance to model factors associated with its use. 
However, descriptive analyses (Table 6.5) suggest that among the 2,446 men receiving 
surveillance, pre-MMA PADT use was not associated with use of guideline-concordant 
surveillance over guideline-discordant surveillance (p=0.22). 
Discussion 
To the best of our knowledge, ours is the first study to look at overall guideline 
concordance for localized prostate cancer in a post-MMA population and identify emerging 
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patterns of care (161). Contrary to our hypothesis, after adjusting for patient and physician 
characteristics, high levels of pre-MMA ADT overuse were associated with lower NCCN 
guideline concordance post-MMA. Physicians who we categorized as overusing ADT pre-MMA 
were less likely to provide NCCN guideline-recommended care in more recent years. There may 
be several reasons for this. Our sample included all physician groups. Radiation oncologists 
were less likely to overuse PADT in the pre-MMA period (ADT adjuvant to radiation is guideline 
concordant; PADT would be prescribed by the diagnosing urologist) and may have maintained 
these practices into the current period (93). Although the most recently trained urologists were 
also less likely to overuse ADT (93), and these same urologists also are more likely to adopt new 
robotic technology (162) despite its lack of strong recommendation by NCCN (12), MIRP has not 
penetrated the Medicare population as quickly as it may have younger populations of prostate 
cancer patients. Thus, the net effect of changes due to the training imprint may have yet to be 
realized.  
Further, some physicians appeared to replace PADT use with active surveillance. 
However, surveillance techniques have not yet reached levels currently endorsed by guidelines 
and it may be directed to the wrong group of patients. Although levels of guideline-discordant 
surveillance in our study mirror those found in other studies (4), we identified very little NCCN 
guideline-concordant surveillance, that which consisted of a non-diagnostic prostate biopsy and 
at least two PSA tests or DREs within 18 months of diagnosis. A much larger number of men 
received some follow-up that included a PSA test. Little is known about the low rates of uptake 
of biopsy-monitored active surveillance (4), and no studies to date have assessed the degree to 
which urologists provide the currently recommended level of surveillance intensity. Prior 
research has generally assessed the absence of definitive therapy, or less often, the confirmed 
receipt of PSA testing and/or evidence of post-diagnosis medical visits (163). However, 
standards of active surveillance have intensified over the last decade (4, 12, 20-22), with one 
component of that approach, prostate biopsy, becoming increasingly important. However, 
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prostate biopsy is an invasive and painful procedure, and many physicians may perceive that 
their patients would not consent to it (164, 165). Moreover, risks of infection and other 
complications are higher among men who undergo repeat biopsies (154, 155), and the 
contribution of more sophisticated biopsies to patients’ prognosis are in doubt (156). Thus, some 
physicians may be reluctant to offer the procedure as part of surveillance. 
Lastly, the use of PADT among high ADT users in the pre-MMA period was still relatively 
high at 17%. This may be due to the volume response that we observed in an earlier study (93). 
The majority of urologists studied had either low, stable ADT overuse or decreased their ADT 
overuse sharply over the 2000s. However, the residual overuse observed may be attributed to 
the group of increasing users, a sizeable group of urologists who increased overuse of ADT 
coincident with MMA reimbursement changes (93).  
Among the 4,104 physicians providing care to patients with localized prostate cancer in a 
national, population-based sample, there is an opportunity to improve the quality of initial 
treatment delivered. In this study sample, concordance with the then-applicable NCCN 
consensus guidelines was only 60%. An often used benchmark for guideline-concordance is 80% 
adherence to quality measures (121), suggesting that improvements in prostate cancer care 
among the elderly are needed. Even assuming all MIRP to be delivered by high volume 
surgeons, as recent research indicates (150) and NCCN allows, guideline-concordant care did 
not reach 80%. However, we did not find racial/ethnic differences in guideline concordance. We 
only detected lower odds of receipt of high quality care to be associated with men whose 
racial/ethnic status was not available in the SEER registry. Other studies have found differences 
in prostate cancer treatments delivered between African Americans and white Americans (166-
169), but studies assessing overall guideline concordant care have not identified racial 
disparities (121, 135). Because prostate cancer offers multiple treatment options for each risk 
category, racial differences in the specific treatment selected can be present without that care 
indicating a quality problem. Nonetheless, additional research to ascertain whether the 
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guideline recommendations themselves are appropriate for men of all racial and ethnic groups 
may be needed. Additionally, research is needed to determine whether care decisions reflect the 
preferences of all patients.  
Like other studies (40), our analysis found that new technologies are being rapidly 
adopted. IMRT, although expensive (170) and not well established in terms of comparative 
effectiveness, is a guideline-recommended option. Therefore, by these standards its use is 
appropriate. MIRP, which may be comparable to open prostatectomy in outcomes but is not yet 
guideline-recommended, has not reached the level of penetration of IMRT. It is not known 
whether this is due to lack of evidence or guideline recommendations, poor reimbursement 
relative to the technology investment hospitals must make, or clinical applicability to the post-
MMA Medicare prostate cancer patient population. However, other studies of MIRP uptake 
have shown much greater use among all-age populations than we found among the elderly (150, 
151). Greater patient age and less differentiated cancers were associated with MIRP use over 
open prostatectomy. Whether MIRP may be beneficial or superior to open prostatectomy in 
these situations is unknown, but the comparative effectiveness of MIRP versus open 
prostatectomy should be monitored among these risk groups.  
Our study has several limitations. First, we cannot directly compare guideline 
concordance pre-MMA to that post-MMA, in part because PSA levels were not recorded in SEER 
registries prior to 2004. Secondly, there may be questions about the validity of our claims-based 
approach to detect NCCN-level active surveillance, especially given the low prevalence of 
prostate biopsy in our cohort. However, our estimates are in line with other recent claims 
studies identifying prostate biopsy when extrapolating to our cohort (142, 171). Third, NCCN 
guidelines make guarded recommendations regarding MIRP during the period of our study, 
conceding that MIRP conducted by an experienced surgeon produces similar outcomes to open 
prostatectomy. We could not evaluate the technical experience of urologists performing the 
procedure in our sample. Thus, we may have underestimated the guideline concordance of care 
106 
 
for those receiving MIRP. Fourth, our study is not based on a random sample of physicians or 
patients and may not be generalizable (63). However the SEER registries represent 
approximately one quarter of the U.S. population and are similar to the national population in 
the proportion of minorities and low income residents in the U.S. (91). Further, the median age 
of prostate cancer diagnosis in the US is 66.0 (1), thus our study results are generalizable to at 
least half of the prostate cancer patient population. Finally, we relied on registry records for 
stage, grade and PSA information by which to stratify patients to determine guideline 
concordance. Missing or incorrect information in the registry may have resulted in patients with 
metastatic disease or clinically advanced disease being in our sample, and thus we may have 
underestimated guideline concordance (172, 173). 
Conclusions  
Although fewer men are exposed to the harms of ADT, declining use of PADT following 
changes in Medicare reimbursement policy may not have improved the overall quality of care for 
men with localized prostate cancer. PADT may have been replaced by other care that is 
discordant with current consensus recommendations. Although we cannot determine whether 
new treatment modalities replaced PADT, regardless of reimbursement, the quality of prostate 
cancer treatment does not appear to reach common benchmarks, which provides an opportunity 
to devise better policy-level interventions that target overuse and improve overall care quality. 
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Figure 6.1. Cohort Exclusions 
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Figure 6.2. Localized Prostate Cancer Treatment by D’Amico Risk, 2005–2009 
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Table 6.1. Patient Characteristics by Receipt of Guideline-Concordant Care 
  
Discordant 
Care 
Concordant 
Care   
  Mean (Standard Deviation) or N ( %)   
 N= 10,910 N= 16,405 p 
NCCN Guideline Concordance 10,910 (39.9%) 16,405 (60.1%) <0.001 
Year of Diagnosis  
  
<0.001 
2005 3,295 (30.2%) 5,262 (32.1%) 
 2006 3,662 (33.6%) 5,597 (34.1%) 
 2007 3.953 (36.2%) 5,546 (33.8%) 
 T Stage 
  
<0.001 
T1 6,404 (58.7%) 9,786 (59.7%) 
 T2 4,453 (40.8%) 6,483 (39.5%) 
 T3 51 (0.5%) 136 (0.8%) 
 Grade 
  
<0.001 
Well differentiated, 2-4 77 (0.7%) 108 (0.7%) 
 Moderately differentiated 5-7* 5,313 (48.7%) 7,560 (46.1%) 
 Poorly Differentiated, 8-10 5,497 (50.4%) 8,688 (53%) 
 Undifferentiated 23 (0.2%) 49 (0.3%) 
 PSA level 10.2 (12.7) 9.3 (10.8) <0.001 
Comorbidities 
  
<0.001 
0 7,282 (66.7%)  10,820 (66.0%) 
 1 2,311 (21.2%) 3,782 (23.1%) 
 2 794 (7.3%) 1,126 (6.9%) 
 3 or more 523 (4.8%) 677 (4.1%) 
 Age in years 74.3 (6.1) 72.7 (4.8) <0.001 
Race/ethnicity 
  
<0.001 
Non-Hispanic white 8,321 (76.3%) 12, 935 (78.8%) 
 Non-Hispanic black 885 (8.1%) 1,402 (8.5%) 
 Hispanic 659 (6.0%) 1,047 (6.4%) 
 Other 477 (4.4%) 759 (4.6%) 
 Missing 568 (5.2%) 262 (1.6%) 
 Marital Status 
  
<0.001 
Not Married 2,016 (18.5%) 3,064 (18.7%) 
 Married 7,357 (67.45) 12,126 (73.9%) 
 Missing 1,537 (14.1%) 1,215 (7.4%) 
 Pre-treatment Primary Care Use 
  
0.22 
0-2 visits in prior year 1,782 (16.3%) 2,639 (16.1%) 
 3-5 visits in prior year 4,979 (45.6%) 7,661 (46.7%) 
 6 or more visits in prior year 4,149  (38.0%) 6,105 (37.2%) 
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Primary Care Consultation 
  
<0.001 
No 4,330 (39.7%) 6,920 (42.2%) 
 Yes 6,580 (60.3%) 9.485 (57.8%) 
 Radiation Oncology Consultation 
  
<0.001 
No 6,385 (58.5%) 3,812 (23.2%) 
 Yes 4,525 (41.5%) 12,593 (76.8%) 
 Medical Oncology Consultation 
  
0.32 
No 10,250 (94.0%) 15,364 (93.7%) 
 Yes 660 (6.0%) 1,041 (6.3%) 
 Urology Consultation 
  
0.63 
No 243 (2.2%) 351 (2.1%) 
 Yes 10,667 (97.8%) 16,054 (97.9%) 
 Rural Residence 
  
0.95 
No 10,726 (98.3%) 16,130 (98.3%) 
 Yes 184 (1.7%) 275 (1.7%) 
 State of SEER Registry 
  
<0.001 
Seattle 690 (6.3%) 1,030 (6.3%) 
 Connecticut 542 (5%) 1,152 (7.0%) 
 Detroit 707 (6.5%) 1,089 (6.6%) 
 Hawaii 152 (1.4%) 299 (1.8%) 
 Iowa 567 (5.2%) 1,045 (6.4%) 
 New Mexico 278 (2.5%) 400 (2.4%) 
 California 3,890 (35.7%) 5,163 (31.5%) 
 Utah 466 (4.3%) 438 (2.7%) 
 Georgia 484 (4.4%) 591 (3.6%_) 
 Kentucky 751 (6.9%) 1,761 (6.2%) 
 Louisiana 884 (8.1%) 1,184 (7.2%) 
 New Jersey 1,499 (13.7%) 3,004 (18.3%) 
 Median Income of Patients' Communities 
 
0.18 
$2,506-35,031 2,387 (21.9%) 3,489 (21.3%) 
 $35,051-46,079 2,545 (23.3%) 3,790 (23.1%) 
 $46,084-60,668 2,540 (23.3%) 4,015 (24.5%) 
 $60,669-200,008 2,856 (26.2%) 4,285 (26.1%) 
 Missing 582 (5.3%) 826 (5.0%) 
 Proportion of Patient's Community w/o High School Education 0.21 
0-9.7% 2,876 (26.4%) 4,204 (25.6%) 
 9.7-15.5% 2,607 (23.9%) 4,069 (24.8%) 
 15.5%-25.2% 2,513 (23.0%) 3,863 (23.5%) 
 25.2%-100% 2,337 (21.4%) 3,449 (21%) 
 Missing 577 (5.3%) 820 (5.0%)   
P-values by t-test for continuous variables and chi2 test for binary / categorical variables 
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Table 6.2. Physician Characteristics by High Guideline Concordance 
  <80% Concordant >80% Concordant  
  Mean (Standard Deviation) or N (%)   
 N= 2,736 N= 1,368 p 
Average Physician-level ADT 
Overuse 2000-2003 0.2 (0.3) 0.1 (0.2) <0.001 
NCCN Guideline Concordance 0.2 (0.3) 1.0 (0.1) <0.001 
Specialty 
  
<0.001 
Urology 1600 (58.5%) 416 (30.4%) 
 Radiation Oncology 339 (12.4%) 638 (46.6%) 
 Medical Oncology 101 (3.7%) 23 (1.7%) 
 Primary Care 515 (18.8%) 148 (10.8%) 
 Other 181 (6.6%) 143 (10.5%) 
 Time in Practice 
  
0.04 
<20 years 1,014 (37.1%) 552 (40.4%) 
 >20 years 1,722 (62.9%) 816 (59.6%) 
 Gender 
  
<0.001 
Male 2,558 (93.5%) 1,186 (86.7%) 
 Female 178 (6.5%) 182 (13.3%) 
 Training 
  
0.006 
Foreign Trained 413 (15.1%) 252 (18.4%) 
 U.S. Trained 2,323 (84.9%) 1,116 (81.6%) 
 Board Certified 
  
0.07 
No 214 (7.8%) 86 (6.3%) 
 Yes 2,522 (92.2%) 1,282 (93.7%) 
 Medical School Affiliation 
  
<0.001 
None 1,212 (44.3%) 521 (38.1%) 
 Some  1,481 (54.1%) 845 (61.8%) 
 Missing 43 (1.6%) 2 (0.1%) 
 Physician Prostate Panel Size 
  
<0.001 
0-20 prostate patients/year 1,842 (67.3%) 1,053 (77.0%) 
 21-37 prostate patients/year 622 (22.7%) 223 (16.3%) 
 38 or more prostate patients/year 272 (9.9%) 92 (6.7%) 
 Practice Type 
  
<0.001 
Group Practice 2,069 (75.6%) 1,052 (76.9%0 
 Solo Practice 494 (18.1%) 197 (14.4%) 
 Missing 173 (6.3%) 119 (8.7%) 
 Proportion of Patients Minority 
  
0.01 
0-9.7% 1,139 (41.6%) 618 (45.2%) 
 9.7-15.5% 707 (25.8%) 297 (21.7%) 
 15.5%-25.2% 890 (32.5%) 453 (33.1%) 
 
P-values by t-test for continuous variables and chi2 test for binary / categorical variables 
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  Odds 
Ratio 
95% Confidence 
Interval  
Pre-MMA ADT Use 0.25 0.19 0.34 
Specialty 
   Urology 1.00 
  Radiation Oncology 3.59 2.03 4.26 
Medical Oncology 0.33 0.20 0.54 
Primary Care 0.29 0.22 0.37 
Other 1.09 0.83 1.44 
Time in Practice 
   <20 years 1.00 
  >20 years 1.07 0.95 1.20 
Gender 
   Male 1.00 
  Female 1.32 1.03 1.69 
Training 
   Foreign Trained 1.00 
  U.S. Trained 0.83 0.70 0.99 
Board Certified 
   No 1.00 
  Yes 1.10 0.85 1.42 
Medical School Affiliation 
   None 1.00 
  Some  0.94 0.82 1.06 
Missing 0.11 0.23 0.40 
Physician Prostate Panel Size 
  <20 prostate patients/year 1.00 
  21-37 prostate patients/year 0.98 0.87 1.09 
>38 prostate patients/year 0.84 0.73 0.96 
Practice Type 
   Group Practice 1.00 
  Solo Practice 1.09 0.92 1.30 
Missing 0.99 0.77 1.28 
Proportion of Patients Minority 
  0-9.7% 1.00 
  9.7-15.5% 1.00 0.89 1.12 
15.5%-25.2% 1.09 0.95 1.25 
N=27,158 patients; n=4,104 physicians 
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Table 6.3. Regression Results for Pre-MMA Use on Uptake of New Treatment Modalities 
 
Minimally Invasive 
Radical Prostatectomy 
Intensity Modulated 
Radiation Therapy 
  
Odds 
Ratio 
95% 
Confidence 
Interval  Odds Ratio 
95% 
Confidence 
Interval  
Pre-MMA ADT Use 2.63 0.91 7.67 1.15 0.39 3.44 
Specialty 
      Urology 1.00 
  
1.00 
  Radiation Oncology 15.75 2.88 86.30 28.34 18.67 43.01 
Medical Oncology 147.34 19.45 1116.18 21.77 4.07 116.47 
Primary Care 72.91 30.18 176.15 31.44 12.54 78.79 
Other 6.84 2.78 16.87 6.64 3.18 13.84 
Time in Practice 
      <20 years 1.00 
  
1.00 
  >20 years 0.53 0.34 0.84 1.03 0.81 1.32 
Gender 
      Male 1.00 
  
1.00 
  Female 0.67 0.21 2.10 1.22 0.75 1.99 
Training 
      Foreign Trained 1.00 
  
1.00 
  U.S. Trained 1.11 0.56 2.22 0.84 0.56 1.27 
Board Certified 
      No 1.00 
  
1.00 
  Yes 1.05 0.40 2.73 1.99 0.99 4.01 
Medical School Affiliation 
     None 1.00 
  
1.00 
  Some  2.82 1.74 4.57 1.28 0.95 1.73 
Missing 0.16 0.00 128.84 6.95 0.05 938.22 
Physician Prostate Panel Size 
     <20 prostate patients/year 1.00 
  
1.00 
  21-37 prostate patients/year 1.76 1.18 2.64 0.89 0.72 1.10 
>38 prostate patients/year 2.65 1.60 4.38 0.86 0.67 1.11 
Practice Type 
      Group Practice 1.00 
  
1.00 
  Solo Practice 0.46 0.24 0.87 0.74 0.47 1.18 
Missing 1.50 0.57 3.96 0.97 0.56 1.70 
Proportion of Patients Minority 
     0-9.7% 1.00 
  
1.00 
  9.7-15.5% 1.03 1.18 1.53 1.19 0.97 1.45 
15.5%-25.2% 0.86 0.52 1.43 1.24 0.96 1.60 
Year of Diagnosis  
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2005 1.00 
  
1.00 
  2006 2.39 1.75 3.25 1.49 1.32 1.69 
2007 3.92 2.86 5.36 2.15 1.88 2.46 
T Stage 
      T1 1.00 
  
1.00 
  T2 0.76 0.60 0.97 1.14 1.02 1.26 
T3 0.16 0.05 0.54 2.55 1.34 4.82 
Grade 
      Well differentiated, 2-4 1.00 
  
1.00 
  Moderately differentiated 5-
7* 74.42 8.58 645.08 0.83 0.42 1.62 
Poorly Differentiated, 8-10 87.97 10.16 761.87 2.23 1.14 4.36 
Undifferentiated 3.97 0.09 174.53 1.30 0.38 4.45 
PSA level 0.98 0.96 0.99 1.01 1.01 1.02 
Comorbidities 
      0 1.00 
  
1.00 
  1 0.69 0.50 0.93 1.06 0.94 1.20 
2 0.69 0.39 1.22 1.12 0.91 1.36 
3 or more 0.28 0.11 0.71 1.54 1.18 2.01 
Age in years 9.64 3.58 25.98 1.24 0.94 1.63 
Age2 0.98 0.98 0.99 1.00 1.00 1.00 
Race/ethnicity 
      Non-Hispanic white 1.00 
  
1.00 
  Non-Hispanic black 1.37 0.67 2.74 1.04 0.85 1.28 
Hispanic 0.73 0.39 1.38 1.67 1.30 2.15 
Other 2.92 1.33 6.39 1.39 1.03 1.87 
Missing 2.31 0.59 9.11 0.81 0.52 1.27 
RacexPre-MMA Use 
      Non-Hispanic whitexPre-
MMA 1.00 
  
1.00 
  Non-Hispanic blackxPre-
MMA 0.12 0.01 1.76 0.38 0.04 4.07 
HispanicxPre-MMA 0.51 0.07 3.77 5.91 0.61 57.35 
OtherxPre-MMA 2.92 1.33 6.39 10.30 0.68 156.59 
MissingxPre-MMA 2.31 0.59 9.11 0.14 0.01 2.67 
Marital Status 
      Not Married 1.00 
  
1.00 
  Married 1.20 0.86 1.68 0.98 0.86 1.12 
Missing 0.86 0.43 1.75 1.17 0.91 1.51 
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Pre-treatment Primary Care Use 
     0-2 visits in prior year 1.00 
  
1.00 
  3-5 visits in prior year 1.51 1.02 2.23 1.14 0.97 1.35 
6 or more visits in prior year 1.36 0.88 2.10 1.23 1.03 1.48 
Primary Care Consultation 
     No 1.00 
  
1.00 
  Yes 1.33 0.98 1.80 0.84 0.74 0.95 
Radiation Oncology Consultation 
     No 1.00 
  
1.00 
  Yes 2.00 1.46 2.74 0.38 0.29 0.51 
Medical Oncology Consultation 
     No 1.00 
  
1.00 
  Yes 0.96 0.53 1.72 1.07 0.86 1.35 
Urology Consultation 
      No 1.00 
  
1.00 
  Yes 22.46 5.68 88.81 1.30 0.93 1.81 
Rural Residence 
      No 1.00 
  
1.00 
  Yes 0.60 0.25 1.46 0.59 0.38 0.91 
State of SEER Registry 
      Seattle 1.00 
  
1.00 
  Connecticut 7.49 2.08 27.01 1.14 0.54 2.40 
Detroit 7.30 2.10 25.36 2.09 0.97 4.49 
Hawaii 15.06 2.05 110.54 5.27 1.69 16.39 
Iowa 1.49 0.44 5.06 1.32 0.61 2.82 
New Mexico 0.81 0.16 4.25 0.93 0.38 2.28 
California 6.56 2.51 17.17 1.21 0.68 2.14 
Utah 1.57 0.37 6.66 0.10 0.03 0.30 
Georgia 2.24 0.44 11.50 0.82 0.36 1.89 
Kentucky 14.89 4.40 50.39 0.47 0.22 1.00 
Louisiana 4.84 1.36 17.29 1.26 0.57 2.77 
New Jersey 8.44 2.91 24.51 1.80 0.96 3.37 
Median Income of Patients' Communities 
    $2,506-35,031 1.00 
  
1.00 
  $35,051-46,079 0.99 0.65 1.50 1.14 0.95 1.36 
$46,084-60,668 0.82 0.50 1.36 1.11 0.89 1.38 
$60,669-200,008 1.06 0.59 1.92 1.05 0.80 1.37 
Missing 1.07 0.00 2357.77 0.41 0.03 4.92 
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Proportion of Patient's Community w/o High School Education 
  0-9.7% 1.00 
  
1.00 
  9.7-15.5% 0.99 0.69 1.42 0.91 0.78 1.07 
15.5%-25.2% 0.94 0.62 1.44 0.83 0.68 1.01 
25.2%-100% 0.78 0.45 1.35 0.84 0.66 1.08 
Missing 0.85 0.00 1916.92 2.05 0.17 24.92 
Constant 0.00 0.00 0.00 0.00 0.00 0.15 
N=27,158 patients; n=4,104 physicians       
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Table 6.4. Characteristics of Patients by Receipt of Active Surveillance 
 
No Active 
Surveillance 
Active 
Surveillance 
   Mean (Standard Deviation) or % 
 N=2,275 N=171 p 
Year of Diagnosis  
  
<0.001 
2005 31.6 20.5 
 2006 34.9 31.0 
 2007 33.5 48.5 
 T Stage 
  
0.20 
T1 58.2 64.9 
 T2 41.5 35.1 
 T3 0.2 0.0 
 Grade 
  
0.009 
Well differentiated, 2-4 1.7 0.0 
 Moderately differentiated 5-7* 69.7 81.3 
 Poorly Differentiated, 8-10 28.5 18.7 
 Undifferentiated 0.1 0.0 
 PSA level 9.0 (10.6) 6.1 (4.0) <0.001 
Comorbidities 
  
0.20 
0 66.1 70.2 
 1 21.4 22.2 
 2 7.5 5.8 
 3 or more 5.1 1.8 
 Age in years 76.1 (6.0) 72.9 (4.5) <0.001 
Race/ethnicity 
  
0.17 
Non-Hispanic white 74.2 81.3 
 Non-Hispanic black 7.1 4.1 
 Hispanic 5.2 2.9 
 Other 2.9 1.2 
 Missing 10.6 10.5 
 Marital Status 
  
0.02 
Not Married 18.4 17.0 
 Married 59.3 69.0 
 Missing 22.3 14.0 
 Pre-treatment Primary Care Use 
  
0.69 
0-2 visits in prior year 16.0 17.5 
 3-5 visits in prior year 45.7 47.4 
 6 or more visits in prior year 38.3 35.1 
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Primary Care Consultation 
  
<0.001 
No 31.8 46.2 
 Yes 68.2 53.8 
 Radiation Oncology Consultation 
  
0.06 
No 77.7 71.3 
 Yes 22.3 28.7 
 Medical Oncology Consultation 
  
0.22 
No 92.6 90.2 
 Yes 7.4 9.9 
 Urology Consultation 
  
0.49 
No 3.3 2.3 
 Yes 96.7 97.7 
 Rural Residence 
  
0.83 
No 98.6 98.8 
 Yes 1.4 1.2 
 State of SEER Registry 
  
<0.001 
Seattle 5.4 10.5 
 Connecticut 6.1 5.3 
 Detroit 6.9 7.0 
 Hawaii 0.9 0.0 
 Iowa 5.1 0.0 
 New Mexico 4.3 0.6 
 California 38.5 46.2 
 Utah 4.6 5.3 
 Georgia 3.1 3.5 
 Kentucky 5.9 5.8 
 Louisiana 8.0 1.2 
 New Jersey 11.3 14.6 
 Median Income of Patients' Communities 
 
<0.001 
$2,506-35,031 21.1 7.0 
 $35,051-46,079 24.5 20.5 
 $46,084-60,668 23.3 25.7 
 $60,669-200,008 26.2 42.1 
 Missing 4.9 4.7 
 
Proportion of Patient's Community 
w/o High School Education 
  
<0.001 
0-9.7% 27.9 45.6 
 9.7-15.5% 24.3 21.1 
 15.5%-25.2% 24.2 17.5 
 25.2%-100% 18.9 11.1 
 Missing 4.8 4.7 
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Time in Practice 
  
0.19 
<20 years 32.0 36.8 
 >20 years 68.0 63.2 
 Gender 
  
0.63 
Male 97.0 97.7 
 Female 3.0 2.3 
 Training 
  
0.56 
Foreign Trained 12.0 13.5 
 U.S. Trained 88.0 86.5 
 Board Certified 
  
<0.001 
No 5.9 12.9 
 Yes 94.1 87.1 
 Medical School Affiliation 
  
<0.001 
None 50.4 26.9 
 Some  49.1 73.1 
 Missing 0.5 0.0 
 Physician Prostate Panel Size 
  
<0.001 
0-20 prostate patients/year 46.0 41.5 
 21-37 prostate patients/year 35.5 26.9 
 38 or more prostate patients/year 18.5 31.6 
 Practice Type 
  
0.08 
Group Practice 78.8 81.9 
 Solo Practice 16.6 11.1 
 Missing 4.7 7.0 
 Proportion of Patients Minority 
  
<0.001 
0-9.7% 38.1 37.4 
 9.7-15.5% 31.0 44.4 
 15.5%-25.2% 30.9 18.1   
P-values by t-test for continuous variables and chi2 test for binary/categorical variables 
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CHAPTER 7 SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY, 
PRACTICE, AND RESEARCH 
Summary of Findings 
This dissertation examined factors associated with overuse of medical care, a common 
and costly problem in healthcare quality which has received little attention, but has emerged as 
a national priority for improving the U.S. healthcare system. Within this context we studied the 
declining overuse of Androgen Deprivation Therapy among clinically localized prostate cancer 
patients in fee-for-service Medicare, a trend which should have improved the quality of care 
prostate cancer patients receive, since the treatment is not recommended by national consensus 
guidelines. We assessed reimbursement policy as a lever for not only reducing overuse but also 
for improving quality of care in situations of overuse. We also explored physician and practice 
characteristics associated with decreasing overuse, reimbursement responsiveness, and 
guideline concordance. And, we assessed how changing practice patterns coincident with 
changing ADT use impacted prostate cancer quality of care. 
Economic theory informed our conceptual model and we used economic tools to assess 
our hypotheses. Our national, population-based sample of prostate cancer patients was drawn 
from the SEER cancer registries and matched with complete Medicare claims. We identified 
treating physicians of prostate cancer patients and matched AMA physician and practice data to 
the enhanced claims. We created three distinct cohorts of localized prostate cancer patients to 
explore various components of overuse of ADT. Two analyses modeled factors associated with 
overuse of ADT and one analysis modeled the factors associated with NCCN-guideline 
concordant care. Our second analysis of ADT overuse used multilevel logistic regression and an 
innovative reimbursement generosity index which exploited variation among Medicare carriers 
in reimbursing for ADT during a period of guideline stability. We used multilevel mixed effects 
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modeling to control for tumor, patient, physician, and practice factors known to be associated 
with prostate cancer treatment decisions, quality of care, and overuse of healthcare; and to 
adjust standard errors for clustering of patients within physicians.  We conducted multiple 
sensitivity analyses to assess the robustness of our findings. 
Prior to MMA and during a period of guideline stability (2000-2003), we found limited 
evidence that urologists were responsive to ADT reimbursement differences (OR 1.00, 95% CI, 
0.99, 1.00), despite higher ADT overuse in areas of favorable ADT reimbursement observed in 
unadjusted analysis, and contrary to our expectations.  However, we found a small, but negative 
association between all prostate treatment reimbursement and physicians’ overuse of ADT, 
although the confidence interval rounded to 1 (OR 0.99, 95% CI 0.99, 1.00). Physicians in high 
reimbursement areas, relative to all treatments, were less likely to overuse ADT, suggesting that 
physicians with alternative treatment options or alternative reimbursement may have been less 
likely to overuse ADT. Exploratory analyses among urology group practices demonstrated that 
physicians in multi-specialty groups, presumably with superior access to more treatment 
options, were less likely to overuse ADT, compared to single–specialty urology group practices. 
Looking at changes in ADT overuse across the entire period of MMA’s implementation of 
reimbursement cuts (2000-2007), we observed three patterns of ADT use. A large group of 
urologists (n=1,478) maintained low and consistent ADT overuse among localized prostate 
cancer patients throughout the period. However, coincident with the ADT reimbursement 
reductions, we identified two other groups of urologists who changed their patterns of ADT 
overuse. The larger of these two groups (n=394) decreased overuse and adopted patterns of 
overuse similar to the static users by the end of the 2007 treatment window. A smaller but 
substantial group of urologists (n=276) increased overuse of ADT coincident with reductions in 
reimbursement and achieved the highest levels of overuse observed in the study. Among this 
group of physicians ADT overuse was 32.6% among the 2,817 patients they treated over the 
study period, suggesting a potential quality problem. We could not distinguish increasing users 
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from decreasing users based on urologists’ characteristics, but the patients of these two groups 
of physicians differed. Increasing users’ patients were older, had more comorbid conditions, and 
were more likely to be non-Hispanic black or “other” race. They also lived in communities of 
fewer resources.  Although there is no guideline recommendation that patients with these 
characteristics should receive PADT, other research suggests they often do. Thus, it is possible 
that rather than responding to reimbursement by intensifying the discounted service, as 
economic theory and empirical work have shown, these providers may have been responding to 
the changing clinical characteristics of their patient panel. 
 Nonetheless, overall ADT overuse in our T1 and T2 well- and moderately differentiated 
prostate cancer cohort remained 13.6% post-MMA. Rates were even higher in the full cohort of 
localized prostate cancer patients and evidence increasingly supports that PADT’s harms 
outweigh its benefits, so understanding determinants of overuse is especially important.  Our 
analysis of physician characteristics associated with ADT overuse throughout the MMA 
implementation period used multilevel logistic regression to examine the association of time in 
practice with ADT overuse. Physicians’ time in practice was not associated with ADT overuse 
(OR 0.89; 95% CI 0.75 -1.05) throughout the era. However, solo practice type (OR 1.65; 95% CI 
1.34-2.02) and lack of medical school affiliation (OR 0.65; 95% CI 0.55-0.77) were, suggesting 
that interventions to address overuse may be hard to deliver.  
Although we found that ADT overuse persisted, overall changes in ADT overuse could 
have improved quality of care. Therefore, our third analysis assessed the effect of pre-MMA ADT 
overuse on the concordance of post-MMA care with National Comprehensive Cancer Network 
(NCCN) guidelines among clinically localized prostate cancer patients of varying risk of disease 
progression. We used multilevel logistic regression to test the association between guideline 
concordance and prior ADT overuse and, in individual models, the association between prior 
ADT overuse and use of new treatment modalities. Our study showed that physicians’ pre-MMA 
ADT overuse was associated with delivering guideline-concordant care post-MMA (OR 0.25, 
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95% CI 0.18, 0.34). However, contrary to our expectations, physicians who were high users of 
ADT in the earlier period were more likely to overuse ADT and provide guideline-discordant 
care among their localized cancer patients in the contemporary period. Nevertheless, after 
stratifying patients according to risk for disease progression and assigning care received as 
guideline-concordant or -discordant, we found no racial differences in the quality of care 
delivered.  
We also assessed the changing modalities of other prostate cancer treatment options, 
expecting that changes in ADT overuse may have been driven uptake of emerging modalities 
among other prostate cancer treatment options. However, in separate analyses for each 
treatment category, the modality of treatment was not associated with pre-MMA PADT overuse. 
Among the 6,265 men who received some form of radical prostatectomy, their treating 
physicians’ pre-MMA PADT overuse was not associated with use of MIRP rather than open 
radical prostatectomy (OR 2.63, 95% CI 0.90, 7.67). Among the 15,876 who received radiation, 
pre-MMA PADT overuse was not associated with use of IMRT over the other radiation 
modalities (OR 1.15, 95% CI 0.39, 3.44). Too few patients received NCCN-concordant active 
surveillance to model factors associated with its use. However, descriptive analyses (Table 6.5) 
suggest that among the 2,446 men receiving surveillance, pre-MMA ADT use was not associated 
with use of NCCN-concordant surveillance over non-biopsy surveillance (p=0.22). 
Implications for policy, practice, and research 
Policy 
Current efforts to reduce Medicare spending include limiting across-the-board increases 
for physician reimbursement (174). However, the effect of reimbursement change on care 
delivery is contextual and multiple responses are possible. Several economic studies suggest that 
physicians will actually intensify utilization of discounted services, known as the volume 
response. However, this effect has not been universal among all specialists or procedures (136). 
Our study suggests that among urologists treating prostate cancer this type of strategy may not 
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have the intended effect on decreasing costs. Urologists boast treating the widest variety of 
conditions with the greatest number of different procedures among specialists. Moreover the 
treatment of prostate cancer has a number of treatment options, each with multiple modalities. 
Therefore it is essential that reimbursement policy should not be expected to reduce overuse 
uniformly especially in situations where there are multiple treatment options. Some physicians 
may have resources to substitute services, but others may not. Policy makers should consider 
more targeted, nuanced reimbursement policy strategies, such as value-based reimbursement, 
which take into account the treatment options, specialty providing the service and alternatives 
to the discounted care. 
In addition, even in situations of overuse, reimbursement reductions may not improve 
quality of care. Quality of prostate cancer care, as measured by NCCN guideline concordance, 
allows for multiple treatment options. Even if reimbursement differentials may motivate some 
physicians’ treatment selection, patients may not consent to, or be candidates for, that 
treatment. Thus, reimbursement policies should not be expected to necessarily improve quality, 
unless there are guideline-concordant treatment alternatives that patients are willing to accept. 
Reimbursement policies should carefully consider unintended consequences of change, even in 
situations of overuse, where common sense suggests that reducing reimbursement should 
reduce overuse. 
Finally, clinical policy, codified in clinical practice guidelines, should make efforts to 
clarify treatment of older and more vulnerable patients. Research, including these studies, 
consistently suggest that older patients are more likely to receive ADT, even when there is no 
benefit and the potential for harm. Even for patients with potentially limited life expectancy, the 
acute side effects of ADT may not be detrimental enough to quality of life to dissuade its use. 
Earlier NCCN guidelines allowed for men with less than 5 years life expectancy to receive ADT. 
However, this recommendation changed in 2004. To date, physicians appear not to have 
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changed their care of older patients to meet the new recommendations. A clearer policy message 
should be developed to help physicians struggling to find options for their oldest patients. 
Practice 
 The results of this work also suggest several changes to clinical, quality improvement, 
and implementation practice. First, although the majority of urologists are not overusing ADT, 
some urologists and other providers still do.  Physicians may need support and tools to better 
manage localized prostate cancer patients so that they do not have to fall back on ADT as a 
treatment strategy. In addition, our results suggest that Active Surveillance may be an 
underused therapy in low- and intermediate-risk prostate cancer, but overused among men with 
high-risk disease. Careful stratification of patients may help remedy this misuse of ADT. 
Treatment calculators or pocket tools to simplify stratification for physicians may be helpful. 
Patient decision support tools may need to be improved to better present individual patients’ 
competing risks so that active surveillance is more likely to be chosen by patients who may 
benefit from that option. 
Secondly, our findings suggest a roadmap for quality improvement practice. Although 
some studies suggest that physicians nearing the end of their career are less likely to change 
practice, our longitudinal study in fee-for-service Medicare did not find this to be the case. 
Quality improvement interventions for localized prostate cancer treatment should not focus on 
physicians with the greatest time in practice, even though they may maintain practice beyond 
traditional retirement age. Instead, they may more effective by instituting programs for solo 
practitioners and by devising strategies to reach physicians unaffiliated with academic 
institutions. 
Third, implementation practice should note that interventions designed to encourage 
uptake of new technology and practices may not work equally well in situations of overuse. 
Efforts to modify implementation efforts to focus on the determinants of overuse in a particular 
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setting may be helpful. Moreover, efforts to help physicians evaluate and prioritize emerging 
evidence around new technologies as they are considering their adoption. 
Research 
A number of research questions are engendered by this research, but at least five issues 
should be prioritized.   First, ADT overuse remains expensive (135), but few studies have 
assessed the effect of ADT reductions on total prostate cancer care costs. The changes in 
prostate cancer treatments over the decade seen here and in other studies (40) may have 
substantially increased overall prostate cancer costs. Assessments of the full financial impact of 
reductions in ADT overuse on prostate cancer treatment costs are needed. Secondly, our 
research identified a potential clinical explanation for the volume response. To support and fully 
inform economic theory, claims-based analyses of factors associated with increasing overuse 
should be repeated in studies using medical record abstraction. Next, as we further efforts to 
reduce overuse of medical treatments, strategies to reach isolated healthcare providers will be 
needed. Identifying the financial pressures, quality improvement infrastructure, and quality 
improvement motivations of solo practitioners and those without medical school affiliation are 
important. Although urology practices have undergone consolidation over the last decades, 
urology still has the highest rate of solo practitioners among all specialties. Most research 
translation and quality improvement strategies are focused on medical school or large 
community networks which may miss the providers most likely to need help. Fourth, the 
comparative effectiveness of localized prostate cancer treatments is incomplete and the 
guidelines may need to be revised based on better data. In particular, the comparative 
effectiveness of different modalities of treatment has not been well established. Although 
guidelines promote biopsy-driven active surveillance, no studies suggest the intensive method is 
superior to PSA-monitored active surveillance, or even the less intensive watchful waiting 
approach. Patients and some physicians may be resistant to this therapy and be persuaded to 
undergo more definitive treatment that can have complications that seriously impact quality of 
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life. Additional guidance on this strategy may prevent these poor outcomes. Finally, we need 
better measures of physicians, patient panels, and practices. Available claims data are 
informative, but coarse, whereas clinical practice is much more nuanced. Demographics are 
important confounders, but they themselves are confounded by other aspects of training. In 
addition, information regarding when physicians change practices, how the practices are 
organized by specialty, compensation structure, payer distributions, and quality improvement 
programs are important confounders which need to be accounted for. Moreover, data on the 
infrastructure within solo practices, especially those in urology would be important to have.  
Conclusion 
ADT overuse declined significantly after MMA implementation, but rates of overuse 
remain high among some urologists who may be professionally isolated and difficult to reach. 
These urologists may treat more vulnerable populations, which may explain health disparities in 
prostate cancer treatment quality. Clarifying treatment guidelines for vulnerable patients may 
improve quality of care. Further, in a pre-MMA period of stable guideline recommendations and 
exogenous variation in physician reimbursement, we detected no association between ADT 
overuse and reimbursement greater than the national average. Thus, reducing reimbursement 
through policy changes such as the MMA may not have the intended effect on limiting overuse 
when other treatment options are available. However, we did detect a small response to 
reimbursement when we considered ADT reimbursement relative to all treatment. While 
reimbursement policy still may not have the intended effect, more nuanced and target policies 
should be developed. Finally, we observed that decreases in ADT overuse coincident with MMA 
were not replaced with other guideline-concordant care. Thus quality of prostate cancer care 
may not have improved. Reimbursement reductions may not be an effective lever to improve 
quality, unless physicians have access to guideline-concordant alternatives. 
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APPENDIX A. TREATMENT CLAIMS 
Treatment ICD-9 Codes CPT/HCPCS Codes 
Androgen 
Deprivation Therapy 
(GnRH agonist) 
 J0128, J1950, J9202, J9217, J9218, 
J9219, J9225, J9226, J3315, C9216, 
C9430, or S0165 
Non-surveillance 
Prostate Treatment 
Codes 
60, 60.1, 60.21, 60.29, 
60.3, 60.4, 60.5,  60.61-
60.69, 62.3, 62.4, 62.41, 
62.42, 92.2, 92.21, 92.22, 
92.23, 92.24, 92.25, 
92.26, 92.27, 92.28, 
92.29, 99.25,  V58.0,  
V58.1x,  V66.1,  V66.2,  
V67.1,  V67.2 
00865, 54520, 54522, 54530, 54535, 
54690, 55801, 55810, 55812, 55815, 
55821, 55831, 55840, 55842, 55845, 
55860, 55866, 55873, 55875, 55876, 
76873, 77301, 77305, 77310, 77315, 
77321, 77326, 77327, 77328, 77338, 
77371, 77372, 77373, 77380, 77381, 
77402, 77403, 77404, 77406, 77407, 
77408, 77409, 77411, 77412, 77413, 
77414, 77416, 77418, 77423, 77432, 
77435, 77520, 77522, 77523, 77525,  
77750-77760, 77761, 77762, 77763, 
77774, 77775, 77776, 77777, 77778, 77779, 
77780, 77781, 77782, 77783, 77784, 
77785, 77786, 77787, 77789, 77790,  
77791- 77798, 77799,   G0356,   J1675,      
J9000-J9164,   0073T,  0082T,  0083T,  
0182T,  4164F,  A9527,  C1715,  C1716,  
C1717,  C1719,  C1728,  C2634,  C2635,  
C2636,  C2637,  C2638,  C2639,  C2640,  
C2641,  C2642,  C2643,  C2698,  C2699,    
C9725,  G0174,  G0178,  G0251,  G0339,  
G0340,   J1050,  J1051,   J9165,  J9166-
J9201,   J9203-J9216,   J9220-J9224,   
J9227- J9998,  J9999,  Q0083-Q0085,  
Q3001,  S0175,  S9560, C2616 
Abbreviations: ICD-9: International Classification of Diseases, 9th Revision; CPT: Current 
Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; GnRH: 
Gonadotropin-Releasing Hormone. 
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APPENDIX B. REIMBURSEMENT GENEROSITY CALCULATION 
The reimbursement generosity index was calculated as:  
𝑅𝑖𝑡 = ∑ �𝑃𝑖𝑡𝑔 − 𝑃𝑡𝑔�𝑊𝑡𝑔𝑔∈𝑔(𝑖,𝑡)∑ 𝑊𝑡𝑔𝑔∈𝑔(𝑖,𝑡)  
where Pitg is the average reimbursement for patients receiving GnRH agonist g 
prescribed by provider i in year t, and Ptg is the SEER average reimbursement of GnRH agonist 
g in year t. Wtg, the weight for GnRH agonist g, is the  ratio of SEER-wide spending on that 
regimen to total spending on all GnRH agonists. Each medical ADT regimen was dose-
standardized by converting each instance of GnRH agonist in use on separate days to a monthly 
dosing regimen. Intended duration was determined from the unit designation of the “carrier 
miles/time/units/serv count” field in carrier claims or the “revenue center unit count” field in 
outpatient claims. Claims for 12-month implant were assumed to represent 12 months of 
therapy regardless of unit designation.  
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APPENDIX C. TREATMENT CLAIMS 
Treatment ICD-9 /  
Revenue Center 
Codes 
CPT/HCPCS Codes 
Active 
Surveillance-
Standard 
 [84152-84154, G0103 (PSA) OR G0102 (DRE)] + 99201-
99215 (E&M)  
Active 
Surveillance-
NCCN 
60.1, 60.11 [84152-84154, G0103 (PSA) OR G0102 (DRE) OR + 99201-
99215 (E&M)] + 55700, 55705, 
55706, 76942, 10021, 10022, 88172,  88173, C1710, G0416, 
G0417,  G0418, or  G0419 (Biopsy) 
Radical 
Prostatectomy 
60, 60.4, 60.5, 
60.60, 60.61, 
60.62, 60.63, 
60.64, 60.65, 
60.66, 60.67, 
60.68, 60.69 
55801, 55821, 55831, 55810, 55812, 55815, 55840, 55842, 
55845, 00865 
Minimally 
Invasive Radical 
Prostatectomy 
 55866 
Other 
prostatectomy 
60.21, 60.29  
Radiation 
Planning and 
Management 
 77261, 77262, 77263, 77299, 77431, 77499 
Conformal 
Radiation 
Planning 
  77310, 77315, 77321 
Conformal 
Radiation 
0330, 0333, 0339 
 
77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416 
Brachytherapy 
planning 
 76873, 77326, 77327, 77328 
Brachytherapy 92.20, 92.27, 92.28 55860, 55875, 55876, 77761, 77762, 77763, 77776, 77777, 
77778, 77781, 77782, 77783, 77784, 77785, 77786, 77787, 
77789, 77790, 77799, Q3001, A9527, C1715, C1716, C1717, 
C1719, C1728, C2616, C2634, C2635, C2636, C2637, C2638, 
C2639, C2640, C2641, C2642, C2643, C2698, C2699, 
C9725, 0182T 
IMRT Planning  77301, 77338 
IMRT  77418, 0073T, G0174, G0178 
Stereotactic 
radiation 
  
Proton Therapy 92.24, 92.26 77380, 77381, 77520, 77522, 77523, 77525 
Androgen 
Deprivation 
Therapy (GnRH 
agonist) 
 J9202, J1950, J9217, J9218, J9219, J3315, J9225, J9226 or 
J1675  
J1050, J1051, J9165,  
Orchiectomy 62.3, 62.4, 62.41, 
62.42 
54520, 54522, 54530, 54535, 54690 
Chemotherapy 99.25, V58.11-
V58.19, V66.2, 
V67.2  
Q0083, Q0084, Q0085, J9000, J9000, J9001, J9002, 
J9003, J9004, J9005, J9006, J9007, J9008, J9009, 
J9010, J9011, J9012, J9013, J9014, J9015, J9016, J9017, 
J9018, J9019, J9020, J9021, J9022, J9023, J9024, J9025, 
J9026, J9027, J9028, J9029, J9030, J9031, J9032, J9033, 
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J9034, J9035, J9036, J9037, J9038, J9039, J9040, J9041, 
J9042, J9043, J9044, J9045, J9046, J9047, J9048, J9049, 
J9050, J9051, J9052, J9053, J9054, J9055, J9056, J9057, 
J9058, J9059, J9060, J9061, J9062, J9063, J9064, J9065, 
J9066, J9067, J9068, J9069, J9070, J9071, J9072, J9073, 
J9074, J9075, J9076, J9077, J9078, J9079, J9080, J9081, 
J9082, J9083, J9084, J9085, J9086, J9087, J9088, 
J9089, J9090, J9091, J9092, J9093, J9094, J9095, J9096, 
J9097, J9098, J9099, J9100, J9101, J9102, J9103, J9104, 
J9105, J9106, J9107, J9108, J9109, J9110, J9111, J9112, 
J9113, J9114, J9115, J9116, J9117, J9118, J9119, J9120, 
J9121, J9122, J9123, J9124, J9125, J9126, J9127, J9128, 
J9129, J9130, J9131, J9132, J9133, J9134, J9135, J9136, 
J9137, J9138, J9139, J9140, J9141, J9142, J9143, J9144, 
J9145, J9146, J9147, J9148, J9149, J9150, J9151, J9152, 
J9153, J9154, J9155, J9156, J9157, J9158, J9159, J9160, 
J9161, J9162, J9163, J9164, J9166, J9167, J9168, J9169, 
J9170, J9171, J9172, J9173, J9174, J9175, J9176, J9177, 
J9178, J9179, J9180, J9181, J9182, J9183, J9184, J9185, 
J9186, J9187, J9188, J9189, J9190, J9191, J9192, J9193, 
J9194, J9195, J9196, J9197, J9198, J9199, J9200, J9201, 
J9203, J9204, J9205, J9206, J9207, J9208, J9209, J9210, 
J9211, J9212, J9213, J9214, J9215, J9216, J9220, J9221, 
J9222, J9223, J9224, J9227, J9228, J9229, J9230, J9231, 
J9232, J9233, J9234, J9235, J9236, J9237, J9238, J9239, 
J9240, J9241, J9242, J9243, J9244, J9245, J9246, J9247, 
J9248, J9249, J9250, J9251, J9252, J9253, J9254, J9255, 
J9256, J9257, J9258, J9259, J9260, J9261, J9262, J9263, 
J9264, J9265, J9266, J9267, J9268, J9269, J9270, J9271, 
J9272, J9273, J9274, J9275, J9276, J9277, J9278, J9279, 
J9280, J9281, J9282, J9283, J9284, J9285, J9286, J9287, 
J9288, J9289, J9290, J9291, J9292, J9293, J9294, J9295, 
J9296, J9297, J9298, J9299, J9300, J9301, J9302, J9303, 
J9304, J9305, J9306, J9307, J9308, J9309, J9310, J9311, 
J9312, J9313, J9314, J9315, J9316, J9317, J9318, J9319, 
J9320, J9321, J9322, J9323, J9324, J9325, J9326, J9327, 
J9328, J9329, J9330, J9331, J9332, J9333, J9334, J9335, 
J9336, J9337, J9338, J9339, J9340, J9341, J9342, J9343, 
J9344, J9345, J9346, J9347, J9348, J9349, J9350, J9351, 
J9352, J9353, J9354, J9355, J9356, J9357, J9358, J9359, 
J9360, J9361, J9362, J9363, J9364, J9365, J9366, J9367, 
J9368, J9369, J9370, J9371, J9372, J9373, J9374, J9375, 
J9376, J9377, J9378, J9379, J9380, J9381, J9382, J9383, 
J9384, J9385, J9386, J9387, J9388, J9389, J9390, J9391, 
J9392, J9393, J9394, J9395, J9396, J9397, J9398, J9399, 
J9400, J9401, J9402, J9403, J9404, J9405, J9406, J9407, 
J9408, J9409, J9410, J9411, J9412, J9413, J9414, J9415, 
J9416, J9417, J9418, J9419, J9420, J9421, J9422, J9423, 
J9424, J9425, J9426, J9427, J9428, J9429, J9430, J9431, 
J9432, J9433, J9434, J9435, J9436, J9437, J9438, J9439, 
J9440, J9441, J9442, J9443, J9444, J9445, J9446, J9447, 
J9448, J9449, J9450, J9451, J9452, J9453, J9454, J9455, 
J9456, J9457, J9458, J9459, J9460, J9461, J9462, J9463, 
J9464, J9465, J9466, J9467, J9468, J9469, J9470, J9471, 
J9472, J9473, J9474, J9475, J9476, J9477, J9478, J9479, 
J9480, J9481, J9482, J9483, J9484, J9485, J9486, J9487, 
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J9488, J9489, J9490, J9491, J9492, J9493, J9494, J9495, 
J9496, J9497, J9498, J9499, J9500, J9501, J9502, J9503, 
J9504, J9505, J9506, J9507, J9508, J9509, J9510, J9511, 
J9512, J9513, J9514, J9515, J9516, J9517, J9518, J9519, 
J9520, J9521, J9522, J9523, J9524, J9525, J9526, J9527, 
J9528, J9529, J9530, J9531, J9532, J9533, J9534, J9535, 
J9536, J9537, J9538, J9539, J9540, J9541, J9542, J9543, 
J9544, J9545, J9546, J9547, J9548, J9549, J9550, J9551, 
J9552, J9553, J9554, J9555, J9556, J9557, J9558, J9559, 
J9560, J9561, J9562, J9563, J9564, J9565, J9566, J9567, 
J9568, J9569, J9570, J9571, J9572, J9573, J9574, J9575, 
J9576, J9577, J9578, J9579, J9580, J9581, J9582, J9583, 
J9584, J9585, J9586, J9587, J9588, J9589, J9590, J9591, 
J9592, J9593, J9594, J9595, J9596, J9597, J9598, J9599, 
J9600, J9601, J9602, J9603, J9604, J9605, J9606, J9607, 
J9608, J9609, J9610, J9611, J9612, J9613, J9614, J9615, 
J9616, J9617, J9618, J9619, J9620, J9621, J9622, J9623, 
J9624, J9625, J9626, J9627, J9628, J9629, J9630, J9631, 
J9632, J9633, J9634, J9635, J9636, J9637, J9638, J9639, 
J9640, J9641, J9642, J9643, J9644, J9645, J9646, J9647, 
J9648, J9649, J9650, J9651, J9652, J9653, J9654, J9655, 
J9656, J9657, J9658, J9659, J9660, J9661, J9662, J9663, 
J9664, J9665, J9666, J9667, J9668, J9669, J9670, J9671, 
J9672, J9673, J9674, J9675, J9676, J9677, J9678, J9679, 
J9680, J9681, J9682, J9683, J9684, J9685, J9686, J9687, 
J9688, J9689, J9690, J9691, J9692, J9693, J9694, J9695, 
J9696, J9697, J9698, J9699, J9700, J9701, J9702, J9703, 
J9704, J9705, J9706, J9707, J9708, J9709, J9710, J9711, 
J9712, J9713, J9714, J9715, J9716, J9717, J9718, J9719, 
J9720, J9721, J9722, J9723, J9724, J9725, J9726, J9727, 
J9728, J9729, J9730, J9731, J9732, J9733, J9734, J9735, 
J9736, J9737, J9738, J9739, J9740, J9741, J9742, J9743, 
J9744, J9745, J9746, J9747, J9748, J9749, J9750, J9751, 
J9752, J9753, J9754, J9755, J9756, J9757, J9758, J9759, 
J9760, J9761, J9762, J9763, J9764, J9765, J9766, J9767, 
J9768, J9769, J9770, J9771, J9772, J9773, J9774, J9775, 
J9776, J9777, J9778, J9779, J9780, J9781, J9782, J9783, 
J9784, J9785, J9786, J9787, J9788, J9789, J9790, J9791, 
J9792, J9793, J9794, J9795, J9796, J9797, J9798, J9799, 
J9800, J9801, J9802, J9803, J9804, J9805, J9806, 
J9807, J9808, J9809, J9810, J9811, J9812, J9813, J9814, 
J9815, J9816, J9817, J9818, J9819, J9820, J9821, J9822, 
J9823, J9824, J9825, J9826, J9827, J9828, J9829, J9830, 
J9831, J9832, J9833, J9834, J9835, J9836, J9837, J9838, 
J9839, J9840, J9841, J9842, J9843, J9844, J9845, J9846, 
J9847, J9848, J9849, J9850, J9851, J9852, J9853, J9854, 
J9855, J9856, J9857, J9858, J9859, J9860, J9861, J9862, 
J9863, J9864, J9865, J9866, J9867, J9868, J9869, J9870, 
J9871, J9872, J9873, J9874, J9875, J9876, J9877, J9878, 
J9879, J9880, J9881, J9882, J9883, J9884, J9885, J9886, 
J9887, J9888, J9889, J9890, J9891, J9892, J9893, J9894, 
J9895, J9896, J9897, J9898, J9899, J9900, J9901, J9902, 
J9903, J9904, J9905, J9906, J9907, J9908, J9909, J9910, 
J9911, J9912, J9913, J9914, J9915, J9916, J9917, J9918, 
J9919, J9920, J9921, J9922, J9923, J9924, J9925, J9926, 
J9927, J9928, J9929, J9930, J9931, J9932, J9933, J9934, 
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J9935, J9936, J9937, J9938, J9939, J9940, J9941, J9942, 
J9943, J9944, J9945, J9946, J9947, J9948, J9949, J9950, 
J9951, J9952, J9953, J9954, J9955, J9956, J9957, J9958, 
J9959, J9960, J9961, J9962, J9963, J9964, J9965, J9966, 
J9967, J9968, J9969, J9970, J9971, J9972, J9973, J9974, 
J9975, J9976, J9977, J9978, J9979, J9980, J9981, J9982, 
J9983, J9984, J9985, J9986, J9987, J9988, J9989, J9990, 
J9991, J9992, J9993, J9994, J9995, J9996, J9997, J9998 
Other  55873 (cryosurgery);  77371, 77372, 77373, 77432, 77435, 
0082T, 0083T,  G0251 (stereotactic radiation); J9165, 
J1050, J1051, G0356,  s0175, S9560, 4164F, J1675 (other 
hormones); J9999 (unspecified drug) 
Abbreviations: ICD-9: International Classification of Diseases , 9th Revision; CPT: Current 
Procedural Terminology; HCPCS: Healthcare Common Procedure Coding System; PSA: Prostate-
specific Antigen; E&M: Evaluation and Management 
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